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Multiple   sclerosis   (MS)   is   a   neurodegenerative   autoimmune   disease   believed   to   be  
mediated   by   autoreactive   CD4+   T   cells,   however   the   exact   disease   mechanisms   are   not  
known.  More  than  200  genetic  risk  factors  and  several  environmental  risk  factors  have  been  
associated  with  the  disease.  Amongst  genetic  risk  factors,   the  MHC  class  II  molecule  HLA-­
DRB1*15:01   (HLA-­DR15)   confers   the   strongest   risk.   In   addition,   >200   single   nucleotide  
polymorphisms  (SNPs)  have  been  associated  with  MS  risk,  mostly  mapping  to  genes  involved  
in  adaptive  immunity  and  T  helper  cell  pathways.  Epstein-­Barr  virus  (EBV)  is  a  ubiquitous  virus  
infecting  the  majority  of  the  human  adult  population.  Even  though  in  the  majority  of  cases  the  
infection  goes  unnoticed,  in  a  subset  of  young  adults  the  virus  can  cause  an  acute  infection  
known  as   infectious  mononucleosis   (IM).   Interestingly,   strong   evidence   now   supports  EBV  
infection   to  be  an  environmental   risk   factor   for  MS  and   to  synergize  with   the  HLA   locus   to  
further  increase  this  risk.  The  interactions  between  MS  genetics  and  the  environment  remain  
to  be  understood.  
In   this   PhD   thesis,   we   aimed   to   investigate   the   interaction   between  MS-­associated  
genetic  risk  factors  and  EBV  using  our  humanized  mouse  model  of  EBV  infection.  We  have  
demonstrated  that  animals  reconstituted  with  donors  positive  for  HLA-­DR15  show  higher  basal  
activation  in  the  T  cell  compartment.  Upon  EBV  infection,  we  saw  higher  frequencies  of  CD8
+  
T  cells  and  higher  numbers  of  activated  T  cells.  Despite  this,  the  animals  displayed  higher  EBV  
viral   loads,  suggesting  defects  in  EBV  immune  control.  Upon  performing  T  cell  cloning  from  
these   EBV-­infected   mice,   we   observed   that   HLA-­DR15-­restricted   CD4+   T   cell   clones  
demonstrated   cross-­reactive   responses   towards   allogeneic   lymphoblastoid   cell   lines   when  
compared  to  HLA-­DR4-­restricted  clones.  To  develop  on  these  results,  we  next  aimed  to  create  
an   HLA-­DR15   transgenic   humanized   mouse   model,   which   we   could   use   to   study   these  
responses  further.  While  we  saw  HLA-­DR15  expression  in  mouse  tissues,  these  animals  did  
not   reconstitute   human   immune   cells,   possibly   due   to   incorrect   insertion   of   transgene   and  
activation  of  the  murine  myeloid  cells.  We  will  next  breed  them  to  the  murine  MHC  class  II-­
deficient  NSG  mouse  strain  and  examine  effects  on  reconstitution  in  this  setting.  
Finally,  we  aimed  to  investigate  MS-­associated  risk  variants,  their  causality  and  effect  
on  T  cell  responses  upon  EBV  infection.  Even  though  individually  these  variants  only  slightly  
increase  the  risk  of  MS,  they  likely  act  together   in   linked  pathways  interacting  with  the  HLA  
locus  and  environmental  factors.  Upon  short-­listing  several  candidates,  we  developed  a  SNP-­
typing  method   of   our   donors.  We   reconstituted   animals  with   donors   homozygous   positive,  
negative  or  heterozygous  for  the  SNP  downstream  of  the  EOMES  gene,  the  transcription  factor  
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involved   in   T   and  NK   cell   cytotoxicity   and   effector   functions.   In   these   animals,   we   did   not  
observe  differences  in  bulk  T  cell  expression  of  EOMES  at  steady  state  or  during  EBV  infection.  
We  further  want  to  investigate  this  in  T  cell  clones  and  include  additional  risk  variants.    
Together,   we   have   provided   some   evidence   into   the   interaction   between   MS-­
associated  genetic   and  environmental   risk   factors.  HLA-­DR15  might   prime   for  more   cross-­
reactive  specificities,  while  single  risk  variants  could  act   to  decrease   the   threshold  of  T  cell  
activation   and   immune   dysregulation.   As   a   result,   HLA-­DR15   restricted   T   cells  might   less  
efficiently   control   EBV   infection,   lead   to   higher   immune   activation   and   expansion   of  





















1   Introduction 
  
1.1   Epstein-Barr virus 
  
1.1.1   Discovery 
After  successfully  culturing  tumor  cells  from  Burkitt’s  lymphoma  (BL)  in  vitro  (Epstein  
and  Barr,  1964),  Epstein  discovered   the   first  human   tumor  virus,  Epstein-­Barr   virus   (EBV),  
when  observing  virus  particles  in  the  cytoplasm  of  these  lymphoblast  cell  lines  (LCLs)  (Epstein  
et  al.,  1964).  In  a  study  a  few  years  later,  Henle  and  colleagues  demonstrated  that  cultured  
cells   from   BL   harboring   EBV   managed   to   induce   the   growth   of   peripheral   leukocytes   of  
a  healthy  donor  (Henle  et  al.,  1967).      
Jondal  and  Klein  discovered  EBV  receptors  on  B  cells,  and  Pattengale  and  colleagues  
additionally   found   that   EBV   infects   B   cells   and   transforms   them   into   proliferating  
B  lymphoblasts  (Jondal  and  Klein,  1973;;  Pattengale  et  al.,  1974).  Twenty  years  later,  it  was  
shown   that   the  B  cell   is   the  site  of   the   full  EBV   life  cycle   (Thorley-­Lawson  et  al.,  1996).   In  
addition,  >90%  of  persistently  EBV-­infected  cells  in  the  peripheral  blood  of  the  asymptomatic  
host   are   in   fact   resting,   non-­activated   B   cells,   proposing   this   to   be   the   cell   of   long-­term  
persistence  (Miyashita  et  al.,  1997).  However,  even  though  in  a  latent  state,  the  virus  actively  
replicates   and   sheds   into   the   saliva.   Immunohistology   suggested   that,   in   acutely-­infected  
patients,   the   replication   of   the   virus   occurs   in   B   cells   found   in   the   epithelium   of   mucosal  
lymphoid  tissues  (Anagnostopoulos  et  al.,  1995).  In  1998,  it  was  then  demonstrated  that  EBV  
infection  in  vivo  likely  follows  antigen-­driven  activation.  Whilst  in  lymphoid  tissue  EBV  infects  
naïve   and  memory  B   cells,   EBV-­infected   cells   in   the   periphery   are   in   fact  memory  B   cells  
(Babcock  et  al.,  1998).    
  
1.1.2   Mode of infection 
EBV  is  one  of  eight  viruses  in  the  family  of  known  human  herpesviruses  and  together  
with  Kaposi’s  sarcoma-­associated  herpesvirus  (KSHV),  it  belongs  to  the  gamma  herpesvirus  
subfamily   (Hislop   et   al.,   2007).   It   carries   a   large,   double-­stranded   DNA   genome   which   is  
172  kilobase  pairs  long  (Yates  et  al.,  1985).  
To   infect   B   cells,   EBV   uses   its   glycoprotein   (gp)   gp350   (BLLF1)   to   bind   to   the  
complement   receptors   CD21   or   CD35   and   also   gp42   (BZLF2)   binding   to   MHC   class   II  
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molecules.  Targeting  integrins  by  gH  (gp85)  and  gL  (gp25)  then  promote  viral  fusion  with  the  
cell  membrane  that  is  executed  by  the  gB  (gp110)  protein  (Shannon-­Lowe  and  Rowe,  2014).    
EBV  and  the  human  host  have  developed  a  fine  balance  which  allows  for  their  mutual  
coexistence.  The  virus  has  two  stages  of  life  cycle  -­  lytic  and  latent  infection.  Following  oral  
transmission   to   a   naïve   host,   EBV   is   probably   delivered   across   the   polarized   mucosal  
epithelium  by  transcytosis  (Tugizov  et  al.,  2003;;  Tugizov  et  al.,  2013).  Interestingly,  Dunmire  
and  colleagues  found  EBV  viral  loads  in  the  oral  cavity  only  five  to  six  weeks  post  primary  EBV  
infection  and  before  the  onset  of  symptoms,  suggesting  high  levels  of  lytic  replication  not  taking  
place  within  epithelial  cells.  Instead,  their  data  suggest  that  B  cells  could  be  the  major  cell  type  
infected   in   the   nasopharyngeal   sites   and   disseminating   into   peripheral   blood   after   oral  
transmission.  This  is  reflected  by  low  levels  of  viral  genomes  measured  in  the  peripheral  blood  
prior  to  the  oral  cavity.  A  few  days  before  acute  disease  onset,  high  viral  loads  were  detected  
in   the   oral   wash,   possibly   resulting   from   viral   reactivation   in   latently   infected   B   cells   and  
subsequent  infection  of  epithelial  cells  (Dunmire  et  al.,  2015).  
Upon  B  cell  infection,  EBV  switches  into  the  latent  growth-­transforming  program.  The  
infected  B  cell  pool  is  expanded  and  in  acute  disease  represents  up  to  10%  of  all  B  cells  in  the  
peripheral  blood  (Hislop  et  al.,  2007).  Even  though  most  of  the  infected  B  cells  are  eventually  
removed  by  the  immune  system,  some  cells  downregulate  antigen  expression  and  enter  the  
memory  B  cell  pool.  In  this  way,  the  virus  persists  for  the  life  of  the  individual.  The  recirculating  
B  cell  population  may  receive  stimuli  such  as  antigenic  stimulation  or  signals  for  plasma  cell  
differentiation  and  periodically  switch  back  to  the  lytic  cycle  to  produce  and  spread  infectious  
virions  to  a  new  host  (Hislop  et  al.,  2007)  (Fig.  1).  Transmission  is  further   improved  by  lytic  
replication   in  a  permissive  cell   type  such  as  specialized  mucosal  epithelial   cells   (Shannon-­
Lowe  et  al.,  2006)  and  the  derived  virus  is  additionally  more  efficient  in  infecting  B  cells  in  the  
new  host  (Borza  and  Hutt-­Fletcher,  2002;;  Hutt-­Fletcher,  2007).  There  are  high  amounts  of  viral  
shedding  into  the  throat  after  symptomatic  primary  infection  and  this  can  persist  in  saliva  for  
even   longer   than  6  months   (Balfour  et  al.,  2005;;  Fafi-­Kremer  et  al.,  2005).   In  addition,   low  
levels  of  virus  shedding   into   the  saliva  has  been  observed   in   the   throats  of   long-­term  virus  




Figure  1:  EBV  primary  infection  and  persistence.  After  oral  transmission,  EBV  passes  through  the  
epithelial  cell  layer  to  infect  local  B  cells  in  secondary  lymphoid  tissues  and  the  tonsils  and  drives  them  
into  latency  (Lat)  III.  If  infected  B  cells  are  memory  cells,  they  can  directly  enter  latency  0.  Latency  III  
cells  further  differentiate  via  latency  II  through  the  germinal  center  to  latency  0  memory  B  cells,  which  
recirculate  in  peripheral  blood.  B  cells  can  enter  the  lytic  cycle  early  after  infection,  start  virus  reactivation  





  T  cells  to  both  latent  and  lytic  antigens,  as  well  as  NK  cells  during  lytic  
infection.  From  memory  B  cells  in  the  circulation,  differentiation  into  plasma  cells  reactivates  the  lytic  
cycle,  infection  of  epithelial  cells  and  subsequent  release  of  virions  into  saliva,  infecting  a  new  host  or  




  T  cells  control  both  latent  and  lytic  
and  NK  cells  lytic  programs,  however  the  response  is  much  smaller  than  during  primary  infection.  







1.1.3   Latent and lytic cycles 
During  the  lytic  cycle,  the  virus  sequentially  expresses  three  sets  of  proteins.  First,  the  
immediate  early  (IE)  proteins  serve  as  the  transactivators  of  early  gene  expression.  Next,  early  
(E)  proteins  are  expressed  and  consist  of  essential  components  of  the  viral  DNA  replication  
complex  and  finally,  late  (L)  proteins  form  the  structure  of  the  virion  (Hislop  et  al.,  2007).    
The  virus  also  carries  genes  which  are  crucial  for  it  to  successfully  establish  the  latent  
state.  The  latently  infected  cells  first  undergo  a  phase  of  cell  proliferation,  which  is  associated  
with   the   transient  expression  of   the  viral   latent  genes.  This  allows   for   the  expansion  of   the  
latently  infected  cell  pool  before  viral  genes  are  suppressed,  holding  a  stable  reservoir  of  viral-­
infected   but   antigen-­negative   cells   (Hislop   et   al.,   2007).   EBV’s   B   cell   growth-­transforming  
ability  depends  on  latent  genes  encoding  six  EBV  nuclear  antigens  (EBNA)  -­1,  2,  3A,  3B,  3C  
and  LP,  as  well  as  two  latent  membrane  proteins  (LMP)  1  and  2.  All  eight  of  these  proteins  are  
expressed  in  EBV-­transformed  LCLs  in  vitro  (Hislop  et  al.,  2007).  
EBV  infection  of  epithelial  cells  is  not  very  well  characterized,  however  it  is  thought  that  
epithelial  cells  can  mainly  support  lytic  replication,  while  both  latent  and  lytic  infection  programs  
take  place  in  B  cells  (Thorley-­Lawson  and  Gross,  2004).  In  B  cells,  different  latency  programs  
depend  on  the  differentiation  stage  of   the   infected  cell.   Infection  of  naïve  B  cells  shows  the  
expression  of  all  eight  EBV   latent  proteins   in   latency   III.  After  entering   the  germinal  center,  
B  cells  only  express  three  latent  proteins;;  EBNA1,  LMP1  and  LMP2,  in  latency  II.  In  the  latency  
I  program,  only  EBNA1  is  expressed  in  homeostatically  proliferating  infected  memory  B  cells.  
Finally,  non-­proliferating   infected  memory  B  cells   in   the  periphery  are   in   the   latency  0  state  
where  no  EBV  proteins  are  expressed  (Babcock  et  al.,  1998;;  Babcock  et  al.,  2000;;  Hochberg  
et  al.,  2004).  Lytic  replication  is  induced  during  differentiation  of  infected  memory  B  cells  into  
plasma  cells  and  results  in  the  activation  of  the  promoter  for  the  gene  triggering  viral  replication,  
BZLF1  (Laichalk  and  Thorley-­Lawson,  2005).  
The  EBV  antigen  LMP-­1  is  a  member  of  the  TNFR  superfamily  and  acts  to  mimic  the  
B  cell  CD40  receptor.  It  assists  antigen-­stimulated  B  cells  to  enter  the  germinal  center  reaction  
after   interaction  with  CD4
+  T  cells   to  differentiate   into  memory  B  cells  or  antibody-­secreting  
plasma  cells  (Farrell,  1998).  LMP-­1  plays  a  crucial  role  in  human  B  cell  transformation  (Farrell,  
1998)   and   is   required   for   LCL   growth   in   vitro   (Hayward,   2004),   however,   EBNA   protein  
expression  is  also  needed  for  sufficient  immortalization.  EBNA2  is  one  of  the  first  viral  genes  
expressed  after  B  cell  infection  and  important  for  B  cell  transformation.  It  mimics  function  of  
intracellular  Notch  by  binding  to  a  transcriptional  repressor  downstream  of  Notch,  converting  it  
into  a  transcriptional  activator  and  activating  gene  transcription  of  bound  promoters.  EBNA-­LP  
acts  as  a  positive  regulator  of  EBNA2.  On  the  other  hand,  the  three  EBV  proteins  EBNA3A,  
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3B  and  3C  compete  with  EBNA2  for  binding  the  transcriptional  repressor  and  thus  blocking  
the   transcriptional   activation   and   dampening   gene   transcription.   Like   LMP-­1,   EBNA2   and  
EBNA3C  are  also  essential  for  EBV  immortalization  of  infected  B  cells  into  LCLs  (Hayward,  
2004).  
EBNA1  is  the  only  nuclear  EBV  protein  expressed  in  both  the  latent  and  lytic  programs  
(Sivachandran  et  al.,  2012).  It  is  critical  in  maintaining  the  viral  episome  in  infected,  proliferating  
B   cells   by   binding   to   the   latent   origin   of   replication,   oriP   (Yates   et   al.,   1985).   Unlike   lytic  
replication,  which  uses  a  viral  DNA  polymerase,  the  viral  genome  in  latently  infected  cells  uses  
the  host  cell  replication  machinery  to  replicate  once  per  cell  cycle  and  gets  passed  to  daughter  
cells  (Adams,  1987;;  Yates  and  Guan,  1991).  EBNA1  binding  of  the  oriP  additionally  effects  the  
expression  of  other  latency  genes  (Gahn  and  Sugden,  1995)  and  cell  proliferation  and  survival  
(Kennedy  et  al.,  2003;;  Sivachandran  et  al.,  2008).  
The  differentiation  of  the  infected  memory  B  cell  into  a  plasma  cell  can  trigger  the  switch  
to   the   lytic  cycle.  BZLF1   is   the   first  EBV   lytic  gene   to  be  expressed   (Laichalk  and  Thorley-­
Lawson,  2005).  It  transactivates  its  own  promoter,  Zp,  and  the  other  immediate-­early  promoter,  
Rp,  inducing  the  expression  of  BRLF1  transcription  factor  (Miller  et  al.,  2007).  Together,  these  
two  proteins  then  induce  the  expression  of  other  EBV  lytic  genes  (Feederle  et  al.,  2000).  BZLF1  
also  binds  to  the  origin  of  lytic  DNA  replication,  oriLyt,  and  recruits  viral  DNA  polymerase  and  
factors  that  are  needed  for  lytic  replication  (Lieberman  et  al.,  1990;;  Gao  et  al.,  1998).    
  
1.1.4   Acute primary EBV infection – infectious mononucleosis 
1.1.4.1  Discovery 
In   the   1880s,   Nil   Filatov,   a   Russian   pediatrician,   first   recognized   a   unique   illness    
(Filatov  and  Earle,  1904).  A  few  decades  later,  Sprunt  and  Evans  gave  the  disease  its  current  
name,   infectious   mononucleosis   (IM),   to   the   disease   which   presented   itself   as   an   acute  
infection   causing   fever,   cervical   lymphadenopathy   and   pharyngitis,   as   well   as   displaying  
atypical  large  lymphocytes  in  the  peripheral  blood  (Sprunt  and  Evans,  1920).  Even  though  the  
etiology   of   the   illness   was   unknown,   it   later   turned   out   to   provide   great   advances   in   EBV  
research.  
Similar  to  the  experiments  done  with  BL  cell  lines,  peripheral  blood  lymphocytes  of  IM  
patients  had   the  capacity   to  establish  growing  cultures   (Pope,  1967)  and  additionally,   their  
infiltrates  induced  the  growth  of  fetal  human  lymphocytes  in  vitro  (Pope  et  al.,  1968).  This  work  
suggested   the  presence  of  a  viral  agent   involved   in   the  proliferation,  perhaps   the  same  as  
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found  in  BL  cells.  This  was  further  supported  by  work  that  detected  EBV  in  all  LCLs  grown  out  
from  individuals  in  the  acute  phase  or  with  a  past  history  of  IM  (Diehl  et  al.,  1968).    
The   first   serological  evidence  of  a   link  between  EBV  and   IM  came   from  a  study  by  
Henle  and  colleagues  in  1967,  when  to  their  luck  a  lab  technician  became  EBV  seropositive  
after  contracting  IM.  As  a  result  of  this,  sera  from  IM,  as  well  as  BL  patients  were  examined  
and  strikingly,  100%  had,  and  mostly  high,  anti-­EBV  antibody  titers  and  negative  pre-­infection  
sera.  Controls  were  20-­50%  positive  with  mostly  low  titers  (Henle  et  al.,  1968).    
These  anti-­EBV  antibodies  were  additionally  observed  by  indirect  immunofluorescence  
(Niederman   et   al.,   1968),   found   to   be   complement-­fixing   (Gerber   et   al.,   1968),   virus-­
neutralizing  (Miller  et  al.,  1972),  and  they  reached  peak  levels  a  few  weeks  after  disease  onset  
and  persisted  for  years  later  (Niederman  et  al.,  1970).  
Several  efforts   to   isolate   the  virus   from   IM  patients   followed.  EBV  was   found   in   the  
throat  washings  of  IM  patients,  as  well  as  EBV-­seropositive,  but  not  EBV-­seronegative  healthy  
donors  and  was  able   to   transform  cord-­blood   leukocytes   (Gerber   et   al.,   1972;;  Miller   et   al.,  
1973).  More  work  has  shown  that  the  virus  is  found  in  the  throat  of  healthy  individuals  without  
a  past  history  of  IM,  as  well  as  individuals  receiving  immunosuppressive  therapy.  Whilst  in  IM  
patients,  EBV  is  present  in  the  throat  and  oropharynx  several  weeks  or  months  after  clinical  
illness   (Miller   et   al.,   1973;;  Niederman   et   al.,   1976),  EBV  presence   in   the   throat   of   healthy  
individuals  without  a  past  history  of  IM  and/or  individuals  receiving  immunosuppressive  therapy  
(Strauch  et  al.,  1974)  hinted  towards  a  reactivation  of  the  latent  virus  from  oropharyngeal  sites.  
Work   by   Niederman   and   colleagues   was   able   to   demonstrate   that   oral   fluids   contain  
extracellular  EBV,  suggesting  a  cell  type  in  which  the  virus  undergoes  its  full  life  cycle.  They  
demonstrated  with  an  early  IM  patient  that  saliva  was  invariably  positive  with  the  virus,  whilst  
other   oral   sites   were   intermittently   positive.   Infectious   virus   was   present   in   low   titers   and  
excreted  intermittently  both  in  patients  with  IM  and  healthy  individuals,  which  together  offered  
an   explanation   for   the   moderate   contagiousness   of   this   infection   and   widespread   and  
continuous  transmission  by  intimate  contact  (Niederman  et  al.,  1976).    
  
1.1.4.2 Epidemiology and clinical manifestations of the acute illness 
EBV   is   an   extremely   common   agent   and   has   a   worldwide   distribution   (Niederman,  
1982).   When   EBV   is   acquired   early   in   childhood,   it   usually   remains   as   an   asymptomatic  
primary  infection  (Biggar  et  al.,  1978a).  How  EBV  is  transmitted  at  this  early  age  is  not  known,  
however   a   likely   explanation   is   infection   by   parents   or   siblings,   who   have   periodic   EBV  
shedding  into  their  oral  secretions  (Sumaya  and  Ench,  1986).  A  study  of  Melanesian  children  
found  EBV  acquisition  very  early  in  infancy,  suggesting  its  spread  by  interpersonal  contact  with  
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several  carriers,  such  as  pre-­chewing  food  for  babies  and  infants  (Lang  et  al.,  1977).  Extremely  
early  acquisition  of  primary  EBV  infection  has  also  been  shown  for  example  in  newborns  in  
Accra,  Ghana,  where  81%  of   infants  were   infected  by   the  age  of  21  months   (Biggar  et  al.,  
1978b;;  Piriou  et  al.,  2012).  
An  appropriate  immune  response  to  EBV  is  behind  the  fine  balance  that  exists  with  its  
human  host.  EBV-­associated  diseases  or  pathologies  mostly  arrive  either  when  an  individual  
is   severely   immunocompromised   or   if   an   exaggerated,   hyperactive   immune   response   is  
mounted  to  the  virus  (Hislop  et  al.,  2007).    
IM  is  a  well-­recognized  disease  in  the  developed  world  with  advanced  sociohygienic  
standards,  with  peak   incidence  occurring   in  adolescents  and  young  adults.   In  up  to  25%  of  
cases,   mostly   in   the   West,   primary   EBV   infection   can   be   delayed   until   early   adulthood  
(Crawford  et  al.,  2006).  When  EBV  transmission  happens  later  in  life,  primarily  following  deep  
kissing,  it  is  then  able  to  cause  this  acute  illness  (Hoagland,  1955;;  Niederman,  1982;;  Balfour  
et  al.,  2013).    
The   incubation   period   of   EBV   before   the   onset   of   IM   symptoms   is   33   to   49   days  
(Hoagland,  1955;;  Svedmyr  et  al.,  1984),  with  most  frequently-­experienced  symptoms  of  sore  
throat,   cervical   lymphadenopathy,   fatigue,   upper   respiratory   track   symptoms,   head   ache,  
decreased  appetite,  fever,  body  aches  and  abdominal  pain.  The  illness  lasts  between  3  and  
66   days,   however   viral   shedding   has   been   observed   prior   to   symptoms   in   the  majority   of  
patients.  Oral  cell  pellets  and  whole  blood  lasted  EBV  DNA-­positive  for  a  mean  of  272  and  95  
days,  respectively  (Balfour  et  al.,  2013;;  Dunmire  et  al.,  2015).  
It   is   still   not   completely  understood  why   IM   is   largely  a  disease  of  adolescents  and  
young   adults   and   why   primary   infection   sometimes   presents   as   asymptomatic.   First,   it   is  
possible  that  in  preadolescents,  the  disease  is  simply  not  recognized.  The  heterophile  antibody  
test,  a  routine  IM  diagnostic  test,  has  shown  to  be  unreliable  in  children  under  the  age  of  four  
years.   Evaluating   a   peripheral   blood   smear   for   atypical   lymphocytes   characteristic   of   IM,  
followed   by   EBV-­specific   assays,   has   proven   more   successful   in   identifying   IM   in   young  
children  (Horwitz  et  al.,  1981).  
Secondly,  during  the  acute  and  convalescent  stages  of  IM,  patients  can  have  between  
8  000  and  >1  000  000  EBV  copies  /  ml  of  saliva  up  to  6  months  post  diagnosis,  versus  0  –  10  
000  EBV  copies  /  ml  of  saliva  in  healthy  EBV  carriers  (Fafi-­Kremer  et  al.,  2005;;  Hadinoto  et  
al.,  2008;;  Balfour  et  al.,  2013).  Another  possibility  could   therefore  be   that   large  amounts  of  
infectious  virus  are  transmitted  by  deep  kissing,  where  on  the  other  hand,  only  small  infectious  
inoculums  are  transmitted  from  asymptomatic  parents  or  siblings.  A  third  and  fourth  possible  
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 and NK cells in IM 
There  is  evidence  from  IM  patients  (Williams  et  al.,  2005;;  Balfour  et  al.,  2013),  primary  
human  immune  deficiencies  (Benoit  et  al.,  2000;;  Parolini  et  al.,  2000)  and  humanized  mouse  
models  (Strowig  et  al.,  2009;;  Yajima  et  al.,  2009;;  Chijioke  et  al.,  2013)  to  suggest  that  both  NK  
cells,  and  T  cells,  play  a  role  in  EBV  control.    
One  possible  reason  for  IM  in  adolescence  is  the  difference  in  the  CD8+  T  cell  response  
mounted  against  the  transmitted  virus  in  adolescence  and  early  adulthood.  A  study  by  Clute  
and  colleagues  found  influenza-­specific  memory  CD8+  T  cells  cross-­react  with  EBV  (Clute  et  
al.,   2005).  However,   in   a   study   published   a   few   years   later,   even   though   the   authors   saw  
bystander  activation  of  influenza-­specific  memory  CD8+  T  cells  during  IM,  these  cells  did  not  
expand.  Hence,   the  CD8+   T   cell   expansion  was   composed  mainly   of   latent   and   lytic  EBV-­
specific  T  cells  (Steven  et  al.,  1996;;  Steven  et  al.,  1997;;  Hoshino  et  al.,  1999;;  Odumade  et  al.,  
2012).   Whether   these   CD8+  T   cells   play   a   pathologic   or   protective   role   in   IM   is   unclear.  
A  reduction  in  activated,  EBV-­specific  CD8+  T  cells  was  parallel  to  a  drop  in  EBV  genome  load  
in   PBMCs,   suggesting   an   effective   clearing   of   virus-­infected   cells   (Hoshino   et   al.,   1999).  
However,  in  a  special  cohort  of  donors  undergoing  primary  asymptomatic  EBV  infection,  the  
seroconversion  occurred  in  the  presence  of  normal  levels  of  CD8+  T  cells,  as  opposed  to  the  
expected  significant   lymphocytosis  seen   in   IM  patients.  Additionally,   the   large  expansion  of  
CD8+  T  cells  observed   in   IM  patients  was   largely  clonal   in  composition,   indicating  antigen-­
driven  amplification   (in  one   IM  patient,  44%  of  circulating  CD8+  T  cells   recognized  a  single  
epitope  (Callan  et  al.,  1998))  (Annels  et  al.,  2000).  In  contrast,  asymptomatic  seroconverters  
showed  regular,  Gaussian-­like  profiles  in  the  TCR  repertoire  throughout  the  course  of  infection  
until  persistence.  Surprisingly,  both   IM  patients  and  asymptomatic  seroconverters  had  high  
cell-­associated  EBV  viral  loads  (Silins  et  al.,  2001).    
Similar  data  was  seen  obtained  in  another  cohort  of  asymptomatic  primary  infections.  
Together  with  the  observations  that  while  CD8+  T  cells  did  not  rise  to  the  levels  observed  in  IM  
patients   in  asymptomatic   infections,  40%  of   the  T  cells  were  activated  and  at   least  15%  of  
these  cells  were  specific   to  one  EBV   lytic  cycle  epitope.  Notably,  one  asymptomatic  donor  
showed   no   CD8+   T   cell   expansion   or   activation,   nor   detectable   EBV-­specific   CD8+   T   cell  
responses   during   primary   infection   and   three  months   later,   despite   high   EBV   loads   in   the  
blood.  Only  16  months  later  was  an  EBV-­specific  CD8+  T  cell  response  detected  (Abbott  et  al.,  
2017).    
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This  suggests  that  the  T  cells,  when  expanded  beyond  homeostasis  in  IM,  may  become  
counterproductive  and  immunopathogenic  (Silins  et  al.,  2001)  and  that  viral  loads  alone  cannot  
drive   symptoms,   as   asymptomatic   infections   tend   to   have   similarly   high   viral   loads   as   IM  
patients  (Abbott  et  al.,  2017).  
While   the   activation   of   NK   cells,   as   determined   by   levels   of   granzyme   B,   was   not  
significant,  an  expansion  of  NK  cells  in  the  blood  of  IM  patients  was  observed.  This  coincided  
with  CD8+  T  cell  lymphocytosis,  positively  correlating  with  CD8+  T  cell  numbers  and  disease  
severity  (Balfour  et  al.,  2013).  In  an  earlier  study  however,  even  though  there  was  an  elevation  
in   NK   cell   numbers,   which   comprised   an   increased   proportion   of   CD56bright   NK   cells   (the  
dominant  NK  cell  subset   in   lymphoid  tissues)  with  an  enhanced  ability   to   lyse  EBV-­infected  
B  cells,  the  NK  cell  numbers  correlated  inversely  with  viral  loads  (Williams  et  al.,  2005).    
In  vitro,  this  CD56bright  NK  cell  subset  proliferated  and  produced  large  amounts  of  IFNγ,  
which  restricted  EBV  B  cell  transformation.  Tonsillar  NK  cells  were  additionally  more  efficient  
than   peripheral   blood   NK   cells   (Strowig   et   al.,   2008).   Interestingly,   using   a   NOD-­scid   γc
-­/-­  
humanized  mouse  model  of  EBV  infection,  NK  cells,  mostly  the  early-­differentiation  phenotype  
subset  CD56dim  NKG2A+  killer-­cell   immunoglobulin-­like   receptor   (KIR)-­,  were  also   increased  
during  an  IM-­like  disease  and  preceded  the  peak  of  the  T  cell  response.  They  preferentially  
targeted  lytically  infected  cells  and  upon  their  depletion,  log  higher  viral  loads  were  observed.    
Additionally,  when  NK   cells  were   expanded   and   further   differentiated,   they   controlled  EBV  
infection  less  well,  suggesting  that  NK  cells  with  an  early-­differentiation  phenotype  are  better  
at  viral  control  (Chijioke  et  al.,  2013).    
In   line   with   this,   a   study   by   Azzi   and   colleagues   has   demonstrated   a   preferential  
proliferation  of   this  early  differentiated,  CD56dim  NKG2A+  KIR-­  NK  cell  subset   in  pediatric   IM  
patients,   versus   in   either   adolescents   or   adults.   This   NK   cell   subset   degranulates   and  
proliferates  on  exposure  to  EBV  lytic  antigens  and  is  seen  to  persist  for  several  months  after  
acute  IM  (Azzi  et  al.,  2014).  This  suggests  that  this  early-­differentiated  NK  cell  subset  could  
serve  an  important  role  early  in  infection  by  controlling  lytic  replication  and  limiting  the  number  
of   infectious   virus   particles   entering   the   B   cell   pool   and   also   by   reducing   the   CD8+   T   cell  
response  by  reducing  available  lytic  antigens,  its  main  drivers.  Also,  there  could  be  an  impaired  
NK  cell  control,  as  IM  is  a  disease  which  shows  high  viral   loads  and  an  exaggerated  T  cell  
response.  Individuals  with  asymptomatic  infection  did  not  seem  to  show  the  expansion  of  either  
total  NK  cells  or  of  the  CD56dim  NKG2A+  KIR-­  NK  cell  subset.  The  authors  however  suggest  
that  NK  cell  populations  in  the  blood  do  not  neccesarily  reflect  NK  cell  subsets  and  action  in  
oropharyngeal  sites  (Abbott  et  al.,  2017).  Nevertheless,  as  IM  mainly  manifests  in  adolescents  
and  young  adults,  who  have  decreased  frequencies  of  this  early-­differentiated  NK  cell  subset,  
an  age-­dependent  impaired  NK  cell-­mediated  immune  control  could  be  a  factor  contributing  to  
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IM  (Azzi  et  al.,  2014).  However,   the  role  of  NK  cells   in   the  control  of  EBV  transformation   is  
debatable,   as   clinical   evidence   shows   that   patients   receiving   T   cell-­depleted   stem   cell  
transplants  develop  EBV-­driven  lymphoproliferative  disease  most  commonly  in  the  first  3  to  6  
months  after   transplantation.   In   this   time,  NK  cells  are  present  while  T  cells  are  still  absent  
(O'Reilly  et  al.,  1997).  
  
1.1.5 T cell responses to EBV 
As  mentioned  before,  in  acute  disease,  there  is  a  vast  expansion  of  EBV-­specific  CD8+  
T   cells.  Much  progress  has  been  made   in  deciphering  EBV  specificities   in   the  blood  of   IM  
patients  (Steven  et  al.,  1996;;  Steven  et  al.,  1997;;  Callan  et  al.,  1998;;  Catalina  et  al.,  2001;;  
Hislop  et  al.,  2002;;  Pudney  et  al.,  2005).  The  most  dominant  responses  in  acute  infection  are  
specific  for  IE  and  E  lytic  cycle  antigens,  representing  anywhere  between  1%  and  40%  of  total  
CD8+  T  cells.  In  addition,  IE  epitopes  are  most  efficiently  presented  and  recognized  by  effector  
CD8+  T  cells.  As  the  lytic  cycle  progresses  (IE  >  E  >  L),  the  efficiency  in  epitope  presentation  
and   immunodominance  decreases   (Pudney   et  al.,   2005).  On   the  other  hand,   responses   to  
latent  antigens  during  acute  infection  are  delayed  and  in  lower  frequencies,  representing  0.1%  
to  5%  of  total  CD8+  T  cells.  The  most  dominant  latent  epitopes  are  from  the  EBNA3A,  3B  and  
3C  family  of  proteins.    
Interestingly,  the  size  or  the  response  to  an  epitope  observed  in  primary  infection  does  
not  correlate  with  memory  responses  to  an  epitope  of  the  same  type  (Hislop  et  al.,  2002)  and  
clones   that   dominate   in   the   acute   infection   are   heavily   culled   as   the   primary   response  
decreases   and   T-­cell   memory   arises   (Callan   et   al.,   2000).   In   a   study   by   Catalina   and  
colleagues,   they   show   that   whille   specific   CD8+   T   cells   to   the   lytic   protein   BMLF-­1   are  
maintained  through  latency,  CD8+  T  cell  specificities  to  other  lytic  proteins,  BZLF-­1  and  BRLF-­
1,  were  not  maintained.  On   the  other  hand,  specificities   to   latent  antigens  were  maintained  
1  year  post  EBV  infection  (Catalina  et  al.,  2001).  In  another  study,  BZLF1-­specific  CD8+  T  cells  
continuously   increased   during   the   presentation   of   IM   and   were   still   present   during  
convalescence  (Precopio  et  al.,  2003).  
Even   though   latent  EBV   infection   is   usually   largely   controlled,   viral   shedding   in   the  
oropharynx  remains  high  for  months  in  patients  with  IM.  Upon  observing  responses  localized  
to   the   tonsils,   it   was   shown   that   during   acute   IM,   EBV-­specific   effectors   were   much   less  
frequent   in   the   tonsil   than   in  blood.   In   recently   recovered  patients,  CD8+  T  cells  specific   to  
latent  epitopes  were  faster  to  acquire  CCR7,  populate  the  tonsil  and  remain  there,  relative  to  
lytic  specificities.  On  the  other  hand,  asymptomatic  EBV  carriers  not  only  possessed  a  large  
proportion  of  total  tonsillar  EBV-­specific  CD8+  T  cells,  but  also  a  great  enrichment  of  both  lytic  
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and  latent  epitope  reactivities  in  the  tonsil,  suggesting  appropriate  homing  of  EBV-­specific  cells  
during  efficient  immune  control  (Hislop  et  al.,  2005).  
EBV-­specific  CD8+  T  cells  in  IM  blood  are  of  CD45RO+  activated  effector  phenotype  
(Callan  et  al.,  1998).  They  additionally  express  intracellular  perforin,  are  cytotoxic  and  show  
heterogeneity   in   inflammatory   cytokine   production.   As   the   majority   of   T   cells   are   culled  
following   acute   infection,   EBV-­specific   T   cells   are   sensitive   to   apoptosis.   It   has   been  
demonstrated  that  the  majority  of  EBV-­specific  T  cells  in  IM  patients  have  low  levels  of  anti-­
apoptotic  Bcl-­2  (Tamaru  et  al.,  1993;;  Callan  et  al.,  2000)  and  are  programmed  for  cell  death  
via   the  mitochondrial/cytokine   rescuable   pathway.  When  PBMCs   isolated   from   IM   patients  
were  stimulated  with  cytokines  IL-­2,  IL-­7  and  IL-­15,   it   improved  the  survival  of  EBV-­specific  
T  cells,  protecting  them  against  cell  death  (Callan  et  al.,  2000).  
EBV-­specific  memory  CD8
+  T  cells  specific  for  lytic  and  latent  epitopes  are  negative  for  
activation  markers,  yet  still  keep  their  cytotoxic  potential,  as  seen  in  ex  vivo  studies  (Hislop  et  
al.,  2001).  Even  though  much  lower  than  in  acute  disease,  lytic  epitope-­specific  CD8+  T  cells  
constitute  around  0.2%   to  2%  and   latent  specificities  0.05%   to  1%  of   the   total  CD8+  T  cell  
population  to  control  the  asymptomatic  infection  (Hislop  et  al.,  2007).  At  IM  diagnosis,  EBV-­
specific  CD8+   T   cells   consist  mainly   of  CD27+  memory  T   cells   and  CD27-­   effector   T   cells.  
Six  months  after  IM  diagnosis,  the  remaining  CD8+  T  cells  consist  mainly  of  the  CD27+  memory  
T  cells  (Scherrenburg  et  al.,  2008).  
Unlike  for  CD8+  T  cells,  much  is  unknown  about  the  response  of  CD4+  T  cells  in  primary  
EBV   infection,  mostly  due   to   their   low   frequency.  CD4+  T  cells  did  not  expand  during  early  
stages  of  acute  EBV  infection,  however  it  could  be  possible  that  a  slight  expansion  occurred  
during  the  incubation  time  before  disease  onset  and  patient  recruitment.  During  IM,  up  to  2.7%  
of  circulating  effector  and  memory  CD4+  T  cells  are  EBV  specific.  In  contrast  with  the  CD8+  
T  cell  response  largely  recognizing  lytic  proteins,  the  CD4+  cell  response  is  directed  against  
both  lytic  and  latent  antigens  (Precopio  et  al.,  2003).  CD4+  T  cells  against  an  epitope  derived  
from   the   lytic   antigen   BHRF1  were   identified.   These   T   cell   clones   showed   cytolytic   action  
against   autologous   and   allogeneic   LCLs,   together  with   strong   IFNγ   production,   suggesting  
a  contribution  of  EBV-­specific  CD4+  T  cells   in  the  control  of  EBV  replication  (Landais  et  al.,  
2004).  During  IM,  CD4+  T  cells  specific  for  the  lytic  antigen  BZLF1  were  highest  at  presentation  
and   dominant   over   CD8+   T   cells,   and   declined   6   months   after   IM   (Precopio   et   al.,   2003;;  
Scherrenburg  et  al.,  2008).  On  the  other  hand,  CD4+  and  CD8+  T  cells  specific  for  EBNA1  were  
low  for  half  a  year  following  IM  (Scherrenburg  et  al.,  2008).  
During  latency,  memory  EBV-­specific  CD4+  T  cells  are  likely  present  in  low  numbers  
and  may  be  kept  at  sites  of  viral   reactivation  such  as  the  tonsil.   In  a  study  by  Paludan  and  
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colleagues,  EBNA1-­specific  CD4+  T  cells   in   the  peripheral  blood  of  healthy   individuals  with  
latent  EBV  infection  represent  around  0.5%  of  CD4+  T  cells  (Paludan  et  al.,  2002).  EBV-­specific  
CD4+   T   cell   lines   generated   from   healthy,   EBV-­seropositive   individuals   were   specific   for  
EBNA1  and  EBNA3C  (Munz  et  al.,  2000;;  Steigerwald-­Mullen  et  al.,  2000)  and  specificities  to  
EBNA1,  EBNA3C,  LMP1  and  LMP2  were  detected  with  ELISPOT  assays  (Leen  et  al.,  2001).  
Interestingly,  stimulating  donor-­derived  T  cells  with  autologous  LCLs  in  vitro  generates  
EBV-­specific  T  cells   that  have  been  used  successfully   to   target  EBV  positive  malignancies,  
such  as  EBV  positive  post-­transplant  lymphoproliferative  disease  (PTLD)  (Linnerbauer  et  al.,  
2014).   The  CD4+   T   cells   in   these   cultures   express   IFNγ   and   cytotoxic  molecules   and   can  
control  outgrowth  of  tumor  cells  in  vitro  (Long  et  al.,  2009)  and  in  an  in  vivo  mouse  model  of  
PTLD  (Linnerbauer  et  al.,  2014).  The  specificities  of   the  CD4+  T  cells   in   these  cultures  are  
largely  unknown.  CD4+  T  cells  specific  for  virion  antigens  were  tumor-­protective,  however  the  
best  effectors  were  CD4+  T  cells   likely  specific  for  self-­antigens  upregulated  by  transformed  
cells  (Long  et  al.,  2009;;  Linnerbauer  et  al.,  2014).  
  
1.1.6   Humoral immunity to EBV 
Primary   acute   infection   can   be   diagnosed   serologically   by   the   presence   of   IgM  
antibodies  against   the  viral   capsid  antigen   (VCA)   in   the  absence  of   IgG   to  EBNA1.  During  
transition  from  acute  primary  to  persistent  infection,  VCA  IgM  antibodies  disappear  and  VCA  
and/or  EBNA1  IgG  antibodies  emerge  (Silins  et  al.,  2001;;  Middeldorp,  2015).  
In  summary,  EBV  is  a  ubiquitous  human  herpesvirus  which  can  cause  acute  infectious  
mononucleosis  in  a  portion  of  individuals.  In  cases  of  weaker  EBV  immune  surveillance  such  
as   during   immunosuppression,   EBV   is   associated   with   several   cancers   (Delecluse   et   al.,  
2007).  On  the  other  hand,  a  heightened  and  dysregulated  response  to  primary  EBV  infection  









1.2     Multiple Sclerosis 
  
1.2.1 Pathology 
Multiple  sclerosis  (MS)  is  an  immune-­mediated,  demyelinating  and  neurodegenerative  
disease   of   the   central   nervous   system   (CNS)   with  multifactorial   etiology.   The   pathological  
hallmark  of  the  disease  is  the  formation  of  demyelinating  lesions  found  in  the  grey  and  white  
matter   of   the   brain   and   spinal   cord,   yet   the   clinical   manifestations   of   the   disease   are  
heterogeneous   (Sospedra  and  Martin,  2005).  As  a  major  cause  of  neurological  disability   in  
young  adults,  symptoms  include  changes  in  vision,  sensation,  mobility,  cognition  and  balance  
(Brownlee  et  al.,  2017).  
Four   clinical   courses   of   MS   have   been   defined   (Lublin   and   Reingold,   1996).   The  
diagnosis   is   largely  based  on   the  presence  of   symptoms  and  MRI   findings  of  CNS   lesions  
characteristic   to   MS   (Polman   et   al.,   2011);;   their   dissemination   across   the   CNS   and  
dissemination  over   time   (Filippi  et  al.,  2018).  The  majority  of  patients   (85-­90%)  experience  
episodes  of  reversible  neurological  dysfunction,  or  relapses,  in  the  initial  phases  of  the  disease,  
known  as   the  clinically   isolated  syndrome  (CIS)  and  during   relapsing-­remitting  MS  (RRMS)  
(Fig.  2).  These  relapses  last  several  days  to  weeks,  occur  at   irregular  intervals  with  varying  
neurological   recovery  and  are   followed  by  periods  of   remission.  The  mean  age  at  onset  of  
RRMS   is  30  years,  however   there  are  cases  of  pediatric  MS,  where   the   first  demyelination  
event   takes   place   before   the   age   of   18   (Yeshokumar   et   al.,   2017).   The   disease   is   more  
prevalent  in  women,  with  female  to  male  ratio  of  around  3:1  (Orton  et  al.,  2006).  With  time,  the  
disability  may  progress,  permanent  neurological  deficits  can  develop  and  the  disease  is  then  
characterized  as  secondary  progressive  MS  (SPMS)  (Lublin  and  Reingold,  1996).      
A  minority  of  patients  (10-­15%)  is  diagnosed  with  primary  progressive  MS  (PPMS),  in  
which  permanent  neurological  disability  progressively  increases  from  disease  onset  (Polman  
et  al.,  2011).  The  mean  age  at  onset  is  higher  than  for  RRMS  (40  years)  and  without  a  sex  
bias  (Lublin  et  al.,  2014).  Finally,  progressive  relapsing  MS  (PRMS)  is  a  rare  disease  course  
that  is  characterized  by  the  continuing  progression  of  disease  from  onset  with  periods  of  acute  
relapses  (Lublin  and  Reingold,  1996).  In  addition,  the  subtypes  of  the  disease  can  be  classified  
as  active  or  inactive  depending  on  clinical  observations,  relapses  and  lesion  activity  (Lublin  et  





Figure  2:  Evolution  and  disease  course  of  MS.  During  the  subclinical  phase  before  symptom  onset,  
many   risk   factors   interact   together   to  predispose   to  MS,   including  genetics,  EBV   infection,  smoking,  
vitamin  D  deficiency  and  obesity.  The  important  time  for  these  interactions  is  adolescence.  Blue  area  
represents  disease  progression,  with  spikes  indicating  damage  to  the  CNS  during  RRMS,  followed  by  
a  steady  increase  in  neurological  dysfunction  during  SPMS.  During  the  course  of  disease,  brain  volume  
decreases   and   inflammatory   episodes   in   the   CNS   are   more   frequent   than   clinical   relapses   (black  
arrows).  
(Adapted  from  (Olsson  et  al.,  2017).
  
1.2.2 MS immunopathology 
1.2.2.1 Infiltrating lymphocytes 
In  1868,  Charcot  was  the  first  to  describe  MS  symptoms  and  lesions  in  the  brain  and  
spinal  cord  (Pearce,  2005).  Inflammatory  lesions  contain  different  types  of  immune  cells.  Most  
are  T  cells,  dominated  by  CD8+  T  cells,  and  they  infiltrate  early  in  lesion  formation  (Dendrou  et  
al.,   2015).   It   was   demonstrated   that   the   majority   of   infiltrating   CD8+   T   cells   in   actively  
demyelinating  lesions  belonged  to  a  few  clones,  while  there  was  more  heterogeneity  amongst  
CD4+  T  cells  (Babbe  et  al.,  2000).  These  active  lesions  are  mostly  observed  in  patients  with  
acute  or  RRMS.  In  contrast  to  active  lesions,  inactive  lesions  contain  lower  numbers  of  T  cells  
(Frischer   et   al.,   2009).   MS   is   believed   to   be   an   autoimmune   disease   with   autoreactive  
lymphocytes  initiating  responses  against  CNS  autoantigens,  the  nature  of  which  is  unknown  
(Dendrou  et  al.,  2015).  The  disease  is  thought  to  be  induced  and  perpetuated  by  autoreactive  
CD4+  T  cells  for  the  following  reasons.  CD4+  T  cells  infiltrate  into  the  CNS  of  MS  patients  and  
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the  main  genetic  risk  for  MS  is  conferred  by  major  histocompatibility  complex  (MHC)  class  II  
molecules,  HLA-­DR  and  DQ.  Additionally,   humanized  mice   transgenic   for   these  molecules  
and/or  myelin-­basic  protein   (MBP)-­specific  T  cell   receptors  are  susceptible   to  experimental  
autoimmune  encephalomyelitis  (EAE)  and  finally,  CD8+  T  cell  maturation,  antibody  production,  
inflammatory   cytokine  production  and  other   functions  are  partly   controlled  by  CD4+   T   cells  
(Sospedra  and  Martin,  2005)    (Fig.  3).    
B  cells  are  also  present,  but  on  average  the  numbers  are  10  times  lower  than  those  of  
T   cells.   Plasma   cells   are   only   sparsely   present   and   show   little   relation   to   lesional   activity  
(Frischer  et  al.,  2009).    
Most  profound  inflammation  is  observed  in  patients  with  acute  or  RRMS,  followed  by  
progressive   disease.   Interestingly,   in   late   stages   of   disease,   inflammation   is   seen   to  
considerably  decline  in  a  large  proportion  of  patients.  Even  though  T  and,  to  a  lesser  extent,  
B  cells  are  markers  for  disease  activity  and  tissue  damage,  they  interestingly  show  different  
distribution  patterns.  While  T  cells  are  seen  especially  in  active  lesions  and  CNS  parenchyma,  
B  cells  and  plasma  cells  tend  to  accumulate  in  the  connective  tissue  spaces  of  the  brain,  like  
the  meninges  and  perivascular  spaces.  In  addition,  plasma  cells  accumulate  in  later  disease  
stages  and  can  persist  even  after  T  and  B  cell  inflammation  is  cleared  (Frischer  et  al.,  2009),  
which  could  explain  long-­lasting  oligoclonal  bands  in  the  CSF  (Meinl  et  al.,  2006).  
Highlighting   the   role  of  B  cells   in  MS,  B  cell-­depleting  antibody   treatments,  such  as  
rituximab  (anti-­CD20)  and  ocrelizumab  (anti-­CD20)  have  shown  positive  effects  in  MS  patients  
through   the   reduction   of   inflammatory   brain   lesions   (Hauser   et   al.,   2008).   An   important  
question  in  MS  is  how  disease-­relevant  T  and  B  cells  interact  with  each  other  before  disease  
onset   in   the  periphery  and  also   in  structures  such  as   the   tertiary   lymphoid  structures   in   the  
meninges  of  MS  patients.   Indeed,  B   cells   can   contribute   to  MS  pathogenesis  by  acting  as  
antigen-­presenting  cells  (APCs)  to  autoreactive  T  cells  and  providing  co-­stimulatory  signals,  
recruiting  autoreactive  T  cells   into   the  CNS  and  producing  myelin-­specific  antibodies  which  
can   lead   to  myelin  destruction  (Sospedra  and  Martin,  2005).   Interestingly,  auto-­proliferating  
peripheral   T   helper   1   (TH1)   cells   are   more   frequent   in   MS   patients   positive   for   the   HLA-­
DRB1*15:01   (HLA-­DR15)  haplotype,  which   is  mediated  by  memory  B  cells   in  an  HLA-­DR-­
dependent  manner.  Depletion  of  B  cells  with  anti-­CD20  reduces  this  autoproliferation  (Mohme  
et  al.,  2013;;  Jelcic  et  al.,  2018).  
Therapies   that   target   inflammation   and   the   immune   system   have   been   effective   in  
RRMS,  but  with  the  exception  of  the  B  cell  depleting  therapies  not  in  progressive  MS,  pointing  
towards  different  mechanisms  being  responsible  for  these  disease  stages  (Lassmann,  2013)  
and  for  driving  relapses  versus  chronic  disease  progression.   In   the  early  stages  of  MS,   the  
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inflammation  is  associated  with  a  leaky  blood-­brain  barrier  (BBB),  allowing  inflammatory  cells  
to  enter  the  CNS.  On  the  other  hand,  in  progressive  disease,  signs  of  inflammation  are  rather  
seen   around   vessels   with   an   intact   BBB   (Hochmeister   et   al.,   2006),   suggesting   that   the  
inflammatory   response  could  be  partly   trapped   in   the  CNS.   Indeed,   in  patients  with  SPMS,  
inflammatory   cell-­containing   structures   resembling   lymphoid   follicles   with   high   numbers   of  
B   cells   and   plasma   cells   were   observed   in   the   meninges   (Serafini   et   al.,   2004).   These  
structures  were  associated  with  an  increase  in  meningeal   inflammation,  grey  matter  cortical  
demyelination   and   accelerated   clinical   course   (Howell   et   al.,   2011).   However,   secondary  
progressive  disease  might  not  only  be  the  follow-­up  after  relapsing-­remitting  phase,  but  might  
in  fact  be  the  result  of  a  distinct  pathophysiological  mechanism  (Dendrou  et  al.,  2015).  
Experimental  autoimmune  encephalomyelitis  (EAE)   is   the  accepted  animal  model  of  
MS,  in  which  CNS  inflammation  and  disability  are  results  of  sensitization  with  CNS  antigens.  
While  EAE  has  provided  valuable  insights  into  basic  immune  mechanisms  in  the  CNS,  there  
have  also  been  some  discrepancies  with  human  MS   (Gold  et  al.,  2006).  Several   therapies  
which  seemed  attractive  from  EAE  studies  failed  in  human  patients.    
EAE  worsened  under  TNF  treatment  (Kuroda  and  Shimamoto,  1991)  and  there  was  
disease   protection   after   administration   of   neutralizing   anti-­TNF   antibodies   (Ruddle   et   al.,  
1990).  However,  when  lenercept,  a  recombinant  TNF  receptor,  was  used  in  a  phase  II  clinical  
trial,  patients  experienced  exacerbations  of  disease  and   the  exacerbations  occurred  earlier  
when   compared  with   patients   receiving   placebo.  Neurologic   deficits   in   addition  were  more  
severe   in   lenercept-­treated   patients   (1999).   IFNγ  was   partially   protective   in   EAE,   however  
administering  it  to  patients  resulted  in  disease  exacerbation  and  relapses  (Panitch  et  al.,  1987).  
Similarly,   the   interleukin   (IL)-­12   p40   cytokines   IL-­12   and   IL-­23,   with   central   roles   in   the  
differentiation  of  the  proinflammatory  TH1  and  TH17  CD4
+  T  cells,  have  been  implicated  in  both  
MS  and  EAE.  Neutralizing  the  IL-­12  p40  subunit  prevented  EAE  development  in  rodents  and  
non-­human  primates  (Leonard  et  al.,  1995;;  Brok  et  al.,  2002)  and  in  marmosets  was  able  to  
delay   demyelination   and   suppress   inflammation   of   pre-­existing   brain   lesions   (t   Hart   et   al.,  
2005).   However,   when  MS   patients   were   treated   with   ustekinumab,   a   neutralizing   human  
monoclonal  antibody  against  IL-­12/23  p40,  their  disease  activity  was  not  improved  (Segal  et  
al.,   2008),   suggesting   either   poor   availability   to   the   CNS,   or   the   involvement   of   other  




Figure  3:  Peripheral   immune  system  dysregulation.  Most  autoreactive  T   cells  are  deleted   in   the  
thymus   as   part   of   central   tolerance.   Nevertheless,   some   autoreactive   T   cells   are   released   into   the  
periphery   and   should  be   removed  during  peripheral   tolerance.   If   this   process   is   defective,   either   by  
inefficient  function  of  regulatory  T  cells  (TREG)  or  resistance  of  lymphocytes,  autoreactive  T  and  B  cells  
can   get   activated,   differentiate   into   effector   cells   through   processes   of   molecular   mimicry,   novel  
autoantigen  presentation,  bystander  activation  or  leak  of  CNS  antigens  into  the  periphery.  Differentiated  
activated  lymphocytes  can  then  infiltrate  into  the  CNS  and  trigger  or  perpetuate  inflammation  and  tissue  
damage.  Both  environmental  and  genetic  risk  factors  act  alone  or  interact  together  to  contribute  to  these  
events.  Dashed  arrows  indicate  differentiation.  
(Dendrou  et  al.,  2015).
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1.2.2.2 CNS-resident cells 
Macrophages  and  microglial  cells  were  observed  in  all  active  lesions  (Frischer  et  al.,  
2009).  The  highest  numbers  of  macrophages  infiltrate  early  and  late  active  lesions,  typically  
seen  in  acute  or  RRMS,  and  contain  different  myelin  components  in  their  lysosomes  (Bruck  et  
al.,  1995).  On  the  other  hand,  the  majority  of  lesions  in  progressive  disease  show  an  inactive  
lesion  core,  surrounded  by  a  thin  edge  of  activated  microglia  and  macrophages  (Prineas  et  al.,  
2001).  
Oxidative   burst   and   oxidative   damage,   mediated   by   activated   macrophages   and  
microglia  driven  by  inflammation,  is  an  important  mechanism  contributing  to  tissue  injury  in  all  
lesions  in  MS  (Lassmann  and  van  Horssen,  2011).  Oxidative  damage  causes  mitochondrial  
injury  and  dysfunction.  This  can  mediate  tissue  damage  through  processes  of  energy  failure,  
apoptosis   induction  and  increased  production  of  reactive  oxygen  species  (ROS),  as  well  as  
being  involved  in  oligodendrocyte  destruction  (Veto  et  al.,  2010).  Indeed,  the  molecules  that  
play   a   role   in   oxidative   burst   pathways   are   strongly   up-­regulated   in   active   MS   lesions  
(Lassmann  and  van  Horssen,  2011).  
Damage  to  oligodendrocytes,  in  addition  to  their  destruction  through  apoptosis  (Barnett  
and   Prineas,   2004)   and   consequent   demyelination,   are   results   of   inflammation.   Axonal  
degeneration,  likely  caused  by  the  effects  of  the  inflammatory  environment,  is  a  consequence  
of  demyelination  and  their  damage  is  seen  in  both  active  and  chronic  lesions  in  the  brains  of  
MS  patients  (Trapp  et  al.,  1998).  Acute  axonal  damage  is  most  extensive  in  the  early  stages  
of  disease  and  correlates  to  the  numbers  of  CD8
+  T  cells  (Kuhlmann  et  al.,  2002).  In  addition,  
with  lesion  maturation,  axonal  loss  is  seen  and  correlates  to  irreversible  neurological  disability  
(Bjartmar  et  al.,  2000).  Upon  examining  all   lesion  stages   from  MS  patients,  a  correlation   is  
observed  between  the  number  of  inflammatory  cells  with  the  extent  of  acute  axonal  injury.  The  
correlation   is   strongest   for   T   cells,   HLA-­D   positive   macrophages   and   microglia   and   was  
observed  in  all  MS  patients  (Frischer  et  al.,  2009).  
  
1.2.3 Genetic MS risk factors 
MS  is  a  multifactorial  autoimmune  disease  and  the  etiology  of  the  disease  is  not  yet  
completely  understood.  The  disease  clusters  with  complex  genetic  diseases,  characterized  by  
moderate  disease-­risk  heritability  and  intricate  gene-­environment  interactions  (Oksenberg  et  
al.,  2008).  There  are  hundreds  of  risk  factors  that  have  been  implicated  in  this  disease,  both  
genetic  and  environmental.  
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1.2.3.1 HLA locus 
MHC   molecules   present   extracellular   or   intracellular   peptides   to   T   cells   and   are  
essential  for  the  start  of  the  adaptive  immune  response.  As  is  the  case  with  many  autoimmune  
diseases,  the  human  leukocyte  antigen  (HLA)  gene  cluster  on  chromosome  6p21.3  coding  for  
MHC  has  for  decades  been  associated  with  the  disease.  Now,  with  clear  evidence,   it   is  the  
strongest   susceptibility   locus   for  MS   in   the   genome   (Sawcer   et   al.,   2005).   From   this   HLA  
cluster,  the  MHC  class  II  haplotype,  which  consists  of  the  alleles  HLA-­DRB1*15:01  (DR2b,  or  
HLA-­DR15),  HLA-­DRB5*01:01   (DR2a),  HLA-­DQA1*01:02  and  HLA-­DQB1*06:02  existing   in  
linkage  disequilibrium,  bears   the  greatest   effect   on   risk   (Sawcer   et   al.,   2014).   Isolating   the  
association  of   individual   variants  has  been  difficult  due   to   the  extensive  polymorphism  and  
linkage  disequilibrium  that  exists  within  the  MHC  region  of  the  genome  (Horton  et  al.,  2008).  
In   the   last   few  years  however,  with   the   rise  of   technical  and  statistical  methods   to   type   for  
single   nucleotide   polymorphisms   (SNPs)   in   large   cohorts,   progress   has   been   made   in  
identifying  further  genetic  determinants  (Sawcer  et  al.,  2005;;  Bush  et  al.,  2010).  It  has  become  
apparent   that   the   HLA-­DR15   allele   drives   the   association,   with   the   other   alleles   in   the  
haplotype  being  associated  due  to  linkage  disequilibrium  with  HLA-­DR15  (Patsopoulos  et  al.,  
2013).    
The  MHC  class  II  variant  HLA-­DR15  increases  the  risk  of  MS  with  an  odds  ratio  (OR)  
of   3,  whilst   an  MHC   class   I   variant  HLA-­A*02   associates  with   protection   from   the   disease  
(OR  ∼  0.6)  (Brynedal  et  al.,  2007;;  Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013;;  Patsopoulos  et  
al.,  2013).  
  
1.2.3.2 Non-HLA loci  
Over   the   last   decade,   several   genome-­wide   association   studies   (GWAS)   identified  
many  loci  that  appeared  to  have  a  role  in  MS  susceptibility  (Hafler  et  al.,  2007;;  Wellcome  Trust  
Case   Control   et   al.,   2007;;   Australia   and   New   Zealand   Multiple   Sclerosis   Genetics,   2009;;  
Baranzini  et  al.,  2009;;  De  Jager  et  al.,  2009;;  Sanna  et  al.,  2010;;  Patsopoulos  et  al.,  2011).  
However,  it  seemed  larger  sample  sizes  would  be  required  to  examine  the  complex  genetic  
architecture.   In   2011,   the   International   Multiple   Sclerosis   Genetics   Consortium   (IMSGC)  
performed   a   collaborative   GWAS,   including   9777   subjects.   In   addition   to   replicating   the  
majority  of  the  loci  previously  observed,  this  work  identified  29  novel  variants  associated  with  
MS   risk   (Sawcer   et   al.,   2011).   Two   years   later,   the   IMSGC   expanded   this   to   include   five  
additional   loci,   which   in   the   previous   study   have   shown   sub-­genome-­wide   significance  
(International  Multiple  Sclerosis  Genetics  et  al.,  2013)  and  also  performed  an   ImmunoChip  
custom   genotyping   array   on   14   498  multiple   sclerosis   subjects,   identifying   further   48   new  
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susceptibility   loci   (Beecham  et  al.,  2013).   In   the   last   few  years,   two   larger  studies   from   the  
IMSGC   genotyping   genome-­wide   data   of   tens   of   thousands   of   MS   patients   and   controls  
increased  the  number  of   risk  variants  associated  with  MS  to  >230,  mostly   lying  outside   the  
MHC  locus  (Cotsapas  and  Genetics,  2018;;  International  Multiple  Sclerosis  Genetics,  2019).    
In   the   first  described  110  variants,  15  of   them  were  predicted  to  be  coding  variants,  
with  an  additional  35   in  strong   linkage  disequilibrium  with  other  coding  variants.  Also,  all  of  
these  SNPs  coincide  with  areas  of  chromatin  suggestive  of   regulatory   function;;  91  variants  
change  at  least  one  regulatory  sequence  motif  and  a  further  18  are  in  linkage  disequilibrium  
with  other  variants  that  can  do  so.  Moreover,  27  variants  are  placed  within  transcription-­factor  
binding  sites  and  again,  51  show  to  be  in  linkage  disequilibrium  with  similar  SNPs.  Among  the  
variants,  15  are  quantitative  trait  loci  for  gene  expression,  with  16  in  linkage  disequilibrium  with  
others   (Sawcer   et   al.,   2014).   The   nearest   gene   to   the   specific   SNP   was   identified   and  
interestingly,   these  MS-­associated  SNPs   frequently   lie   in  gene   regulatory   regions  of  genes  
that  mainly  play  a  role  in  the  adaptive  immune  response,  more  specifically  in  T  cell  activation  
and   proliferation   and   T   helper   cell   differentiation.   The   relevant   genes   include   cytokine  
pathways,   co-­stimulatory   molecules   and   immunologically-­relevant   signal   transduction  
molecules   (Sawcer   et   al.,   2014).   In   a   larger   meta-­analysis   by   the   IMSGC   in   2018,   low-­
frequency  risk  variants  were  shown  to  make  up  5%  of  MS  heritability.  Whilst   the  study  also  
highlights  T  cell  homeostasis  pathways,  IFNγ  biology  and  NFkB  signaling  in  MS  pathogenesis,  
it  identifies  four  novel  genes  driving  MS  risk,  two  of  which  (PRKRA  and  NLRP8)  are  involved  
in   innate   immunity   and   HDAC7   with   roles   in   thymic   T   cell   development   (Cotsapas   and  
Genetics,  2018).    
Interestingly,  the  study  by  IMSGC  in  2019  mapping  MS  genomics  highlights  pathways  
involved   in   both   innate   and   adaptive   immunity   and   spanning   many   cell   types,   with   an  
enrichment  of  MS-­associated  genes  was  seen   in  microglia.   In  addition,  a   few   loci   influence  
gene  expression   in   the  human  cortex  but  not   in   individual   immune  cells  within  and   there   is  
robust   evidence   for   a   susceptibility   locus   on   the   X   chromosome   (International   Multiple  
Sclerosis   Genetics,   2019).   All   these   studies   further   highlight   the   immune-­mediated  
pathogenesis  of  MS  (Sawcer  et  al.,  2014).  
  The  direct  effects  and  roles  of  these  risk  variants  are  largely  unknown,  however  a  few  
have  observable  functional  effects.  As  one  example,  the  SNP  rs1800693  in  TNFRSF1A  leads  
to  higher  concentrations  of  the  soluble  form  of  the  tumor  necrosis  factor  receptor  1  (TNFR1),  
which  can  in  turn  block  TNF  (Gregory  et  al.,  2012).  As  drugs  that  act  to  block  TNF  have  led  to  
exacerbation  of  MS  (van  Oosten  et  al.,  1996;;  Arnason  et  al.,  1999),  this  work  clearly  shows  
the   importance   of   studying   the   functional   consequences   of   the   disease-­association   risk  
variants.    
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The  MS-­associated  variants  that  have  been  discovered  are  thought  to  only  represent  
about  25%  of  the  heritability  in  the  disease.  While  another  25%  could  account  for  variants  that  
have  not  yet  been  discovered,  it  is  possible  that  the  other  50%  is  “phantom  heritability”  (Zuk  et  
al.,  2012),  which  results  from  risk  factor  interactions  (Sawcer  et  al.,  2014).    Even  though  the  
odds  ratios  of   individual  SNPs  are  estimated  to  be  quite  small  (around  1.14-­1.58),   it   is  very  
unlikely  that  they  act   in   isolation,  as  the  genetic  risk  of  MS  is  clearly  polygenic  (Bush  et  al.,  
2010).    
Within   families,   the   risk   of   MS   between   siblings   was   reported   to   be   15-­20-­fold  
increased,   and   the   concordance   rate   between   identical   twins  was   30%   (Oksenberg   et   al.,  
2008;;  Beecham  et  al.,  2013).  However,  more  recent  population-­based  studies  have  estimated  
the  sibling’s   risk   to  be  7-­fold   (Westerlind  et  al.,  2014).  Together,   this  suggests   that  a   large  
portion  of  MS  risk  lies  outside  genetics.    
  
1.2.4 Environmental MS risk factors 
Even  though  MS  is  a  relatively  common  disease,  the  burden  of  MS  across  the  world  is  
not   the   same.   There   are   a   great   number   of   environmental   factors   that   influence  MS   risk,  
ranging  from  gender,  age,  ethnicity,  latitude  to  viral  agents.  MS  is  a  rare  disease  in  the  tropical  
and  subtropical  regions  and  the  incidence  and  prevalence  increases  with  latitude,  both  to  the  
north  and  south  of  the  equator.  The  prevalence  saw  a  10.4%  increase  from  1990  to  2016,  with  
highest   to   lowest   prevalence   estimated   in   high-­income  North   America   (164.6   per   100   000  
population),   western   Europe   (127.0),   Australasia   (91.1),   eastern   sub-­Saharan   Africa   (3.3),  
central  sub-­Saharan  Africa  (2.8)  and  Oceania  (2.0)  (Wallin  et  al.,  2019).    
Among   pre-­teen   children,   the   prevalence   of   MS   is   similar   between   the   two   sexes,  
however  during  adolescence,  the  prevalence  starts  to  diverge,  increasing  more  for  girls  than  
for  boys  (Wallin  et  al.,  2019).  Women  additionally  see  a  higher  increase  in  MS  incidence  (Koch-­
Henriksen  et  al.,  2018),  and  the  female  to  male  ratio  is  1.5-­2.5:1  in  most  populations  (3.2:1  in  
Canada)  and  increasing  over  the  last  50  years  (Orton  et  al.,  2006).  As  genetic  differences  are  
unlikely  in  this  short  period  of  time,  the  increase  is  likely  to  result  from  environmental  or  gene-­
environment  interactions  (Orton  et  al.,  2006).    
Whilst  genetic  predisposition  is  a  very   likely  contributor  to  the  geographic  variations,  
migration  studies  further  support  a  role  for  environmental  factors.  A  crucial  period  of  exposure  
to  environmental   triggers  seems  to  be  in  the  first   two  decades  of   life,  as  immigrant  children  
take  on  the  MS  risk  of  the  host  country,  whilst  older  migrants  retain  the  low  risk  of  their  country  
of  origin.  Likewise,  migrants  that  have  come  from  low  risk  countries  to  high  risk  retain  low  risk,  
however  their  children  show  an  MS  risk  approaching  the  host  country  (Gale  and  Martyn,  1995).    
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The   possibility   of   an   infectious   agent   responsible   for   the   epidemiology   of   MS   was  
examined.   Two   hypotheses   were   originally   proposed.   The   first,   termed   the   poliomyelitis  
hypothesis  (Poskanzer  et  al.,  1963),  postulated  that  a  virus  acquired  early  in  childhood  would  
confer  protection,  whereas  if  acquired  later  in  life  would  increase  the  risk  of  MS.  The  second,  
termed   prevalence   hypothesis   (Kurtzke,   1993),   suggested   that   a   high-­risk   MS   area   has  
a  common  pathogen,  which  asymptomatically  persists  in  the  majority  of  individuals  and  only  
rarely,  and  years  after  primary  infection,  could  cause  MS  symptoms.  With  more  evidence  for  
the  former  hypothesis,  it  changed  more  into  a  general  hygiene  hypothesis.  First  proposed  in  
a  study   in   Israel,   it   linked  better  hygiene   to   the  etiology  of  MS   (Leibowitz  et  al.,  1966)  and  
suggested  that  the  increased  prevalence  of  autoimmune  diseases  in  industrialized  countries  
is  partly  due  to  the  reduction  of  infectious  diseases  in  these  areas  (Bach,  2002).  Additionally,  
hypotheses   arose   that   the   pathogenesis   of   MS   could   be   autoimmune,   with   a   common  
pathogen  driving  or  initiating  autoimmunity,  and  the  risk  increasing  with  age  of  infection  (Hafler,  
1999;;  Hunter   and  Hafler,   2000).  Due   to   a   large   array   of   infectious   agents   and   diversity   of  
immune   responses,   the  chance  of  all   infectious  agents   to  be   involved   in  MS   risk  was  very  




As  EBV  infects  the  majority  of  the  worldwide  population,  the  associated  increase  in  MS  
risk  has  been  puzzling  for  many  years.  However,  studies  in  pediatric  MS  patients  helped  to  
strengthen  the  evidence.  In  a  pediatric  MS  cohort,  it  was  demonstrated  that  83%  of  patients  
had  serological  evidence  of  EBV  infection,  compared  to  42%  control  children  (Alotaibi  et  al.,  
2004),  and  almost  complete  EBV  seropositivity  (98.6%  pediatric  MS  patients  versus  72.1%  in  
controls)   in   a   larger   study   (Pohl   et   al.,   2006).   Additionally,   utilizing   the   stored   serum   of  
>8  million  active-­duty  personnel,  Levin  and  colleagues  could  show  that  all  adult  MS  patients  
seroconverted   to   EBV   before   their   disease   onset.   This   argues   that   EBV   seronegative  
individuals  have  an  extremely   low   risk  of  MS,  but  sharply   increase   their   risk   following  EBV  
seroconversion  (Levin  et  al.,  2010).  Asymptomatic  EBV  infection  confers  MS  risk,  however  this  
risk  sharply  increases  following  IM  in  adolescence  and  early  adulthood  (Thacker  et  al.,  2006;;  
Handel  et  al.,  2010;;  Endriz  et  al.,  2017).  Interestingly,  this  risk  synergizes  with  the  HLA-­DR15  
haplotype  for  a  7-­fold  increased  MS  risk  (Olsson  et  al.,  2017).  An  important  question  in  MS  is  
how  does  EBV  infection  contribute  to  the  risk  of  MS,  whether  it  is  a  question  of  cross-­reactivity  
and  molecular  mimicry  and/or  a  general  role  in  immune  dysregulation,  and  the  mechanisms  
behind   the   synergy   of   genetics  with  EBV.  These  and   related   questions   on   how  an  altered  
immune  response  to  EBV  contributes  to  MS  risk  will  be  discussed  in  more  details  in  this  thesis.  
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1.2.4.2 Smoking, vitamin D deficiency and obesity 
Several  other  environmental   risk   factors  have  been   linked   to  MS.     Smokers  of  both  
sexes  have  an  increased  risk  of  developing  MS  (OR  1.5)  and  the  increase  in  smoking  dose  
increases  the  risk  (Hedstrom  et  al.,  2009;;  Handel  et  al.,  2011).    In  addition,  smoking  interacts  
with  MS-­associated  HLA  risk  alleles,   further   increasing   the  ORs.  As  even  passive  smoking  
shows  an  increased  risk  (OR  1.3),  the  effects  might  be  a  result  of  nonspecific   lung  irritation  
(Hedstrom   et   al.,   2011;;   Hedstrom   et   al.,   2014a),   together   with   smoking-­protomoted  
proinflammatory  pathways  (Shan  et  al.,  2009)  and  citrunillation  of  peptides  (Klareskog  et  al.,  
2009).  
Low  vitamin  D  levels  also  increase  MS  risk.  In  a  study  by  Munger  and  colleagues  using  
stored  serum  of  US  military  personnel,  increasing  levels  of  vitamin  D  significantly  decreased  
the   risk   of   MS   in   Caucasians,   especially   before   20   years   of   age   (Munger   et   al.,   2006).  
Suggesting   an   important   role   in   T   cell   homeostasis,   vitamin   D   was   able   to   inhibit   the  
proliferation  of  CD4
+  T  cells  isolated  from  MS  patients.  In  addition,  a  boost  in  the  development  
of  IL-­10-­producing  cells  and  an  increase  in  regulatory  T  cells  was  seen,  whilst  reducing  the  
amounts  of  cells  secreting  IL-­6  and  IL-­17  (Correale  et  al.,  2009).  Interestingly,  an  interaction  
between  vitamin  D  and  the  HLA-­DR15  allele  has  also  been  observed  in  in  vitro  studies.  A  highly  
conserved  vitamin  D  response  element  was  found  in  the  promoter  of  this  specific  HLA  allele  
and  was  responsive  to  vitamin  D  in   influencing  gene  expression.    This  responsiveness  was  
not  observed  with  other  HLA-­DRB1  haplotypes  (Ramagopalan  et  al.,  2009).    Even  though  this  
finding  was  not  reproduced  in  a  case-­control  study  (Baarnhielm  et  al.,  2012),  the  interaction  is  
yet  to  be  understood.  
Finally,  adolescent  obesity  has  been  associated  with  an  increased  risk  for  MS  (Munger  
et  al.,  2009;;  Hedstrom  et  al.,  2012)  and  particularly   in  girls   for  pediatric-­onset  MS  (Langer-­
Gould  et  al.,  2013).  Again,  an  interaction  with  HLA-­DR15  has  been  observed  (Hedstrom  et  al.,  
2014b).  While  the  mechanisms  behind  the  interactions  are  unknown,   it   is  hypothesized  that  
chronic,  obesity-­related  inflammation  and  activation  of  the  innate  immune  system  (Gregor  and  
Hotamisligil,   2011)   could   lead   to   a   boost   in   the   activation   of   autoreactive   T   cells   via   HLA  
presentation  (Lumeng  et  al.,  2007;;  Hedstrom  et  al.,  2014b).  As  obese  people  have  lower  levels  
of  vitamin  D,  another  hypothesis  points   towards   the  effect  of   lower   levels  of   this  metabolite  
(Wortsman  et  al.,  2000).  Interestingly,  an  interaction  has  been  observed  between  obesity  and  
EBV  infection  (Hedstrom  et  al.,  2014b)  and  remains  largely  speculative.  
In  summary,  MS  is  an  autoimmune  disease  believed  to  be  induced  and  perpetuated  by  
autoreactive  CD4
+  T  cells.  Whilst  more  than  200  genetic  risk  factors  and  several  environmental  
risk  factors  have  been  associated  with  MS  risk,  their  exact  roles  in  disease  pathomechanisms  
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still   require   further   study.   In   particular,   the   interactions   between   MS   genetics   and   the  



























1.3     Humanized mice 
  
1.3.1 Humanized mouse models 
The  study  of  EBV  infection  in  a  murine  model  is  difficult,  as  the  gamma  1  herpesvirus  
subfamily  developed  in  and  evolved  with  monkeys  and  primates  (Ehlers  et  al.,  2010)  and  thus  
has  a  narrow  species  tropism.  The  murine  gamma-­herpesvirus  68  is  a  close  relative  to  EBV  
and  shares  some  similarities  making  it  a  valuable  small  animal  model.  However,  differences  
such   as   the   lungs   as   the   site   of   acute   infection,   infection   of   not   only   B   cells   but   also  
macrophages,  dendritic  cells  and   lung  epithelial   cells,   low  B  cell   transforming  capacity  and  
specificity  of  the  CD8+  T  cell  expansion  (Flano  et  al.,  2002),  amongst  others,  has  made  it  a  less  
ideal  suitable  candidate  to  study  acute  EBV  infection  and  tumorigenesis.    
As  a  model  to  investigate  the  basic  biology  of  EBV,  as  well  as  gain  an  insight  into  EBV-­
specific   immune  control,  mice   reconstituted  with  human   immune  system  components  have  
shown   success.   These   are   severely   immunodeficient   mouse   strains,   which   allow   for   the  
engraftment  of  human  cells  and  study  of  human-­tropic  pathogens.  The  most  popular  are  the  
BALB/c   or   non-­obese   diabetic   (NOD)  mouse   strains,  which   harbor   scid   or  RAG  mutations  
together  with  deletions  of  the  common  gamma  chain  (γc)  of  interleukin  (IL)-­2,4,7,9,15  and  21  
(BALB/c   RAG2-­/-­   γc
-­/-­:   BRG   and   NOD-­scid   γc
-­/-­:   NSG).   With   these   mutations,   animals   lack  
mature  murine  T  and  B   lymphocytes,  as   these  cells  cannot  somatically   rearrange  or   repair  
their  receptors.  In  addition,  without  signaling  through  the  γc,  the  development  of  murine  innate  
lymphocytes   is   abolished,   as  well   as   IL-­15-­dependent  NK   cell  maturation   (Ito   et   al.,   2002;;  
Traggiai  et  al.,  2004;;  Ishikawa  et  al.,  2005;;  Shultz  et  al.,  2005).    
NSG  animals  injected  with  CD34+  progenitor  cells  reconstitute  up  to  50-­80%  of  mature  
human  blood  cells,  including  myeloid  cells,  dendritic  cells  and  lymphocytes.  Human  cells  are  
found  in  peripheral  blood,  bone  marrow,  spleen  and  thymus.  The  thymus  displays  some  signs  
of  a  typical   thymic  architecture  with  cortex  and  medulla  structures  with  mostly  CD3+  human  
T  cells,  as  well  as  human  B  cells  and  human  DC-­like  APCs  (Yahata  et  al.,  2002).  In  addition,  
the   human   CD3+   thymocytes   express   TCR-­αβ,   suggestive   of   terminally   differentiated  
thymocytes   and   hence   evidence   for   a   thymic   program   capable   of   leading   full   T   cell  
development.  In  the  periphery,  the  majority  of  T  cells  express  either  CD4  or  CD8,  TCR-­αβ  and  
CD45RA,  suggestive  of  a  naïve  T  cell  phenotype.  A  fraction  of  T  cells  also  express  TCR-­γδ  
(Yahata  et  al.,  2002).  Reconstitution  is  maintained  for  up  to  a  year  and  unlike  with  the  earlier  
NOD-­scid  animal  model,  T  cell  lymphomas  were  not  observed  (Ishikawa  et  al.,  2005).    
In  a  NOD/shi-­scid/γc
null  (NOG)  humanized  mouse  model  reconstituted  with  cord  blood-­
derived  CD34+  hematopoietic  stem  cells,  most  of   the  IgM  and/or   IgG  positive  B  cells  are   in  
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peripheral  blood  in  the  naïve  state.  Around  40%  of  B  cells  in  the  spleen  are  B  cell  progenitors.  
In  in  vitro  cultures,  stimulated  IgD+  B  cells  were  able  to  produce  both  IgM  and  IgG,  suggesting  
responsiveness   of   mature   B   cells   to   antigenic   challenge   and   Ig   class   switch   capacity.  
Development  of  both  CD4+  and  CD8+  T  cells  was  observed  in  both  the  thymus  and  spleen  and  
while  they  proliferated  upon  stimulation,  the  response  was  not  robust,  especially  from  CD4+  
T   cells.   Upon   examining   CD4+   T   cells   isolated   from   the   thymus   or   spleen,   this  
unresponsiveness  was  induced  in  the  periphery  as  thymic  T  cells  showed  strong  responses,  
suggesting  mechanisms  of  tolerance  induction  against  mouse  periphery.  Interestingly,  a  small  
percentage   of   human  CD4+   T   cells   reconstituted  with   a   significant   delay   in   a  NOG  mouse  
model   lacking  I-­A,  suggesting  the  HLA  molecules  on  the  human  T  cells,  B  cells  or  dendritic  
cells  were  able   to   positively   select  T   cells   in   the   thymus.  Nevertheless,   the  delay   in  T   cell  
development  suggests  that  I-­A  on  mouse  thymus  epithelial  cells  plays  a  significant  role  in  the  
human  T  cell  positive  selection  (Watanabe  et  al.,  2009).  
  
1.3.2 T cell selection in humanized mice 
How  human  T  cells  are  selected  on  mouse  thymic  cells  remains  unclear.  However,  it  
has   been   shown   that   in   the   BRG   and   NSG   model,   reconstituted   T   cells   were   able   to  
discriminate   between   self   and   allogeneic  MHC   (Yahata   et   al.,   2002;;   Traggiai   et   al.,   2004;;  
Ishikawa  et  al.,  2005).  In  the  NSG  mouse,  the  thymus  is  mostly  populated  with  human  T  cells  
and  a  few  B  cells.  Most  of  these  T  cells  are  immature  CD4+CD8+  double  positive,  with  a  small  
fraction  of  single  positive  cells,  suggesting  the  presence  of  T  cell  development  in  the  mouse  
thymus   (Ishikawa  et  al.,  2005).  As   the  development  of  T  cells   is   restricted  by  human  MHC  
(hMHC),   it   is   possible   that   human  B   cells   and  DCs   play   a   role   in   the   thymocyte   selection  
(Yahata   et   al.,   2002).   As   another   possibility,  mouse   epithelial   cells  might   also   support   the  
education  of  human  T  cells   (Yahata  et  al.,  2002),  as   the  human  CD8  co-­receptor   is  able   to  
interact  with  murine  MHC  (mMHC)  class  I  (Moots  et  al.,  1992)  and  human  CD4  with  mMHC  
class  II  (Vignali  et  al.,  1992).  Indeed,  MHC  class  II  positive  mouse  thymic  microenvironment  
was  able  to  positively  select  TCR-­αβ  +  CD4+  single  positive  human  cells.  However,  these  cells  
were   not   responsive   to   PHA   and   IL-­2   and   did   not   represent   a   developmentally   end   stage  
population.  While  they  are  able  to  interact  with  mMHC  class  II  during  maturation,  a  species-­
specific   signal   is   then   required   for   full   maturity   and   functionality   (Res   et   al.,   1997).  
Reconstituted  T  cells  did  not  respond  to  murine  cells,  indicative  of  tolerance.  In  addition,  these  
cells  are  also  not  reactive  to  autologous  HLA  human  antigens,  suggesting  additional  tolerance  
to  autologous  antigens,  possibly  presented  by  human  cells  in  the  thymus.  As  a  result,  during  
negative  selection   in  the  mouse  thymus,   it   is  possible  that  cells  reactive  to  both  autologous  
human  and  murine  antigens  have  been  deleted  (Yahata  et  al.,  2002).  
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1.3.3 EBV infection in humanized mice 
One  method  of  humanized  mouse  generation,  and  a  method  that  is  employed  in  our  
laboratory,   includes   the   intrahepatic   injection   of   human   fetal   liver-­derived   hematopoietic  
progenitor  cells  (HPCs)  into  sublethally  irradiated,  newborn  mice.  Following  EBV  infection  of  
these  animals  with  the  B95-­8  EBV  strain,  which  was  isolated  from  an  American  patient  with  IM  
(Miller   and   Lipman,   1973),   we   see   specific   viral   immune   control.   IFN-­α   responses   by  
plasmacytoid  dendritic  cells  are  seen  early  in  infection,  followed  by  NK  cell  responses  to  lytic  
EBV  antigens  between  weeks  2  and  5  of   the   infection,  and  a  protective  mainly  CD8+  T  cell  
expansion  starting  to  be  prominent  from  week  4  (Chatterjee  et  al.,  2014;;  Gujer  et  al.,  2015).  
Splenomegaly   observed   in   these  animals   is   likely   due   to  T   cell   expansion   in   responses   to  
increasing  viral  titers.  
EBV  infection  in  humanized  mice  can  have  both  latent  and  lytic  programs  (Strowig  et  
al.,  2009;;  Chijioke  et  al.,  2013;;  Tsai  et  al.,  2013)  and  infected  B  cells  are  found  mostly  in  the  
latency   III   program,  as  shown  with   immunohistochemistry   staining   for  EBNA1,  EBNA2  and  
LMP1,  or  with   in  situ  hybridization  staining   for  EBV-­encoded  RNAs   (EBERs)   (Cocco  et  al.,  
2008;;  Strowig  et  al.,  2009).  Depending  on  the  dose  administered,  an  asymptomatic  persistent  
infection  course,  or  a  more  acute   IM-­like   infection  can  be  seen   (Yajima  et  al.,  2008).  Even  
though   lytic   EBV-­infected   B   cells   are   found   in   humanized  mice,   they   are   outnumbered   by  
latently   infected   cells.  Persistent   infection   does  not   depend  on   lytic   replication,   as   an  EBV  
mutant  deficient  for  BZLF1  was  still  able  to  establish  latent  infection  in  humanized  mice  (Ma  et  
al.,  2011;;  Chijioke  et  al.,  2013;;  Antsiferova  et  al.,  2014).      
While   humoral   immune   responses   are   weak   in   humanized   mice   due   to   inefficient  
germinal  center  organization  and  class  switching,  CD4
+  and  CD8+  T  cells  are  reconstituted  and  
both  are   important   for   the  control  of  EBV  (Strowig  et  al.,  2009;;  Yajima  et  al.,  2009).  During  
EBV  infection  of  HLA-­A2  transgenic  animals,  T  cells  against  both  lytic  and  latent  antigens  are  
seen,  even  so  often  with  dissimilar  peptide  specificities  than  in  humans  (Strowig  et  al.,  2009;;  
Shultz   et   al.,   2010).   EBV-­specific   CD8+   T   cells   can   produce   IFNγ   in   response   to   cognate  
epitopes  (Strowig  et  al.,  2009)  and  autologous  LCLs  (Traggiai  et  al.,  2004;;  Melkus  et  al.,  2006;;  
Yajima  et  al.,  2008).  Moreover,  both  CD4+  and  CD8+  T  cells  isolated  from  EBV-­infected  animals  
are  able  to  lyse  LCLs  (Strowig  et  al.,  2009).  Thus,  cell-­mediated,  but  not  antibody  mediated  
immune  responses  to  EBV  can  be  modelled  in  humanized  mice  and  their  modification  by  MS  




1.4 Aims of the study 
 
In  this  PhD  thesis,  the  broad  aim  was  to  investigate  MS-­associated  risk  factors  in  the  
context  of  EBV  infection.  In  the  first  project,  we  investigated  effects  on  EBV  immune  control  
in  the  context  of  the  main  genetic  risk  factor  for  MS,  the  HLA-­DR15  MHC  class  II  allele.  In  the  
second  project,  we  aimed  to  generate  an  NSG  mouse  model  transgenic  for  HLA-­DR15,  with  
which  we  could  study  in  more  detail  results  obtained  in  the  first  project,  as  well  use  this  mouse  
model  to   investigate  autoimmunity   in  the  context  of  this  MHC  molecule.  Finally,   in  the  third  
project,   we   wanted   to   further   look   into   several   other   genetic   risk   variants   that   have   been  
implicated  in  the  risk  of  MS.  Using  our  model  of  EBV  infection,  we  wanted  to  determine  causal  
variants  from  a  pre-­selected  list  of  SNPs,  which  could  contribute  to  defects   in  EBV  immune  
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Immune  responses  to  Epstein  Barr  virus  (EBV)  infection  synergize  with  the  main  genetic  risk  
factor  HLA-­DRB1*15:01   (HLA-­DR15)   to   increase   the   likelihood   to  develop   the  autoimmune  
disease  multiple  sclerosis  at   least  seven-­fold.   In  order  to  gain   insights   into  this  synergy,  we  
investigated  HLA-­DR15  positive  human  immune  compartments  after  reconstitution  in  immune  
compromised  mice  (humanized  mice)  with  and  without  EBV  infection.  We  detected  elevated  
activation  of  both  CD4+  and  CD8+  T  cells   in  HLA-­DR15  positive  humanized  mice  at  steady  
state,  even  when  compared  to   immune  compartments  carrying  the  HLA-­DRB1*04:01  (HLA-­
DR4)   gene,   which   is   associated   with   other   autoimmune   diseases.   Increased   CD8+   T   cell  
expansion  and  activation  was  also  observed  in  HLA-­DR15  positive  humanized  mice  after  EBV  
infection.  Despite  this  higher  immune  activation,  EBV  viral  loads  were  less  well  controlled  in  
the  context  of  HLA-­DR15.  Indeed,  when  we  cloned  HLA-­DR15  or  HLA-­DR4-­restricted  CD4+  
T   cells   specific   for   EBV-­transformed  B   cell   lines   (LCLs),   HLA-­DR15-­restricted  CD4+   T   cell  
clones  recognized  LCLs  less  efficiently  and  demonstrated  cross-­reactivity  towards  allogeneic  
target  cells.  These  findings  suggest  that  EBV  as  one  of  the  main  environmental  risk  factors  
and  HLA-­DR15   as   the  main   genetic   risk   factor   for  multiple   sclerosis   synergize   by   priming  
hyperreactive   T   cell   compartments,   which   then   control   EBV   infection   less   efficiently   and  
















Multiple   sclerosis   is   an   inflammatory,   demyelinating   disease   of   the   central   nervous  
system  (CNS).  It  affects  around  2.5  million  people  worldwide  and  leads  to  substantial  decline  
of   sensory,   motor,   autonomic   and   neurocognitive   functions.   While   considered   to   be   an  
autoimmune,   CD4+   T   cell-­mediated   disorder,   its   etiology   still   remains   poorly   understood  
(Sospedra  and  Martin,  2005).    
Over  the  last  few  years,  genome-­wide  association  studies  have  provided  great  insights  
into   the   complex   genetics   behind   multiple   sclerosis,   identifying   over   100   genetic   loci   that  
contribute  to  the  risk  of  acquiring  the  disease.  The  strongest  association  has  been  observed  
with  the  human  leukocyte  antigen  (HLA)  locus,  and  in  particular,  the  HLA-­DRB1*15:01  (HLA-­
DR15)  allele   in   the  HLA-­DRB1  gene.  Other   identified   loci   represent  mainly   immunologically  
relevant  genes  and  particularly  suggest  a  role  for  T  helper  cell  differentiation  and  function  in  
the  disease  pathogenesis  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013).  
However,  because  the  genetic  background  confers  only  partial  risk  for  the  disease,  the  
role   for  environmental   risk   factors  and   their  synergies  with  multiple  sclerosis  genetics  have  
become  increasingly  apparent  (Olsson  et  al.,  2017),  especially  in  the  first  two  decades  of  life  
(Gale   and   Martyn,   1995).   Amongst   several   environmental   factors   implicated   in   multiple  
sclerosis,   altered   immune   response   to   the   Epstein-­Barr   virus   (EBV),   including  
immunopathology  during  the  acute  primary  EBV  infection  known  as  infectious  mononucleosis  
(IM),  is  associated  with  the  disease  and  synergizes  with  HLA-­DR15  resulting  in  a  seven-­fold  
increased  risk  for  multiple  sclerosis  (Nielsen  et  al.,  2009).  The  mechanisms  behind  this  synergy  
remain  unclear.      
EBV  is  a  ubiquitous  γ-­herpesvirus  infecting  around  95%  of  the  world  adult  population  
(Niederman,   1982).  Following  oral   transmission   (Niederman   et   al.,   1976),   it   starts   a   latent,  
growth  transforming  infection  of  B  cells  and  persists  in  their  memory  compartment  (Pattengale  
et  al.,  1974;;  Babcock  et  al.,  1998).  EBV  is  generally  acquired  early  in  childhood  and  leads  to  
an  asymptomatic  primary  infection  at  young  age  (Biggar  et  al.,  1978a).  However,  if  acquired  in  
adolescence  or  early  adulthood,   it   can  manifest  as   IM   (Niederman,  1982),  an  acute   illness  
presenting  with   fever,  sore   throat,   lymphadenopathy  and   fatigue   (Balfour  et  al.,  2013).  The  
acute  infection  sparks  a  vigorous  immune  response,  characterized  by  immensely  expanded  
EBV-­specific  CD8
+  T  cells  and,  to  a  lesser  extent,  NK  cells  (Odumade  et  al.,  2012;;  Balfour  et  
al.,   2013;;  Chijioke   et   al.,   2013).  Why   IM   is   a   phenomenon   largely   of   late   primary   infection  
remains  incompletely  understood,  however  research  points  towards  immunopathogenic  and  
exaggerated  T  cell  responses  (Silins  et  al.,  2001;;  Abbott  et  al.,  2017).  
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Viral  and   infectious  agents  have  been  thought   to  play  a  role   in  multiple  sclerosis   for  
decades  (Poskanzer  et  al.,  1963;;  Leibowitz  et  al.,  1966;;  Kurtzke,  1993),  however,  because  
EBV  is  distributed  worldwide,  the  evidence  supporting  its  role  in  the  disease  was  puzzling  at  
first.  In  2006,  Pohl  and  colleagues  demonstrated  that  near-­complete  EBV  seropositivity  was  
seen  in  pediatric  multiple  sclerosis  patients,  compared  to  72%  of  control  children  (Pohl  et  al.,  
2006).  Similar  results  were  also  shown  in  an  earlier  study  (Alotaibi  et  al.,  2004)  and  in  addition,  
adult  multiple  sclerosis  patients  all  became  EBV  positive  prior   to  disease  onset,  suggesting  
that  multiple   sclerosis   risk   is   extremely   low   in  EBV   seronegative   individuals,   but   increases  
sharply  after  EBV  infection  (Levin  et  al.,  2010).  Indeed,  higher  anti-­EBV  antibody  titers  were  
observed  before  multiple  sclerosis  onset  (Ascherio  et  al.,  2001)  and  are  associated  with  its  risk  
(Levin  et  al.,  2005).  The  genetic   risk   for  elevated  anti-­EBV  nuclear  antigen  1   (EBNA1)   IgG  
titers  was  also  shown  to  positively  correlate  with  the  development  of  multiple  sclerosis  (Zhou  
et  al.,  2016).  In  addition  to  the  increase  in  risk  following  asymptomatic  EBV  infection,  this  risk  
is  further  increased  after  IM  in  adolescence  or  early  adulthood  (Thacker  et  al.,  2006;;  Handel  
et  al.,  2010;;  Endriz  et  al.,  2017).  IM  and  multiple  sclerosis  share  not  only  similar  patterns  of  
geographical   distribution,   socioeconomic   status   and   ethnicity,   but   also   the   period   of  
adolescence  as  an  important  window  for  both  diseases  (Niederman,  1982;;  Gale  and  Martyn,  
1995).  Thus,  rather  than  EBV  infection  itself,  elevated  T  cell  and  antibody  responses  to  EBV  
are  associated  with  risk  of  multiple  sclerosis.  
Evidence   suggests   dysregulated   adaptive   immunity   to   be   at   the   core   of   multiple  
sclerosis  (Sospedra  and  Martin,  2005;;  Dendrou  et  al.,  2015).  HLA  class  II  molecules,  such  as  
HLA-­DR15,  are  expressed  on  antigen  presenting  cells  (Roche  and  Furuta,  2015).  They  present  
peptides   derived   from   self   or   foreign   proteins   to   CD4
+   T   cells,   which   then   support   and  
strengthen  cellular  and  humoral  immune  responses  (Swain  et  al.,  2012).  Indeed,  in  addition  to  
the   importance   of   CD4+   T   cells   in   multiple   sclerosis   pathogenesis,   evidence   from   CNS-­
infiltrating  immune  cells  in  patients  and  B  cell-­depleting  therapies  suggests  additional  roles  for  
CD8+  T  cells,  B  cells  and  autoantibodies   in   the  disease   (Babbe  et  al.,  2000;;  Hauser  et  al.,  
2008;;  Hauser  et  al.,  2017),  supported  by  or  supporting  autoimmune  CD4+  T  cell  responses.  
Interestingly,  EBV  as  a   risk   factor  has  also  been  shown   to   interact  with  HLA  genes  
implicated  in  multiple  sclerosis  (Olsson  et  al.,  2017).  Antibodies  against  specific  domains  of  
EBNA-­1   in  HLA-­DRB1*15:01  positive   individuals  are  associated  with  a  markedly   increased  
multiple  sclerosis  risk  (Sundstrom  et  al.,  2009)  and  synergize  with  the  susceptible  HLA  allele,  
as  does  IM  (Sundqvist  et  al.,  2012).  However,  adequate  models  are  missing  to  study  these  
interactions.  Using  a  humanized  mouse  model  (huNSG)  of  EBV  infection,  we  investigated  the  
role  of  HLA-­DR15   in   the   immune  control  of  EBV.  Using  data  accumulated   in  our   laboratory  
over  several  years,  we  were  able  to  stratify  animals  reconstituted  with  HLA-­DR15  positive  and  
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negative  donors  and  investigate  basal  T  cell  activation  before  and  after  IM-­like  EBV  infection,  
as  well   as   T   cell   expansion,   viral   loads   and   responses   of  CD4+   T   cells   cloned   from   these  
animals.  With  our  in  vivo  and  in  vitro  data,  we  have  demonstrated  that  T  cells  from  HLA-­DR15  
positive  donors  have  higher  basal  activation  levels.  Despite  enhanced  T  cell  proliferation,  EBV  
viral  loads  are  elevated  which  suggests  an  impaired  T  cell-­mediated  immune  control  of  EBV  
under   the   restriction   of   HLA-­DR15.   Importantly,   we   also   find   evidence   for   increased  
alloreactivity   in  CD4+   T   cell   clones  derived   from  HLA-­DR15   individuals.  Our  data  offers  an  
insight   into  the  gene-­environment   interactions  that  could  lead  or  add  to  the  perturbed  T  cell  







 donors reconstitute hyperactive T cells in huNSG animals  
We   first   wanted   to   investigate   the   effect   of   HLA-­DR15   positive   donors   on   T   cell  
activation  at  steady  state  in  humanized  NOD-­scid  IL2  receptor  γ-­chain-­deficient  (huNSG)  mice,  
as  the  MHC  class  II  molecule  HLA-­DR15  carries  the  strongest  genetic  risk  for  multiple  sclerosis  
(Sawcer  et  al.,  2011).  To  this  end,  we  combined  and  stratified  data  from  more  than  3500  mice  
spanning  six  years  of  reconstitution  experiments  (Fig.  4A  and  B).  Briefly,  following  intrahepatic  
injection  of  human  fetal  liver-­derived  human  hematopoietic  progenitor  cells  (i.e.  donor)  shortly  
after  birth,  animals  were  routinely  bled  after  3  months  to  check  for  the  reconstitution  of  human  
immune  system  components   in  peripheral  blood  at  steady  state.  Animals  reconstituted  with  
HLA-­DR15  positive  donors  demonstrated  a  higher  activation  of  total  T  cells,  CD4
+  and  CD8+  
T  cells  when  compared  to  animals  reconstituted  with  HLA-­DR15  negative  donors  (Fig.  4A).  
This  T  cell  activation  was  mainly  observed  among  CD4+  T  cells,  which  constitute  around  two  
thirds  of  the  T  cells  after  reconstitution.  Furthermore,  a  higher  activation  frequency  in  the  T  cell  
compartment   was   also   seen   upon   reconstitution   with   HLA-­DR15   positive   donors   when  
compared  with  donors  positive  for  HLA-­DR4  (Fig.  4B),  an  MHC  class  II  molecule  implicated  in  
other  autoimmune  diseases,   including   rheumatoid  arthritis  and   type   I  diabetes   (Fugger  and  
Svejgaard,   2000;;   Noble   and   Valdes,   2011).   These   findings   illustrate   that   HLA-­DR15  
hematopoietic  progenitor  cells  reconstitute  hyperactive  T  cells  in  the  huNSG  mouse  model  at  




Figure  4:  Higher  T  cell  activation  in  HLA-­DR15
+
  donor-­reconstituted  huNSG  mice.  Three  months  
post   reconstitution,   animals   were   bled   and   analyzed   for   reconstitution   of   human   immune   system  






),  HLA-­DR15  positive  (DR15
+
)  (A)  and  HLA-­DR4  positive  (DR4
+
)  (B)  donors.  T  cell  activation  was  
analyzed   by   positive   staining   of  HLA-­DR   (DR).  Data   shown   are   combined   from  >   96   (n   of   animals  
=  3579)  (A)  and  51  (n  of  animals  =  1139)  (B)  donors.  *  p  <  0.05,  **  p  <  0.01,  ****  p  <  0.0001,  significant  
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comparisons  are  indicated  and  significance  is  based  on  the  Mann-­Whitney  U  test.  Each  symbol  indicates  
one  animal  (mean  ±  SEM). 
 
2.4.2 HLA-DR15 alters CD8
+
 T cell frequencies and activation during EBV infection of 
huNSG mice 
One  of  the  hallmarks  of  IM  is  the  vast  expansion  of  CD8+  T  cells,  which  are  key  to  the  
immune  control  of  EBV  (Callan  et  al.,  1996;;  Strowig  et  al.,  2009).  As  the  huNSG  mouse  model  
has  been  successfully  used  to  study  IM-­like  EBV  infection  (Gujer  et  al.,  2015),  we  examined  
the  expansion  of  T  cells  following  EBV  infection  in  animals  reconstituted  with  donors  positive  
or  negative  for  HLA-­DR15.    
During  these  experiments,  animals  are  infected  with  a  high  dose  (105  infectious  units)  
of  the  B95-­8  strain  of  EBV  and  monitored  for  four  to  six  weeks  (Fig.  5A).  We  first  wanted  to  
investigate  T  cell  expansion  following  EBV  infection  at  time  of  sacrifice  (Fig.  5B-­I).  Even  though  
EBV   infection   induces  a   large  expansion  of  CD8+   T   cells,  we  observed  higher   frequencies  
(Fig.  5B  and  5C)  and  total  numbers  (Fig.  5D  and  5E)  in  huNSG  mice  reconstituted  with  HLA-­
DR15  positive  versus  negative  donors   in  both  blood  and  spleen.  While  we  didn’t  observe  a  
difference  in  the  frequencies  of  CD4+  T  cells  (Fig.  5F  and  5G)  and  total  numbers  in  spleen  (Fig.  
5I),  we  did  see  higher  total  numbers  of  CD4+  T  cells  in  the  blood  of  HLA-­DR15-­reconstituted  
animals  (Fig.  5H).  Higher  total  numbers  of  total  T  cells  were  also  observed  (Supplementary  





Figure  5:  EBV-­infected  HLA-­DR15
+
-­reconstituted  mice  have  higher  frequencies  of  CD8
+  
T  cells.  
Schematic   depiction   of   analysed   EBV   infection   experiments.   After   3-­5   months   of   human   immune  
compartment  reconstitution,  animals  were  injected  with  10
5
  EBV  infectious  units  or  PBS  intraperitoneally  




T  cells   in  blood  and  spleen  (B  and  C),  total  numbers  of  CD8
+  
T  cells   in  blood  and  spleen  (D  and  E),  
frequencies  of  CD4
+
  T  cells  in  blood  and  spleen  (F  and  G),  and  total  numbers  of  CD4
+
  T  cells  in  blood  





)  and  HLA-­DR15  positive  (DR15
+
)  donors.  Data  shown  are  combined  from  11  to  
24  experiments  and  contain  19-­65  animals  per  group.  *  p  <  0.05,  **  p  <  0.01,  significant  comparisons  
are  indicated  and  significance  is  based  on  the  Mann-­Whitney  U  test.  Each  symbol  indicates  one  animal  
(mean  ±  SEM). 
 
In   addition,   there   were   higher   numbers   of   activated   total   T   cells   (Supplementary  
Fig.  1E,  1F)  and  CD8+  T  cells  (Fig.  6A  and  6B)  in  blood  and  spleen  of  HLA-­DR15-­reconstituted  
animals.   No   differences   were   observed   in   the   activation   of   the   CD4+   T   cell   compartment  
(Fig.  6C  and  6D).  These  observations  suggest  a  more  robust,  HLA-­DR15-­associated  T  cell  




Figure  6:  EBV-­infected  HLA-­DR15
+
-­reconstituted  mice  have  higher  numbers  of  activated  CD8
+  
T  cells.  As  indicated,  animals  were  injected  with  10
5
  EBV  infectious  units  or  PBS  intraperitoneally.  At  
time   of   sacrifice   (4-­6  weeks   post   infection),   total   numbers   of   activated  CD8
+  
T   cells   (A   and  B)   and  
activated  CD4
+
  T  cells  (C  and  D)   in  blood  and  spleen,  respectively,  were  analysed  and  stratified  into  




)  and  HLA-­DR15  positive  (DR15
+
)  donors.  T  cell  
activation   was   analyzed   by   positive   staining   of   HLA-­DR.   Data   shown   are   combined   from   11   to   13  
experiments  and  contain  19-­32  animals  per  group.  *  p  <  0.05,  **  p  <  0.01,  significant  comparisons  are  
indicated  and  significance   is  based  on   the  Mann-­Whitney  U   test.  Each  symbol   indicates  one  animal  
(mean  ±  SEM). 
 
2.4.3 Reduced EBV-specific immune control in HLA-DR15-reconstituted huNSG 
In  our  huNSG  model  of  EBV  infection  (105  infectious  particles),  blood  viral  DNA  loads  
are   usually   detectable   at   three   weeks   post   infection   (Gujer   et   al.,   2015).   Interestingly,   we  
observed  a  higher  EBV  viral  load  at  time  of  sacrifice  in  animals  reconstituted  with  HLA-­DR15  
positive  versus  HLA-­DR15  negative  donors  (Fig.  7A)  or  HLA-­DR4  positive  donors  (Fig.  7B).  It  
has   previously   been   shown   that  CD8+   T   cell   expansion   and   blood   viral   load   are   positively  
correlated  with   disease   severity   in   IM   patients   (Balfour   et   al.,   2013).   Indeed,  we   observed  
positive  correlations  between  EBV  viral  loads  in  the  blood  and  frequencies  of  activated  CD8+  
T   cells   in   the  blood   (Fig.   7C),   as  well   as  EBV  viral   loads   in   the  spleen  and   frequencies  of  
activated  CD8+  T  cells  in  the  spleen  (Fig.  7D).  Total  numbers  of  activated  CD8+  T  cells  in  blood  
and  spleen  also  correlated  with  respective  EBV  viral  loads  (Supplementary  Fig.  2A  and  2B).  
This  data,  together  with  increased  frequencies  (Fig.  5B-­E)  and  activation  (Fig.  6A  and  6B)  of  
CD8+  T  cells,  suggests  a  reduced  EBV-­specific  immune  control  despite  significant  CD8+  T  cell  
expansion  that  is  associated  with  HLA-­DR15.    
The  humoral  immune  response  has  been  challenging  to  study  in  the  huNSG  and  other  
humanized  mouse  models.  These  animals   lack  normal   lymph  node  development  and  have  
poor   germinal   center   organization,   thereby   hampering   B   cell   class   switching   and   affinity  
maturation  (Gujer  et  al.,  2015).  Upon  measuring  serum  anti-­EBV  nuclear  antigen  1  (EBNA1)  
immunoglobulin  M  (IgM),  we  were,  however,  able  to  find  a  fraction  of  EBV-­infected  animals  
positive  for  these  antibodies  (Fig.  7E).  The  humoral  anti-­EBNA1  IgM  titer  from  animals  with  
a  humoral  response  above  threshold  correlated  with  blood  EBV  viral  loads  (Fig.  7F),  however  
due   to   the   infrequency   of   these   IgM   responses,   we  were   not   able   to   compare  HLA-­DR15  
positive  and  negative  animals.  Thus,  EBV  is  less  well  immune  controlled  in  the  context  of  HLA-­
DR15;;  higher  viral  loads  were  observed  despite  elevated  CD8
+  T  cell  expansion.  
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Figure  7:  EBV  viral  loads  in  huNSG  mice  correlate  with  activated  CD8
+  
T  cells  and  humoral  IgM  
responses  and  are  higher  in  HLA-­DR15
+
-­reconstituted  animals.  Blood  EBV  viral   loads  at   time  of  
sacrifice   (4-­6  weeks  post   infection  with  10
5
  EBV   infectious  units)  of  animals   reconstituted  with  HLA-­
DR15   positive   (DR15
+
),   HLA-­DR15   negative   (DR15
-­
)   (n   =   42   and   70,   respectively)   (A),   HLA-­DR15  




)  and  HLA-­DR4  positive   (DR4
+
)   (n  =  38  and  22,   respectively)   (B)  
donors.  Red  lines  depict  the  median  and  significance  is  based  on  the  Mann-­Whitney  U  test  (A  and  B).  
(C)  Frequencies  of  activated  CD8
+
  T  cells  in  blood  were  plotted  relative  to  blood  EBV  viral  loads  (n  =  56).  
(D)  Frequencies  of   activated  CD8
+
   T   cells   in   spleen  were  plotted   relative   to   spleen  EBV  viral   loads  
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(n  =  60).  T  cell  activation  was  analyzed  by  positive  staining  of  HLA-­DR  (C  and  D).  (E)  Animals  were  
injected  with  10
5
  EBV  infectious  units  or  PBS  intraperitoneally.  At  time  of  sacrifice,  serum  was  collected  
and  analysed   for   anti-­EBNA1   IgM  antibodies   via  ELISA.  Red   lines   depict   the  mean  and  dotted   line  
represents  threshold  set  at  mean  +  2x  standard  deviation  of  PBS  animals  (n  PBS  =  33,  EBV  =  71).  (F)  
Levels  of  anti-­EBNA1  IgM  antibodies  of  animals  above  threshold  were  plotted  relative  to  EBV  viral  loads  
in  blood.  Data  shown  are  combined  from  11  to  28  experiments.  *  p  <  0.05,  ***  p  <  0.001,  ****  p  <  0.0001,  
significant   comparisons   are   indicated.   All   correlations   were   analyzed   using   the   nonparametric  
Spearman  correlation,  which  examines  rank  correlation.  Each  symbol  indicates  one  animal. 
 
2.4.4 Alloreactivity and lower specificity in HLA-DR15-restricted T cell clones 
As  T  cells  are  essential  for  the  immune  control  of  EBV  infection  (Strowig  et  al.,  2009)  
and   because   our   results   suggest   that  EBV  might   be   less  well   controlled   under  HLA-­DR15  
restriction,  we  examined  T  cell  responses  of  individual  CD4+  T  cell  clones.  For  this  purpose,  
CD4+  T   cell   clones   were   cloned   from   EBV-­infected,   HLA-­DR15   or   HLA-­DR4-­reconstituted  
animals  using  bare  lymphocyte  syndrome  lymphoblastoid  cell  lines  (BLCLs;;  cells  isolated  from  
bare  lymphocyte  syndrome  patients  lacking  MHC  class  II  expression)  transfected  with  single  
MHC  class  II  molecules  as  targets.  CD4+  T  cells  that  produced  IFNγ  in  response  to  either  HLA-­
DR15+  or  HLA-­DR4+  BLCLs  were  cloned  (Fig.  8A).  During  the  initial  T  cell  clone  screening  for  
IFNγ  production  via  ELISA,  we  observed  BLCL-­restricted  IFNγ  production  in  only  27%  of  HLA-­
DR15-­restricted  T  cell  clones,  versus  in  71%  of  HLA-­DR4-­restricted  T  cell  clones  tested  (data  
not  shown).  Three  HLA-­DR15-­restricted  and  two  HLA-­DR4-­restricted  CD4+  T  cell  clones  used  
in  the  assays  demonstrated  high  levels  of  activation  and  expressed  the  transcription  factor  T-­
bet,  suggestive  of  a  TH1  phenotype.  All,  except  one  HLA-­DR15-­restricted  T  cell  clone,  showed  
low  expression  of  the  transcription  factor  EOMES  (Supplementary  Fig.  3A-­C).    
To  test  their  cytotoxic  ability,  the  CD4+  T  cell  clones  were  incubated  together  with  their  
HLA   matched   or   mismatched   BLCLs   as   targets   (HLA-­DR15-­expressing   or   HLA-­DR4-­
expressing,   depending   on   the   genetic   restriction   of   the   T   cell   clone).  While   at   6   hours   of  
incubation  (Fig.  8B),  the  pattern  is  less  evident,  at  18  hours  of  incubation  (Fig.  8C),  HLA-­DR4-­
restricted  CD4+  T  cell  clones  killed  their  targets  with  higher  specificity  as  HLA-­DR15-­restricted  
CD4+  T   cell   clones  which   showed  higher   alloreactive   responses.   In   addition,   degranulation  
assessed  by  CD107a  surface  expression  and  the  cytotoxic  granule  marker  granzyme  B  were  
used   to  gain   insight   into   the  cytolytic  potential  of   the  T  cell  clones.   Interestingly,  HLA-­DR4-­
restricted  CD4+  T  cell  clones  degranulated  very  specifically,  whilst  HLA-­DR15-­restricted  CD4+  
T  cell  clones  not  only  degranulated   less,  but  also  demonstrated  significant  degranulation  to  
the   allogeneic   target   (Fig.   8D).   HLA-­DR15-­restricted   clones   also   displayed   high   granzyme  
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B  expression  when  incubated  with  both  HLA  matched  and  mismatched  targets,  whilst  HLA-­
DR4-­restricted  clones  seemed  to  up-­regulate  granzyme  B  only  upon  recognition  of  the  HLA  
matched  target  (Fig.  8E).  In  trying  to  isolate  the  specificity  of  the  responses  that  we  observed,  
the  responses  towards  HLA  mismatched  BLCLs  were  subtracted  from  the  recognition  of  HLA  




Figure   8:   HLA-­DR15-­restricted   EBV-­infected   B   cell-­specific   CD4
+
   T   cell   clones   demonstrate  
higher  alloreactivity  in  cytotoxicity.  Schematic  depiction  of  T  cell  cloning.  CD4
+
  T  cell  clones  were  
cloned  from  EBV-­infected  animals  using  bare  lymphocyte  syndrome  lymphoblastoid  cell  lines  (BLCLs)  
transfected  with  single  MHC  class  II  molecules  as  targets  using  the  IFNγ  capture  assay  (A).  HLA-­DR15  
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(DR15)  or  HLA-­DR4  (DR4)-­restricted  CD4
+  
T  cell  clone  responses  are  through  target  cell  killing  after  
6  (B)  and  18  hours  (C),  degranulation  by  marker  CD107a  surface  upregulation  after  8  hours  (D)  and  
granzyme  B  expression  after  8  hours  (E)  in  response  to  the  allogeneic  (allo)  or  autologous  (auto)  BLCL  
(HLA-­DR15-­expressing   or   HLA-­DR4-­expressing,   depending   on   the   genetic   restriction   of   the   T   cell  
clone).  To  suggest  the  specificity  of   the  response,  allo  values  were  additionally  subtracted  from  auto  
values  and  included  in  bottom  panels  (B-­E).  Three  HLA-­DR15-­restricted  and  two  HLA-­DR4-­restricted  
CD4
+  
T  cell   clones  were  used  and  data   from  2   to  7  experiments  are   included.  The  mean  ±  SEM   is  
depicted.  *  p  <  0.05,  **  p  <  0.01,  ***  p  <  0.001,  ****  p  <  0.0001,  significant  comparisons  are  indicated  
and  significance  is  based  on  the  Mann-­Whitney  U  test. 
 
In   good   agreement   with   these   observations,   intracellular   cytokine   staining   for   IFNγ  
(Fig.  9A),  TNFα   (Fig.  9B)  and   IL-­2   (Fig.  9C)   revealed  stronger  alloreactive   responses   from  
CD4+   T   cell   clones   restricted   by   HLA-­DR15.   Again,   this   is   also   evident   when   cytokine  
responses   towards   HLA  mismatched   BLCLs   were   subtracted   from   the   recognition   of   HLA  
matched  targets  (Fig.  9A-­C,  lower  panels).  These  data  suggest  weaker  HLA-­DR15-­restricted  
CD4+  T  cell  responses  against  EBV-­transformed  B  cells,  but  also  inflammatory  responses  that  
show  tendencies  towards  alloreactivity.  Thus,  the  HLA-­DR15  genetic  risk  factor  may  restrict  
EBV  specific  CD4+  T  cell   responses   that   recognize  allogeneic   target  cells  and   that  provide  
insufficient  help  to  CD8+  T  cells  in  order  to  efficiently  control  EBV  infection.  This  could  lead  to  




Figure   9:   HLA-­DR15-­restricted   EBV-­infected   B   cell-­specific   CD4
+
   T   cell   clones   show   higher  
unspecific  cytokine  production.  CD4
+
  T  cell  clones  were  cloned   from  EBV-­infected  animals  using  
bare   lymphocyte   syndrome   lymphoblastoid   cell   lines   (BLCLs)   transfected   with   single   MHC   class   II  
molecules  as  targets.  HLA-­DR15  (DR15)  or  HLA-­DR4  (DR4)-­restricted  CD4
+  
T  cell  clone  functionality  
was  examined   through   the  production  of  cytokines   IFNγ  (A),  TNFα  (B)  and   IL-­2  (C)  after  8  hours  of  
incubation   with   allogeneic   (allo)   or   autologous   (auto)   BLCL   (HLA-­DR15-­expressing   or   HLA-­DR4-­
expressing,   depending   on   the   genetic   restriction   of   the   T   cell   clone).   Allo   values   were   additionally  
subtracted  from  auto  values  and  included  in  bottom  panels  (A-­C).  Three  HLA-­DR15-­restricted  and  two  
HLA-­DR4-­restricted  CD4
+  
T  cell   clones  were  used  and  data   from  7  experiments  are   included.  Lines  
indicate  mean  ±  SEM.  **  p  <  0.01,  ***  p  <  0.001,  ****  p  <  0.0001,  significant  comparisons  are  indicated  










In  vivo  EBV  infection  of  huNSG  mice  has  allowed  us  to  study  the  interaction  between  
the  main  genetic  risk  factor  for  multiple  sclerosis,  HLA-­DR15,  with  the  main  environmental  risk  
factor,   elevated   EBV-­induced   immune   responses   (Olsson   et   al.,   2017).   Similar   to  multiple  
sclerosis  patients,  we  observed  elevated  EBV  induced  T  cell  responses  in  huNSG  mice  with  
HLA-­DR15  positive   immune  compartments   (Lunemann  et  al.,  2008a;;  Angelini  et  al.,  2013).  
These  seemed  to  result  from  a  higher  constitutive  T  cell  activation  and  increased  CD8+  T  cell  
expansion  due  to  less  well  controlled  viral  loads  in  connection  with  this  particular  MHC  class  II  
molecule.  Furthermore,  CD4+  T  cell  clones  from  these  EBV-­infected  huNSG  mice  that  were  
selected  for  HLA-­DR15-­restricted  LCL  recognition  displayed  diminished  immune  recognition  
of   EBV-­infected  B   cells   and   higher   cross-­reactivity   to  HLA-­DR  mismatched   targets.   These  
findings  point  to  both  diminished  immune  control  of  EBV  and  its  proinflammatory  effects,  as  
well   as   increased   cross-­reactivity,   possibly   resulting   in   molecular   mimicry   towards   CNS  
autoantigens   as   possible   pathogenic   mechanisms.   In   this   way,   EBV-­induced   immune  
responses  could  synergize  with  HLA-­DR15  to  enhance  multiple  sclerosis.    
Indeed,  molecular  mimicry  between  EBV  and  myelin-­derived  autoantigens  has  been  
proposed  previously.  Primarily,  EBNA1  and  lytic  EBV  antigen-­specific  antibody,  in  addition  to  
CD4
+  T  cell  responses,  are  elevated  in  patients  with  multiple  sclerosis  and  sometimes  enriched  
in  the  CNS  (Ascherio  et  al.,  2001;;  Lunemann  et  al.,  2008a;;  Lunemann  et  al.,  2008b;;  Levin  et  
al.,  2010;;  Lunemann  et  al.,  2010;;  Angelini  et  al.,  2013;;  Dooley  et  al.,  2016;;  Erdur  et  al.,  2016).  
Some  of  these  have  indeed  been  suggested  to  cross-­react  with  CNS  autoantigens,  like  myelin  
basic  protein,  heterogeneous  nuclear  ribonucleoprotein  L  or  septin-­9  (Lunemann  et  al.,  2008b;;  
Mameli  et  al.,  2014;;  Dooley  et  al.,  2016;;  Lindsey,  2017).  This  cross-­reactivity  could  amplify  
T  cell  and  antibody  responses  against  select  EBV  gene  products,  including  EBNA1,  BFRF3  
and  BRRF2  (Lunemann  et  al.,  2008b;;  Dooley  et  al.,  2016;;  Lindsey,  2017),  as  well  as  lead  to  
the  local  restimulation  in  the  CNS  to  promote  MS-­associated  lesion  formation.  Moreover,  EBV  
might   induce  homing   capacities   in   the   respective   cross-­reactive   lymphocyte   populations   to  
guide  them  to  the  CNS.  In  line  with  this,  the  chemokine  CXCL10  was  shown  to  be  expressed  
by  EBV-­transformed  cells,  attracting  EBV-­specific  T  cells  (Maggio  et  al.,  2002;;  White  et  al.,  
2012)  and  was  also  found  in  the  CSF  of  multiple  sclerosis  patients  (Sorensen  et  al.,  1999).    
Both   B   and   T   cell   homing   of   cross-­reactive   specificities   would   however   be  
a  prerequisite  of  focusing  the  resulting  autoimmunity  on  the  CNS.  Along  these  lines  the  α4/b1  
integrin  has  been  found  to  be  essential  for  CNS  homing  of  T  cells  (Engelhardt  and  Ransohoff,  
2012).   In   addition,   the   chemokine   receptors  CXCR3,   CCR5,   CCR6   and  CCR7   have   been  
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implicated  in  brain  infiltration  of  T  cells  (Balashov  et  al.,  1999;;  Sorensen  et  al.,  1999;;  Arima  et  
al.,   2012;;   Paroni   et   al.,   2017)   and   should   be   investigated   for   presence   of   cross-­reactive  
lymphocyte  populations.  Cross-­reactive  T  and  B  cells  might  then  restimulate  each  other  in  the  
CNS  of  patients  with  multiple  sclerosis  to  promote  relapsing-­remitting  and  progressive  courses  
of  the  disease.    
Such  T  cell  stimulatory  capacity  of  B  cells  in  multiple  sclerosis  brains  could  be  further  
augmented  by  EBV  infection  that  increases  co-­stimulatory  activity  for  T  cell  stimulation  (Leung  
et  al.,  2013).  Along  these  lines,  EBV-­infected  B  cells  have  been  detected  in  the  meninges  and  
lesions  in  the  brains  of  multiple  sclerosis  patients  (Serafini  et  al.,  2007;;  Moreno  et  al.,  2018),  
but  these  findings  are  heavily  debated  (Lassmann  et  al.,  2011).  Considering  EBV  biology  and  
life  cycle,  B  cell  stimulation  of  T  cell  responses  in  secondary  lymphoid  organs  might  be  of  great  
importance.  As  already  mentioned,  EBV  establishes  a  life-­long  infection  in  memory  B  cells  and  
by  doing  so,  modulates  their  differentiation  and  function,  and  promotes  their  survival  (Thorley-­
Lawson,  2001).  Indeed,  memory  B  cells  have  recently  been  shown  to  mediate  the  activation  
of  autoreactive  CD4
+  T  cells  (Jelcic  et  al.,  2018).  It  is  plausible  that  EBV  infects  autoreactive  
B  cells,  or  B  cells  that  might  present  antigen  to  pathogenic,  cross-­reactive  T  cells  over  a  long  
period  of  time.  In  addition,  in  genetically  susceptible  hosts,  acute  immune  pathologies  like  IM  
could   serve   to   decrease   the   threshold   of   T   cell   activation,   facilitating   pathogenic   B-­T   cell  
interactions.  The  exaggerated  EBV-­specific  T  cell  expansion  during  IM  could  expand  T  cells  
that  have  been  selected   in   the   thymus  by  self-­peptides  and  will  only  undergo   full  activation  
under  acute  EBV  infection  to  remain  as  memory  T  cells.  
Indeed,  B  cell  depleting  therapies,  which  leave  oligoclonal  antibody  production  in  the  
CNS  and  systemic  antibody  production  by  long-­lived  plasma  cells  in  the  bone  marrow  usually  
unaffected,  have  demonstrated  beneficial  effects  in  multiple  sclerosis  patients  (Hauser  et  al.,  
2017;;   Montalban   et   al.,   2017).   Furthermore,   adoptive   transfer   of   EBV-­specific   in   vitro-­
expanded  T   cell   lines   into   patients  with  multiple   sclerosis,   even   at   advanced   disease,   has  
demonstrated   some  encouraging   results   (Pender   et   al.,   2014;;  Pender   et   al.,   2018).   These  
T  cells  might  eliminate  an  EBV-­infected  B  cell  compartment  that  stimulates  autoreactive  T  cell  
responses,  possibly  even  in  the  brain.  Thus,  inefficient  immune  control  of  EBV-­infected  B  cells  
in  the  context  of  HLA-­DR15  might  allow  for  both  priming  of  cross-­reactive  T  cell  responses  and  
their   local   restimulation   by   EBV-­infected  B   cells   to   propagate   autoimmunity   in   the  CNS   of  
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2.8 Materials and methods 
 
2.8.1 Animal work  
NOD-­scid   γc
-­/-­   (NSG)   animals   with   or   without   an  HLA-­A2   heavy   chain   transgene   (Jackson  
Laboratory,  Bar  Harbor,  Maine,  USA)  were  maintained  under  specific  pathogen-­free  conditions  
at  the  Institute  of  Experimental  Immunology,  University  of  Zürich.  Newborn  pups  (1-­5  days  old)  
were  sublethally  irradiated  with  1Gy  and  5  to  7  hours  later,  intrahepatically  injected  with  around  
1.5-­3  x  105  human  fetal  liver  (Advanced  Bioscience  Resources)-­derived  and  HLA  typed  CD34+  
hematopoietic  progenitor  cells.  CD34+  cells  were  isolated  by  magnetic  bead  separation  based  
on  manufacturer’s   instructions   (Miltenyi   Biotech)   and   frozen   in   liquid   nitrogen.  After   twelve  
weeks,   peripheral   blood  was   collected   via   tail   vein   and  analysed   for   human  CD45+,  CD3+,  
CD4+,  CD8+  and  HLA-­DR+  cells  by  flow  cytometry.  Animals  3  to  5  months  old  and  engrafted  
with  human   immune  cells  were   intraperitoneally   injected  with  105  EBV  Raji   infectious  units  
(RIU)   or   PBS   and   monitored   for   up   to   6   weeks.   Animals   used   in   each   experiment   were  





EBV  strain  B95-­8  was  produced  in  human  embryonic  kidney  HEK293  cells  (ATCC)  containing  
a  GFP-­encoding  wild  type  EBV  BACmid  (p2089;;  kind  gift  from  H.  Delecluse)  (Delecluse  et  al.,  
1998).  Virus  concentrates  were  titrated  on  Raji  cells  (ATCC)  and  GFP-­expressing  cells  were  
analysed  two  days  later  by  flow  cytometry  (FACSCanto  II  or  LSR  Fortessa,  BD  Biosciences)  
to  determine  the  EBV  RIU.  
 
2.8.3 Enzyme-linked Immunosorbent assay (ELISA) 
IFNγ  in  T  cell  clone  supernatants  was  measured  by  the  Human  IFNγ  ELISA  development  kit  
(Mabtech  AB)   according   to   the  manufacturer’s   instructions.  EBNA-­1   IgM   in   huNSG  mouse  
serum   was   measured   by   the   Epstein-­Barr   virus   EBNA-­1   IgM   ELISA   (IBL   International)  
following  the  manufacturer’s  instructions.  The  threshold  to  determine  positive  IgM  values  was  
set  by  the  mean  +  2x  standard  deviation  of  PBS  animals.    
 
2.8.4 T cell cloning  
CD4+   T   cells   were   isolated   from   the   splenocytes   of   EBV-­infected   animals   (magnetic   bead  
separation,   Miltenyi   Biotec)   and   stimulated   with   HLA-­matched   bare   lymphocyte   syndrome  
lymphoblastoid  cell  line  (BLCLs;;  HLA-­DR15  or  HLA-­DR4-­transfected)  for  3-­4  hours  at  37°C.  
IFNγ-­producing  cells  were  then  selected  for  with  the  IFNγ  Secretion  Assay  –  Detection  kit  (PE),  
human  (Miltenyi  Biotech)  and  diluted  into  96-­well  plates  pre-­filled  with  irradiated  PBMC  feeder  
cells  and  HLA  matched  BLCLs  (20Gy  and  60Gy,  respectively).   IL-­2  (Peprotech)  was  added  
two   days   later   and   subsequently   twice   a   week   at   100-­125  U/ml.   Two   to   four   weeks   later,  
growing  clones  were  screened  with  the  Human  IFNγ  ELISA  development  kit  (Mabtech  AB)  and  
IFNγ-­producing  clones  were  placed  into  culture.  CD4+  T  cell  clones  were  fed  every  two  to  three  
weeks  with  irradiated  PBMC  feeder  cells  and  HLA  matched  BLCLs,  together  with  100-­125  U/ml  
of  IL-­2.    
For  T  cell  clone  killing  assays,  BLCLs  were  labelled  with  PKH26  (Sigma-­Aldrich).  CD4+  T  cell  
clones  were  then  incubated  alone,  or  with  labelled  matched  or  mismatched  BLCLs  at  5:1  ratio  
for  6  or  18  hours.  TO-­PRO-­3  dye  (Life  Technologies)  was  used  as  a  dead  cell  indicator.  For  
degranulation   experiments,   CD4+   T   cell   clones   were   incubated   alone,   or   with   matched   or  
mismatched   BLCLs   at   1:1   ratio   and   labelled   with   CD107a   (BD   Biosciences).   Cells   were  
incubated   for   2   hours   before   the   addition   of  Brefeldin  A   (Sigma-­Aldrich)   and   incubated   for  
further   6   hours.   For   transcription   factor   expression   experiments,   CD4+   T   cell   clones   were  
incubated  alone,  or  with  matched  or  mismatched  BLCLs  at  1:1  ratio  for  8  hours.    
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2.8.5 Flow cytometry 
Whole  blood  was  lysed  with  ACK  lysing  buffer  (Gibco)  and  washed  to  obtain  peripheral  blood  
mononuclear  cells   (PBMCs).  Spleens  were  physically  dissociated   through  a  70  µM  strainer  
and   layered   on   Ficoll-­Paque   (GE   Healthcare)   for   the   separation   of   mononuclear   cells   by  
density  gradient  centrifugation.  Total  numbers  of   leukocytes  were  calculated  from  the  white  
blood  cell   count  measured  by  Beckman  Coulter  AcT  diff  Analyzer.  PBMCs,   splenocytes  or  
CD4+  T  cell  clones  were  stained  with  extracellular  antibodies  for  20  minutes  at  4°C,  washed  
and   resuspended   either   in   PBS   or   fixed   in   1%   paraformaldehyde   (PFA).   For   intracellular  
staining,   extracellular-­stained   samples   were   processed   with   the   Cytofix/Cytoperm  
Fixation/Permeabilization  Kit  (BD  Biosciences)  according  to  manufacturer’s   instructions.  For  
intranuclear   staining,   extracellular-­stained   samples   were   processed   with   the  
Foxp3/Transcription   Factor   Staining   Buffer   Set   (eBioscience,   Thermo   Fisher   Scientific)  
following   the   manufacturer’s   instructions.   Live/dead   Near   IR   (Invitrogen)   or   Zombie   NIR  
(Biolegend)  was  used  for  live  cell  separation.    
Antibody  clones  used  in  this  study:  CD45  (HI30,  Biolegend),  CD3  (OKT3,  UCHT1,  Biolegend),  
CD4  (OKT4,  RPA-­T4,  Biolegend),  CD8  (SK1,  Biolegend),  CD19  (HIB19,  Biolegend),  HLA-­DR  
(G46-­6,   BD  Biosciences,   L243,   Biolegend),   EOMES   (WD1928,   eBioscience),   T-­bet   (4B10,  
eBioscience),  IFNγ  (4S.B3,  eBioscience),  IL-­2  (MQ1-­17H12,  eBioscience),  TNFa  (Mab11,  BD  
Biosciences),  Granzyme  B  (GB11,  BD  Biosciences),  CD107a  (H4A3,  BD  Biosciences).    
Samples  were  acquired  on  the  FACSCanto  II  or  LSR  Fortessa  (BD  Biosciences)  and  analysed  
using  the  Flowjo  Software  (Becton,  Dickinson  &  Company).    
 
2.8.6 Viral load quantification  
Splenic   tissue   was   processed   for   DNA   isolation   using   the   DNeasy   Blood   and   Tissue   Kit  
(QIAGEN)  and   total  DNA   from  whole  blood  was  extracted  using   the  NucliSENS  EasyMAG  
System   (bioMérieux),   following   the   manufacturer’s   instructions.   TaqMan   real-­time   PCR  
(Applied  Biosystems)  was  used  to  quantify  EBV  DNA,  with  modified  primers  for  the  BamH1  W  
fragment  (5′-­CTTCTCAGTCCAGCGCGTTT-­3′  and  5′-­CAGTGGTCCCCCTCCCTAGA-­3′)  and  
a   fluorogenic   probe   (5′-­FAM   CGTAAGCCAGACAGCAGCCAATTGTCAG-­TAMRA-­3′).   All  
samples  were  analysed  in  duplicates.    
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2.8.7 HLA typing 
DNA   was   extracted   using   the   QIAGEN   GmbH   reagent,   according   to   the   manufacturer’s  
instructions.  Commercial  HLA  kits  (Fujirebio  Diagnostics  Inc.)  were  used  to  identify  the  HLA  
alleles   using   a   PCR   sequence-­specific   oligonucleotide   reverse   assay.   Data   analysis   was  
performed  using  the  LIPA  Interpretation  Software  (Fujirebio  Diagnostics  Inc.).  
 
2.8.8 Statistical Analysis 
Statistical   analysis  was   performed  with   the  GraphPad  Prism  Software.   The  Mann-­Whitney  
U  test  was  used  to  analyze  unpaired  data  with  a  non-­Gaussian  distribution.  Correlations  on  
non-­Gaussian   distributed   data   were   analyzed   using   the   Spearman’s   rank   correlation  
coefficient.  The  D’Agostino-­Pearson  omnibus  normality  test  was  used  to  determine  normality  
of  data.  A  p  value  <  0.05  was  considered  statistically  significant.    
 
2.8.9 Ethics statement  
All   animal   experimentation   was   approved   by   the   cantonal   veterinary   office   of   Zürich,  
Switzerland  (protocols  148/2011,  209/2014  and  159/17)  and  conducted  according  to  the  Swiss  
Animal  Welfare  Act,  Tierschutzgesetz  (TSchG).  All  human  sample  studies  were  approved  by  














2.9 Supplementary data 
  
 
Supplementary  Figure  1:  Higher  total  numbers  and  total  activated  T  cells  in  EBV-­infected  huNSG  
animals.   As   indicated   in   Fig.   2A,   animals   were   injected   with   10
5
   EBV   infectious   units   or   PBS  
intraperitoneally  and  monitored  for  4-­6  weeks.  At  time  of  sacrifice  (4-­6  weeks  post  infection),  frequencies  
of  total  T  cells  in  blood  and  spleen  (A  and  B),  total  numbers  of  T  cells  in  blood  and  spleen  (C  and  D)  
and  total  numbers  of  activated  T  cells  in  blood  and  spleen  (E  and  F),  respectively,  were  analysed  and  




)  and  HLA-­DR15  positive  (DR15
+
)  
donors.   T   cell   activation   was   analyzed   by   positive   staining   of   HLA-­DR   (E   and  F).   Data   shown   are  
combined   from  11   to  24  experiments  and  contain  19-­65  animals  per  group.   *  p  <  0.05,   **  p  <  0.01,  
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significant   comparisons   are   indicated   and   significance   is   based   on   the  Mann-­Whitney  U   test.   Each  
symbol  indicates  one  animal  (mean  ±  SEM). 
 
 
Supplementary  Figure  2:  Activated  CD8
+
  T  cells  correlate  to  EBV  viral  load.  (A)  Total  numbers  of  
activated  CD8
+
  T  cells  in  blood  were  plotted  relative  to  blood  EBV  viral  loads  (n  =  52).  (B)  Total  numbers  
of   activated  CD8
+
   T   cells   in   spleen  were   plotted   relative   to   spleen  EBV   viral   loads   (n   =   56).   T   cell  
activation  was  analyzed  by  positive  staining  of  HLA-­DR  (A  and  B).  Data  shown  are  combined  from  11  
experiments.   *   p   <   0.05,   **   p   <   0.01,   ****   p   <   0.0001,   significant   comparisons   are   indicated.   All  
correlations   are   analyzed   using   the   nonparametric   Spearman   correlation,   which   examines   rank  




Supplementary  Figure  3:  CD4
+




  T  cell  clones  
were   cloned   from   EBV-­infected   animals   using   bare   lymphocyte   syndrome   lymphoblastoid   cell   lines  
(BLCLs)  transfected  with  single  MHC  Class  II  molecules  as  targets.  CD4
+
  T  cell  clones  were  incubated  
for  8  hours  alone  (T  only),  with  matched  (auto)  or  mismatched  (allo)  BLCL  and  their  activation  analyzed  
by   positive   staining   for   HLA-­DR   (A),   T-­bet   (B)   and   EOMES   (C)   transcription   factor   expression   are  
shown.  Data  shown  are  combined  from  4  experiments  and  different  symbols  correspond  to  individual  
CD4
+







3 HLA-DR15 transgenic NSG mouse 
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MS  is  an  immune-­mediated,  demyelinating  disease  of  the  CNS  and  the  main  cause  of  
neurological   disability   in   young   adults   (Sospedra   and   Martin,   2005).   The   hallmark   of   the  
disease   are   inflammatory   lesions   within   the   brain   and   spinal   cord,   which   are   infiltrated   by  
immune  cells,  mostly  T  cells   (Dendrou   et   al.,   2015).  The  etiology  of   the  disease   is  not   yet  
completely   understood.   It   clusters   with   other   complex   genetic   diseases,   characterized   by  
moderate  disease-­risk  heritability  and  intricate  gene-­environment  interactions  (Oksenberg  et  
al.,   2008).   There   are   hundreds   of   genetic   and   environmental   risk   factors   that   have   been  
implicated  in  this  disease.  
MHC  molecules  present  extracellular  or  intracellular  peptides  resulting  from  lysosomal  
or  proteasomal  degradation  to  T  cells  and  are  essential  for  the  start  of  the  adaptive  immune  
response  (Cresswell,  2019).  As  is  the  case  with  many  autoimmune  diseases,  the  HLA  gene  
cluster  on  chromosome  6p21.3  coding  for  MHC,  is  the  strongest  genome-­wide  susceptibility  
locus  for  MS  (Sawcer  et  al.,  2005).  From  this  HLA  cluster,  the  MHC  class  II  haplotype,  which  
consists   of   the   alleles  HLA-­DRB1*15:01   (DR2b,   or   HLA-­DR15),   HLA-­DRB5*01:01   (DR2a),  
HLA-­DQA1*01:02  and  HLA-­DQB1*06:02  existing  in  linkage  disequilibrium,  bears  the  greatest  
effect  on  risk  (Sawcer  et  al.,  2014).  It  has  become  apparent  that  the  HLA-­DR15  allele  drives  
the  association  and  increases  the  risk  of  MS  3-­fold  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013;;  
Patsopoulos  et  al.,  2013).  Interestingly,  the  HLA  molecules  have  been  shown  to  synergize  with  
environmental  risk  factors,  such  as  EBV,  to  further  increase  MS  risk  (Olsson  et  al.,  2017).  The  
exact  mechanisms  behind  HLA-­DR15  association  with  MS  and  its  influence  on  the  interaction  
with  EBV  are  important  questions  in  MS.  
Transgenic  and  humanized  mice  have  been  able  to  provide  some  evidence.  In  one  of  
these  models,   animals   transgenic   for   HLA-­DR15,  MBP-­specific   TCR   and   human   CD4   co-­
receptor  developed  CNS  inflammation  and  demyelination  upon  administration  of  MBP  peptide  
plus  adjuvant   (Madsen  et  al.,  1999).   In  our  previous  study,  we  have  used  humanized  NSG  
mice  reconstituted  with  human  CD34
+  hematopoietic  progenitor  cells  (donors)   isolated  from  
human   fetal   livers   to   investigate  T  cell   responses   in  animals   reconstituted  with  HLA-­DR15+  
donors  at  steady  state  and  in  EBV  infection.    
In  this  chapter,  we  aimed  to  create  a  HLA-­DR15  transgenic  mouse  model  on  the  NSG  
mouse   background,   in   order   to   study   in   more   detail   HLA-­DR15-­restricted   T   and   B   cell  
responses  in  the  context  of  cognate  antigen  presentation  on  mouse  myeloid  cells,  as  well  as  
examine  any  resulting  signs  of  autoimmunity.  Additionally,  this  animal  model  could  serve  as  




3.2.1 Constructing and validating the HLA-DR15 gene and plasmid 
As  HLA-­DR15  is  the  strongest  genetic  risk  factor  for  multiple  sclerosis  (Sawcer  et  al.,  
2011;;  Beecham  et  al.,  2013;;  Patsopoulos  et  al.,  2013),  and  because  we  work  with  NSG  mice,  
we  were  interested  in  making  an  HLA-­DR15  transgenic  mouse  strain  of  the  same  background.  
We  created  the  HLA-­DR15  transgene  by  joining  the  sequences  of  the  alpha  chain  DRA*01:01  
via  the  P2A  linker  to  the  beta  chain  DRB1*15:01  (sequences  in  Appendix  2).  We  engineered  
the  construct  with  EcoR1  flanking  sites  in  a  kanamycin  resistant  plasmid  (pMK-­T  +  HLA-­DR15,  
Fig.  10A).  We  incorporated  the  previous  work  of  Kouskoff  and  colleagues,  where  they  describe  
a  cloning  vector  pDOI-­5  that  is  able  to  translate  genetic  material  under  the  mouse  MHC  class  
II  promoter  (Eα  promoter)  (Kouskoff  et  al.,  1993).  This  ampicillin  resistance  vector  contains  the  
sequence  of  the  Eα  promoter,  followed  by  the  sequence  of  a  rabbit  β-­globin  gene,  within  which  
is  an  EcoR1  site  (Fig.  10B).    
To  sequence  the  pMK-­T  +  HLA-­DR15  plasmid,  we  designed  three  overlapping  forward  
primers  spanning  the  length  of  the  gene  (Fig.  11A).  The  sequence  on  the  plasmid  matched  the  
ordered   sequence.   Similarly,   in   order   to   sequence   the   pDOI-­5   plasmid,   we   used   the   Eα  
promoter  sequence   to  design   four  overlapping  primers   (Fig.  11B).  With   the  sequence   from  
primer  3  (EαP3_F),  which  ran  into  the  rabbit  β-­globin  gene,  we  were  able  to  design  the  fourth  
































Figure  10.  Schematic  of  plasmids  used  for  HLA-­DR15  transgenic  mouse.  (A)  HLA-­DRA  a-­chain  
was  joined  with  P2A  linker  to  HLA-­DRB  b-­chain,  flanked  with  EcoRI  sites  and  inserted  into  a  kanamycin  
resistance  backbone.  (B)  The  pDOI-­5  plasmid  has  an  ampicillin  resistance  backbone,  contains  an  Eα  
promoter  followed  by  a  rabbit  b-­globin  gene  containing  an  EcoRI  site.  After  EcoRI  restriction,  our  HLA-­
DR15  gene  fits  into  the  rabbit  b-­globin  gene. 
 
Upon  the  restriction  digest  of  our  pMK-­T  +  HLA-­DR15  plasmid  and  the  pDOI-­5  plasmid  
with   EcoRI,   we   were   able   to   insert   the   cut-­out   HLA-­DR15   gene   into   the   pDOI-­5   plasmid  
(Fig.   10B).   In   order   to   determine   if   the   HLA-­DR15   gene   was   inserted   and   in   the   correct  
orientation,   we   designed   an   additional   fifth   primer   starting   in   the   rabbit   β-­globin   gene   and  
spanning  into  the  inserted  HLA-­DR15  (Fig.  11B).  Like  this,  we  sequenced  10  colonies,  two  of  
which  had  the  insert  in  the  correct  orientation  and  proceeded  with  colony  10  for  further  studies.    
 
 
Figure  11.  Schematic  of  plasmid  primer  design.  (A)  Three  overlapping  primers  designed  to  sequence  
the   length   of   the   HLA-­DR15   gene-­containing   plasmid.   (B)   Five   overlapping   primers   designed   to  
sequence  the  length  of  pDOI-­5  plasmid,  both  with  and  without  inserted  HLA-­DR15  gene. 
  
Next  we  developed  a  PCR  method  capable  of  distinguishing  the  plasmid  in  a  sample.  
We  first  designed  primers  for  a  house-­keeping  gene;;  b-­actin,  to  use  as  a  control.  We  isolated  
DNA  from  an  NSG  mouse  and/or  spiked   in   the  plasmid  and  added  primers  recognising  the  




















worked,   we   observed   that   the   plasmid   was   recognised   by   primers   designed   to   bind   the  
plasmid,  whether  it  was  spiked  into  NSG  DNA  or  was  alone  in  the  reaction  (Fig.  12A).  To  verify  
the   result  with  a  second  house-­keeping  gene  (GAPDH),  we  observed   that  GAPDH  primers  
detect  the  gene  but  not  the  plasmid.  The  plasmid  is  recognised  by  plasmid  primers  when  it  is  
spiked  into  NSG  DNA,  or  alone.  The  plasmid  primers  also  do  not  bind  NSG  DNA  alone.  When  
both  plasmid  primers  and  GAPDH  primers  are  added  to  the  plasmid-­spiked  DNA,  both  bands  
for  the  plasmid  and  GAPDH  are  seen  (Fig.  12B).  With  this,  we  were  able  to  detect  the  100-­fold  
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Figure  12.  Specific  binding  of  plasmid  primers.  Plasmid  primer  binding  for  genotyping  was  validated  
by  the  indicated  combinations  of  plasmid,  plasmid  primers,  DNA  isolated  from  NSG  mouse  and  primers  
towards  house-­keeping  genes;;  b-­actin  (A)  or  GAPDH  (B).  Plasmid  was  isolated  from  bacterial  colony  
10  with  gene  insertion  in  correct  orientation.  A  1  kb  ladder  was  used  and  band  size  of  plasmid  is  1100  
(A)  and  2700  (B)  base  pairs. 
  
As  the  next  step,  we  wanted  to  excise  the  Eα  promoter  with  HLA-­DR15  transgene  out  
of  the  pDOI-­5  plasmid.  For  this  purpose,  the  pDOI-­5  plasmid  carries  four  BglI  restriction  sites  
and  therefore  this  restriction  enzyme  can  be  used  to  liberate  our  sequence  of  interest  from  the  
plasmid  (Fig.  13A).  Of  note,  one  of  those  BglI  sites  lies  within  the  Eα  promoter,  however  this  
was   mentioned   not   to   have   an   impact   on   gene   expression   (Kouskoff   et   al.,   1993).   After  
a  restriction  digest  with  BglI  and  dephosphorylation  with  the  Antarctic  phosphatase  enzyme,  
we  ran  the  product  on  a  gel  and  observed  the  expected  four  bands,  with  the  top  band  (around  
5500bp)  representing  our  product  of  interest.  Many  BglI  restrictions  were  performed  to  get  the  
appropriate  DNA  amount  of  the  linearized  product.  The  DNA  was  sent  to  the  laboratory  of  Dr.  
Johannes  vom  Berg  and  Dr.  Thorsten  Buch  at  the  LTK,  who  super-­ovulated  NSG  females  and  
injected  the  linearized  product,  containing  the  Eα  promoter  followed  by  HLA-­DR15  gene,  into  
the  oocytes  of  these  animals.    
 
 
Figure  13.  BglI  digestion  of  p-­DOI5.  (A)  Schematic  of  four  BglI  sites  on  the  pDOI-­5  plasmid.  (B)  Four  









3.2.2 Gene expression and function 
A   genotyping   protocol   was   optimized   to   genotype   resulting   founders   from   the  
pronuclear  injections.  While  the  DNA  from  positive  animals  and  plasmid  alone  generate  a  band  
in  the  genotyping  PCR,  negative  animals  show  no  band  (Fig.  14A).  Even  though  the  first  round  
was  unsuccessful,   the  second  round  yielded  several  HLA-­DR15  positive  pups,  out  of  which  
two  were  selected  for  breeding  and  a  colony  was  setup  and  housed  in  mouse  facilities  in  Irchel  
and   Schlieren.   Upon   staining   for   human   MHC   class   II   on   spleen   histology   sections,   we  
observed  that  while  an  NSG  mouse  does  not  show  any  expression  (Fig.  14B),  an  HLA-­DR15  
transgenic  NSG  mouse  shows  high  levels  of  expression  across  the  tissue  (Fig.  14C).  Thymic  
and  brain  sections  showed  similar  results  (data  not  shown).    
After  verifying  ex  vivo  expression  of  HLA-­DR15  in  our  transgenic  NSG  mouse  line,  we  
were  next   interested   in  examining   their   reconstitution.  We   reconstituted  similar  numbers  of  
NSG  and  NSG  HLA-­DR15  transgenic  pups  with  human  fetal   liver-­derived  CD34
+  progenitor  
cells.  After  monitoring  the  animals  for  three  months,  we  performed  a  bleeding  and  while  the  
NSG  animals  showed  average   reconstitution   (Fig.  14D),  surprisingly  and  unfortunately,  our  
HLA-­DR15   transgenic  NSG   animals   had   0%   human  CD45+   cells   in   their   peripheral   blood.  
These   data   possibly   suggest   an   incorrectly   or   incompletely   inserted   transgene   DNA   or  
insertion   into   an   important   gene   that   increases   resistance   to   human   immune   system  
component  reconstitution.  Further  characterization  was  done  by  Fabienne  Läderach  and  will  




Figure  14.  High  expression  of  HLA-­DR15  in  transgenic  NSG  mice.  (A)  Genotyping  of  HLA-­DR15-­
transgenic  NSG  mice.  Eight  animals  shown  are  positive  for  transgene,  two  as  negative.  Plasmid  isolated  
from  bacterial  colony  10  with  gene  insertion   in  correct  orientation   is  used  as  control.  100  bp  band  of  
ladder  is  displayed.  Histological  spleen  sections  of  NSG  (B)  and  HLA-­DR15-­transgenic  NSG  (C)  mouse.  
Sections   were   stained   with   human   MHC   class   II   and   images   were   obtained   at   20x   and   100x  
magnification.  Scale  bars  200  µm,  insert  20  µm.  (D)  Composition  of  human  immune  cells  in  peripheral  
blood  of  NSG  animals  three  months  after  reconstitution  with  CD34
+  
hematopoietic  progenitor  cells.  One  

















































































HLA-­DR15  is  the  strongest  genetic  risk  factor  for  MS  (Sawcer  et  al.,  2011;;  Beecham  et  
al.,  2013).  Studies  on  patient  samples  and  through  GWAS  studies  have  been  able  to  shed  light  
on  the  roles  of  this  MHC  class  II  molecule  on  disease  pathogenesis.  Nevertheless,  having  a  
reliable   animal   model   to   study   the   roles   of   HLA-­DR15   in   human   T   cell   selection,   antigen  
presentation,  APC   -­  T   cell   interaction  and  HLA-­DR15-­restricted  T   cell   responses  would  be  
valuable.  
In  this  study,  we  generated  a  transgenic  mouse  model  of  the  NSG  background  carrying  
the  HLA-­DR15   allele   of   the  MHC   class   II  molecule  with   the   aim   of   studying   differences   in  
reconstitution,  T  cell  activation  and  specificity  and  T  and  B  cell  functionality.  Furthermore,  we  
wished  to  examine  differences  in  EBV  immune  control  and  any  signs  of  autoimmunity  in  these  
animals.  The  transgene  was  designed  to  contain  the  HLA-­DRA*01:01  α-­chain  and  the  HLA-­
DRB1*15:01  β-­chain  and  to  insert   into  the  genome  at  random.  After  the  transgene  injection  
into  the  oocytes  of  NSG  females,  we  received  animals  positive  for  the  transgene,  which  were  
set  up  to  breed.  Even  though  we  observed  the  expression  of  human  HLA-­DR  in  these  animals,  
unfortunately   they  did  not   reconstitute  with  human   immune  system  components   like  control  
NSG  mice.    
Introducing  MHC  class  I  or  class  II  molecules  into  mice  of  different  strains  has  been  
done   in   several   studies.   In   efforts   to   gain   insights   into   MS   and   CNS   pathology,   the  
DBAxC57BL/6  mouse  model  was  used  to  express  HLA-­DR15,  together  with  an  MBP-­specific  
T-­cell  receptor  and  the  human  CD4  co-­receptor.  In  this  model,  transgenic  animals  developed  
CNS   inflammation   and   demyelination   under   the   administration   of   the   MBP   peptide   with  
adjuvant  and  pertussis   toxin,  as  well  as  spontaneous  disease   in  a  small   fraction  of  animals  
(Madsen  et  al.,  1999).  In  the  same  model  transgenic  only  for  HLA-­DR15,  the  mouse  myelin  
oligodendrocyte   glycoprotein   (MOG)35-­55   peptide   was   strongly   immunogenic   and  
encephalitogenic  in  the  context  of  HLA-­DR15  (Rich  et  al.,  2004).  In  another  study,  C57BL/6  
RAG-­2-­/-­  mice  transgenic  for  HLA-­DR15  and  an  anti-­MBP  TCR  show  spontaneous  paralysis,  
as  well  as  epitope  spread  in  the  context  of  HLA-­DR15  to  include  epitopes  of  MBP,  MOG  and  
αB-­crystallin  (Ellmerich  et  al.,  2005).  Additionally,  transgenic  mice  for  HLA-­DQB1*06:02,  which  
is   a   part   of   the   HLA-­DR15   haplotype,   show   susceptibility   to   EAE   induction   by   myelin-­
associated  oligodendrocytic  basic  protein  (MOBP)  through  MOBP-­reactive  pathogenic  T  cells  
(Kaushansky  et  al.,  2009).  In  a  model  of  Goodpasture  disease,  animals  transgenic  for  HLA-­
DR15,  a  risk  factor  of  the  disease,  and  immunized  with  α3135-­145  epitope  show  specific  T  cells  
70  
infiltrating   the   kidney,   producing   pro-­inflammatory   cytokines   and   resulting   in   Goodpasture  
disease  (Ooi  et  al.,  2017).    
While  these  mouse  models  are  invaluable  to  gain  insights  into  the  disease,  expressing  
a  specific  TCR  and  immunizing  with  a  specific  peptide  can  be  limiting,  especially  in  a  complex  
disease  such  as  MS.  For  our  purpose,  we  wanted  to  generate  an  HLA-­DR15  transgenic  mouse  
model  of  the  NSG  background  to  study  the  effect  of  this  molecule  in  human  immune  system-­
type  setting  and  to  study  EBV  infection  in  the  context  of  this  molecule.    
Even   though  humanized  mouse   reconstitution   leads   to  multilineage  haematopoiesis  
(Traggiai  et  al.,  2004)  with  different  levels  of  reconstitution,  adaptive  immune  responses  seem  
incomplete  (Watanabe  et  al.,  2009).  This  is  largely  thought  to  be  caused  by  an  inefficient  CD4+  
T  cell  selection  on  murine  MHC  (mMHC)  class  II  molecules  in  the  mouse  thymus  (Watanabe  
et  al.,  2009).  Early  lymphoid  progenitors  which  develop  from  hematopoietic  stem  cells  migrate  
to   the   thymus   and   differentiate   into   CD4+CD8+   double   positive   cells.   They   then   undergo  
positive  and  negative  selection  on  self-­peptides  presented  by  the  MHC  molecules  on  thymic  
epithelial   cells.   The  double   positive   thymocytes   then  differentiate   into  CD4+   or  CD8+  single  
positive  cells  and  repopulate  peripheral  lymphoid  organs.  This  process  of  thymic  selection  is  
essential   for   a   T   cell   repertoire   that   is   self-­tolerant,   yet   immunocompetent   at   recognising  
foreign  antigens  (Takahama  et  al.,  2010).    
Interestingly,  NOD  Rag1-­/-­  IL2Rγc
-­/-­    animals  transgenic  for  HLA-­DR4  reconstituted  with  
human  HSC  in  adulthood  demonstrated  an  increased  frequency  of  CD4+  T  cell  reconstitution  
in  the  blood,  as  well  as  a  better  human  cell  reconstituted  thymus  with  human  cells  compared  
to  control  mice.  The  human  T  cell  compartment  in  these  mice  is  also  functional,  as  observed  
by  high  levels  of  cytokine  production  after  T  cell  stimulation.  Increased  B  cell  function  was  also  
shown,   indicated  by   the  production  of  all  classes  of   immunoglobulins  and  the  production  of  
neutralizing  anti-­tetanus  toxin  IgG  antibodies  (Danner  et  al.,  2011).  
In  an  HLA-­DR1  transgenic  NSG  mouse  model  lacking  expression  of  mMHC  class  II,  
transgene  expression  was  observed  on  murine  thymic  epithelial  cells,  as  well  as  splenic  APCs.  
The  animals   reconstituted   to  similar   levels  as  control  NSG  animals,  however   there  was  an  
increase  in  T  cell  reconstitution  in  transgenic  mice,  even  though  the  T  cell  did  not  show  greater  
TCR  diversity  than  NSG  mice.  In  addition,  in  NSG  animals  lacking  mMHC  class  II  expression,  
fewer  CD4
+   T   cells   in   the   thymus  were   seen,   suggesting   the  necessity   of   either  murine  or  
human  MHC  (hMHC)  class  II  expression  for  human  CD4+  T  cell  development.  There  was  an  
increase  in  mature  naïve  B  cells  in  transgenic  animals,  as  well  as  increased  levels  of  serum  
immunoglobulins,   indicating   successful   class   switching   probably   as   a   result   of   improved  
interactions  between  HLA-­DR1-­restricted  CD4+  T  cells  and  HLA-­DR1+  B  cells  (Goettel  et  al.,  
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2015).  With  regards  to  MHC  class  I,  humanized  mice  transgenic  for  the  MHC  class  I  molecule  
HLA-­A2  were  able  to  elicit  HLA-­A2-­restricted  CD8+  T  cell  responses  against  EBV  and  dengue  
virus,   however  B   cell   function  and  antibody  production  was  not   improved   in   these  animals  
(Jaiswal  et  al.,  2009;;  Strowig  et  al.,  2009;;  Shultz  et  al.,  2010).    
The  pDOI-­5  targeting  vector  that  was  used  in  our  study  to  carry  our  transgene  has  been  
described  by  Kouskoff  and  colleagues  to  express  foreign  cDNAs  in  MHC  class  II  expressing  
cells  (Kouskoff  et  al.,  1993).  In  a  DBAxC57BL/6  mouse  model,  between  10  and  30%  of  MHC  
class  II-­expressing  cells  were  HLA-­DR15+,  no  aberrant  expression  of  the  transgene  was  seen  
and  the  number  of  copies  of  integrated  transgenes  ranged  from  1  to  5  (Madsen  et  al.,  1999).  
In  a  study  by  Suzuki  and  colleagues,  which  used  the  pDOI-­5  vector   to  create  an  HLA-­DR4  
transgenic  NOG  mouse,  HLA-­DR  is  expressed  in  mMHC  class  II  positive  APCs  and  thymic  
epithelial  cells.  Even  though  the  percentage  of  positive  cells  from  mMHC  class  II-­expressing  
cells  is  not  shown,  only  a  fraction  of  these  cells  are  HLA-­DR  positive  (Suzuki  et  al.,  2012).  With  
our  HLA-­DR15  transgenic  NSG  mouse,  we  have  seen  strong  expression  in  several  organs,  
possibly  even  in  cells  not  expressing  mMHC  class  II.  As  we  did  not  perform  targeted  insertion,  
it   is   possible   that   our   transgene   inserted   in   the   genome  many   times,   as   well   as   possibly  
inserting  into  a  ubiquitously  expressed  promoter  region,  resulting  in  expression  across  many  
cell   types.   In  addition,  some  cells  seemed  to  be  expressing  HLA-­DR  strongly,  whilst  others  
less.  Using  immunohistochemistry,  we  were  unable  to  dissect  whether  the  HLA-­DR  signal  that  
we  see  is  extracellular,  intracellular  or  secreted.  We  therefore  aim  to  perform  extracellular  and  
intracellular  staining  of  HLA-­DR  on  mouse  cells  by  FACS  and  examine  protein  expression  by  
Western  blot.  In  addition,  we  are  trying  to  detect  the  location  of  our  transgene  in  the  mouse  
genome.   
Interestingly,  while  some  MHC  class  II  transgenic  animals  still  expressed  mMHC  class  
II  (Danner  et  al.,  2011),  others  were  crossed  with  MHC  class  II  deficient  strains  (Rich  et  al.,  
2004;;  Ellmerich  et  al.,  2005;;  Kaushansky  et  al.,  2009;;  Suzuki  et  al.,  2012;;  Goettel  et  al.,  2015;;  
Ooi  et  al.,  2017).  While  in  the  former,  CD4
+  T  cells  could  be  restricted  to  either  murine  or  hMHC  
class  II,  in  the  latter,  the  T  cells  should  be  selected  only  in  the  context  of  the  hMHC  molecule.  
The  rationale  behind  crossing  animals  to  MHC  class  II  deficient  strains  was  not  mentioned,  
however  Suzuki   and   colleagues  discussed   that   I-­A   sufficient   animals   in   their   study  did   not  
induce   human   IgG   responses,   as   compared   to   I-­A   deficient  mice.   The  mismatch   between  
positive   selection   of   human   T   cells   by   mMHC   class   II   in   the   thymus   and   hMHC   class   II  
expressed   in   the   periphery   by   B   cells   could   be   responsible   for   defective   humoral   immune  
responses  in  humanized  mice.  When  both  I-­A  and  human  transgene  are  present,  the  mMHC  
class   II   is   still   likely   the  dominant  player   in  positive  selection,  as   there   is  an  abundance  of  
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mMHC  class  II  positive  cells  in  the  thymus.  The  T  cell  repertoire  selected  on  the  hMHC  class  
II  could  hence  be  too  small  to  detect  (Suzuki  et  al.,  2012).  
In  addition,   if  mMHC  class   II   is   present,   there   could  be  an   interspecies  a/b  MHC   II  
pairing,  hence  enhanced  positive  selection  (Goettel  et  al.,  2015).  Because  we  observe  strong  
expression  across  tissues,  it  is  possible  that  a  chain  of  our  hMHC  class  II  molecule  paired  with  
a  chain  of  mMHC  class  II,  resulting  in  widespread  expression.  While  the  lack  of  reconstitution  
in  our   transgenic  mouse  model   is  puzzling,   it   is  possible   that   the   transgene   insertion   in  an  
important  part  of  the  genome  selected  a  function  in  the  remaining  mouse  myeloid  cells  that  
confers  resistance  to  human  hematopoietic  reconstitution.  Possibly  the  niche  that   is  usually  
present   in   NSG   mice   for   CD34
+   hematopoietic   progenitor   cells   to   occupy   could   be  
compromised,  or   the  developing  human   immune  cells   released   into   the  periphery  could  be  
deleted  by  an  activated  mouse  myeloid  system.    
Nevertheless,  we  have  started  breeding  our  HLA-­DR15  transgenic  NSG  mouse  to  an  
mMHC  class  II  deficient  mouse  strain  and  will  be  curious  to  examine  HLA-­DR  expression  and  
reconstitution   in   these   animals.   As   a   back-­up   strain   we   have   the   BALB/c   Rag2-­/-­   IL2Rγc
-­/-­  
SIRPαNOD  (BRGS)  mouse  strain  transgenic  for  HLA-­A2  and  HLA-­DR15.  Like  NSG  mice,  these  
animals  have  no  T  or  B  lymphocytes,  no  NK  cells  and  the  ‘don’t  eat  me’  signal  of  the  NOD  
SIRPα   allele   which   inhibits   the   phagocytic   activity   against   human   engrafted   cells.   These  





3.4.1 NSG-DR15 gene synthesis and cloning  
The  HLA-­DRA*0101  a-­chain  was  linked  via  a  P2A  linker  (sequence:  GGC  AGC  GGC  GCC  
ACC  AAC  TTC  AGC  CTG  CTG  AAG  CAG  GCC  GGC  GAC  GTG  GAG  GAG  AAC  CCC  GGC  
CCC)   to   the   HLA-­DRB1*15:01   b-­chain.   Sequences   were   obtained   from   online   sources  
(websites:  hla.alleles.org,  uniprot.org,   full   sequence:  Appendix  2).  The  synthetic  HLA-­DR15  
gene  was  ordered  from  Thermo  Fisher  Scientific  (Invitrogen),  where   it  was  assembled  from  
synthetic  oligonucleotides  and/or  PCR  products  and  inserted  into  the  pMK-­T  vector  backbone  
(Appendix  3).    
To  amplify  the  vector,  it  was  cloned  into  the  DH5a  E.  coli  strain.  Briefly,  50  µl  of  E.  coli  was  
mixed  with  250  ng  of  vector,  heat-­shocked  for  30  seconds  at  42°C  and  put  on  ice  for  5  minutes.  
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300  µl  of  LB  medium  was   then  added  and   the  mix  was   incubated  at  37°C  for  1  hour,  after  
which  5  ml  of  LB  plus  kanamycin  (Merk  Milipore)  was  added.  After  overnight  incubation,  the  
DNA  was  isolated  with  a  miniprep  kit  (PureYield  Plasmid  Miniprep  System,  Promega  Helix).  
Primers  were  designed  manually  (help  from  online  tools;;  Appendix  4)  to  be:  19-­22  base  pairs  
in  length,  melting  temperature  51.1-­52.4°C,  GC  content  40-­52.6%  and  ordered  desalted  and  
without   further  modifications   (Microsynth).  Full   list  of  primers  see   in  Appendix  5.  The  HLA-­
DR15  gene  was  then  sequenced  to  verify  correct  sequences  (Microsynth)  with  three  primers  
spanning  the  length  of  the  gene  (Appendix  5).   
EcoRI   restriction  enzyme  (New  England  BioLabs)  was  used   to  digest   the  HLA-­DR15   insert  
from  the  pMK-­T  vector.  In  a  50  µl  total  reaction  volume,  1  µl  (10  units)  of  EcoRI  enzyme,  5  µl  
(10x)   buffer   and  1  µg  of  DNA  was  used  and   incubated   for   1  hour  at   37°C.  A  1%  agarose  
(Promega)  gel  was  used  to  separate  the  insert  from  the  rest  of  the  vector.  The  band  size  1653  
bp   (size   of   HLA-­DR15   insert)   was   excised   and   DNA   was   cleaned   from   the   gel   as   per  
manufacturer’s  instructions  (Wizard  SV  Gel  and  PCR  Clean-­up  System,  Promega  Helix).    
The  pDOI-­5  vector  plasmid,  carrying  the  Eα  promoter,  was  ordered  from  ATCC  (ATCC  87058,  
(Kouskoff  et  al.,  1993),  1993,  Appendix  3).  To  amplify  the  plasmid,  it  was  cloned  into  the  DH5a  
E.   coli   strain   as   mentioned   above   (ampicillin   resistance   instead   of   kanamycin)   and   after  
overnight   incubation,  the  DNA  was  isolated  with  a  miniprep  kit  (PureYield  Plasmid  Miniprep  
System,   Promega).   The   Eα   promoter   was   then   sequenced   to   verify   correct   sequence  
(Microsynth)  with   three  primers  spanning   the   length  of   the  promoter  (Appendix  1  and  5).   In  
order  to  insert  the  HLA-­DR15  insert,  the  pDOI-­5  vector  was  digested  with  EcoRI  (as  mentioned  
above,   in   30   µl   total   volume   with   700   ng   DNA)   and   dephosphorylated   with   Antarctic  
phosphatase  (New  England  BioLabs).  After  1  hour  incubation  with  EcoRI  restriction  enzyme,  
1  µl   (5  units)  of  Antarctic  phosphatase  enzyme  with  4  µl   (10x)  of  buffer  were  added   to   the  
mixture  and  for  a  total  of  40  µl.  After  30  minutes  incubation  at  37°C,  the  reaction  was  stopped  
by   heat-­inactivation   at   80°C   for   2   minutes   and   followed   by   a   PCR   clean-­up   as   per  
manufacturer’s  instructions  (Wizard  SV  Gel  and  PCR  Clean-­up  System,  Promega  Helix).  
To  ligate  the  EcoRI-­excised  HLA-­DR15  insert  to  the  EcoRI-­cut  and  dephosphorylated  pDOI-­5  
vector,  50  ng  of  vector  was  added  to  3-­fold  molar  excess  of  insert  (34.2  ng  –  calculated  with  
online  ligation  calculator  Promega  or  Gene  link).  Quick  Ligation  buffer  (2x)  and  1  µl  of  Quick  
T4  DNA   ligase  (New  England  BioLabs)  was  added,  mixed,  centrifuged  briefly,   incubated  at  
room  temperature  (25°C)  for  5  minutes  and  kept  on  ice.    
Stbl3  strain  of  E.  coli  was  used  for  transformation.  The  bacteria  were  mixed  with  4  µl  of  ligation  
mix  (rest  stored  at  -­20°C),  left  on  ice  for  30  minutes,  heat-­shocked  for  30  seconds  at  43°C  and  
kept  5  more  minutes  on  ice.  Next,  40  µl  of  S.O.C.  Medium  (Invitrogen)  was  added  and  kept  for  
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45  minutes  at  37°C  at  250  rpm  and  plated  on  LB  plus  ampicillin  (Merck)  on  bacterial  plates.  
After   overnight   incubation   at   37°C,   10   colonies  were   picked   and   placed   into   5  ml   LB   plus  
ampicillin  to  incubate  and  grow  over  night.  500  µl  of  the  grown  colonies  was  placed  into  25%  
glycerol  and  stored  at  -­80°C.  Minipreps  were  performed  on  the  rest  of  the  cultures  from  the  10  
colonies  and  the  isolated  DNA  was  sent  for  sequencing.  To  test  whether  these  colonies  had  
HLA-­DR15  inserted  in  correct  orientation  into  the  pDOI-­5  vector,  three  primers,  used  initially  
to   sequence   the   Eα   promoter,   together   with   a   new   primer   which   spanned   the   end   of   Eα  
promoter  through  the  b-­globin  gene  onto  the  HLA-­DR15  insert  were  used  (Appendix  5).  Two  
colonies  showed  correct  insertion  and  colony  10  was  used  for  further  work.    
BglI  restriction  enzyme  (Thermo  Fisher  Scientific)  was  used  to  cut  away  bacterial  components  
from  the  pDOI-­5  plasmid  (Kouskoff  et  al.,  1993).  In  a  30  µl  total  reaction  volume,  1  µl  of  BglI  
enzyme  (10  units),  3  µl  (10x)  buffer  and  1  µg  DNA  was  used  and  incubated  for  1  hour  at  37°C.  
Dephosphorylation  with  Antarctic  phosphatase  followed  (described  above).  The  product  was  
run  on  an  agarose  gel  to  separate  into  four  bands  corresponding  to  four  BglI  restriction  sites  
on  the  vector.  The  largest  band  (around  5500  bp)  was  excised  from  the  gel  and  DNA  cleaned  
as   per   manufacturer’s   instructions   (Wizard   SV   Gel   and   PCR   Clean-­up   System,   Promega  
Helix),  with  final  elution  in  DEPC-­treated  H20.  The  sequence  was  confirmed  with  sequencing  
with  6  primers  spanning  the  Eα  promoter  and  HLA-­DR15  insert  (Appendix  5).  
 
3.4.2 HLA-DR15 mouse pronuclear injection  
BglI  digestion  was  performed  until  linearized  DNA  amounted  to  10  µg,  at  least  80  ng/µl.  DNA  
was  given  to  the  laboratory  of  Dr.  Johannes  vom  Berg  and  Dr.  Thorsten  Buch  (LTK,  Zurich),  
who  performed  the  pronuclear  injection  into  the  oocytes  of  female  NSG  animals.    
After  successful  founders  carrying  the  transgene  were  obtained,  they  were  then  transferred  to  
our  mouse  facility  in  Schlieren  and  in  Irchel  and  breeding  colonies  were  initiated.    
 
3.4.3 Genotyping PCR 
For  genotyping,  ear  biopsies  were  added  to  100  µl  of  lysis  buffer  (100  mM  Tris  pH  8.0,  100  
mM  NaCl,  10  mM  EDTA  pH  8.0,  0.2%  SDS)  supplemented  with  2  µl  (200  µg/ml)  Proteinase  K  
(Roche)  and  left  overnight  at  56°C  at  550  rpm.  Then,  300  µl  of  distilled  H20  was  added  and  
centrifuged  at  12  000  rpm  for  10  minutes.  After  centrifugation,  400  µl  of  the  supernatant  was  
transferred  to  500  µl  of  isopropanol,  vortexed  and  centrifuged  at  12  000  rpm  for  10  minutes.  
Supernatant  was  removed  and  200  µl   ice-­cold  EtOH  added,  vortexed  and  centrifuged  at  12  
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000  rpm  for  10  minutes.  Supernatant  was  removed  and  DNA  air  dried  for  15-­30  minutes  and  
finally  resuspended  in  DEPC-­treated  H20  (Thermo  Fischer  Scientific).  
Genotyping   PCR   was   done   with   TaKaRa   LA   Taq   DNA   polymerase   (with   Mg2+   buffer)  
(Clontech).  In  a  total  volume  of  25  µl,  0.32  µl  of  each  10  µM  primer  (Microsynth,  Appendix  5),  
2.5  µl  (10x)  PCR  mic,  4  µl  dNTP  mix  (10  mM),  0.25  µl  Takara  LA  Taq,  approximately  15  ng  of  
DNA  and  DEPC-­treated  H20  (Thermo  Fischer  Scientific)  were  added.  For  PCR  program,  stage  
1:  5  minutes  at  95°C,  stage  2:  (32x)  30  seconds  at  94°C,  45  seconds  at  50°C  and  3  minutes  
at  68°C.  6x  DNA  loading  dye  (Thermo  Fischer  Scientific)  was  added  to  the  PCR  product  and  
it  was  loaded  on  a  3%  agarose  (Promega)  gel  containing  10  000x  Gel  Red  (Biotium),  in  addition  
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MS   is  an   immune-­mediated,  demyelinating  disease  of   the  CNS  with  a  multifactorial  
etiology  and  disease  mechanisms  are  still  not  completely  understood  (Sospedra  and  Martin,  
2005).   More   than   two   hundred   genetic   risk   factors,   as   well   as   several   environmental   risk  
factors,   have   been   implicated   in   this   disease   (Olsson   et   al.,   2017;;   International   Multiple  
Sclerosis  Genetics,  2019).  The  strongest  genetic  risk  factor  is  the  HLA-­DR15  haplotype  of  the  
MHC  class  II  molecule  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013;;  Patsopoulos  et  al.,  2013)  
and   the   environmental   risk   factor   with   the   strongest   evidence   is   EBV   infection,   which  
additionally  synergizes  with  the  HLA  locus  to  further  increase  disease  risk  (Olsson  et  al.,  2017).  
In  the  last  decade,  large  GWAS  studies  replicated  and  identified  first  110  and  then  230  
genetic  loci  implicated  in  the  risk  of  MS  which  lie  outside  the  MHC  locus  (Sawcer  et  al.,  2011;;  
Beecham  et  al.,  2013;;  Cotsapas  and  Genetics,  2018;;  International  Multiple  Sclerosis  Genetics,  
2019).  The  nearest  gene  relative  to  the  specific  SNP  was  identified  and  interestingly,   these  
MS-­associated  SNPs  frequently  lie  in  regulatory  regions  of  genes  that  mainly  play  a  role  in  the  
adaptive  immune  response,  more  specifically  in  T  cell  activation  and  proliferation  and  T  helper  
cell  differentiation.  The  relevant  genes   include  cytokine  pathways,  co-­stimulatory  molecules  
and  immunologically  relevant  signal  transduction  molecules  (Sawcer  et  al.,  2014).  In  addition,  
genes  involved  in  innate  immunity  were  also  described  to  be  involved  in  MS  risk  in  the  last  two  
years   (Cotsapas  and  Genetics,  2018;;   International  Multiple  Sclerosis  Genetics,  2019).  This  
further  highlights  the  immune-­mediated  pathogenesis  of  MS  (Sawcer  et  al.,  2014).  Because  
the  odds  ratios  of  individual  SNPs  are  estimated  to  be  quite  small  (around  1.14-­1.58),  it  is  very  
unlikely  that  they  act   in   isolation,  as  the  genetic  risk  of  MS  is  clearly  polygenic  (Bush  et  al.,  
2010).   For   the   majority   of   the   risk   variants,   their   causality   and   function   remain   to   be  
investigated.    
In  this  chapter,  we  aimed  to  develop  a  SNP-­typing  method  for  16  pre-­selected  SNPs  
of   interest.   Then,   using   our   humanized   NSG   mouse   model   reconstituted   with   SNP-­typed  
human  fetal-­liver  derived  CD34
+  hematopoietic  progenitor  cells,  we  looked  at  the  effect  of  the  
SNP  rs2371108  downstream  of  the  EOMES  gene,  which  is  a  transcription  factor  involved  in  T  
and   NK   cell   cytotoxicity   and   effector   functions.   In   particular,   we   were   interested   to   see  
differences  in  EOMES  expression  and  EBV  immune  control  through  changes  in  viral  loads  and  






4.2.1 Pre-selection included 16 MS-associated risk variants 
Large  GWAS  studies  have  shown  that  more  than  two  hundred  SNPs  are  risk  factors  
for   MS   (International   Multiple   Sclerosis   Genetics,   2019).   Using   our   large   dataset   of   past  
humanized  mouse  cohorts,  we  wanted  to  first  examine  whether  certain  SNPs  correlate  to  the  
increase  in  activation  we  observe  in  our  mice  at  steady  state  (Chapter  2,  manuscript  Fig.  4A).  
First,  a  selection  of  donors  was  outsourced  to  be  SNP-­typed  for  110  SNPs  previously  identified  
in  two  GWAS  studies  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013).  Then,  logistic  regression  
and   beta   regression   analyses   were   performed   to   examine   the   relationship   between   T   cell  
activation  and  number  of  risk  alleles  present  in  the  donor;;  homozygous  negative  for  risk  allele,  
heterozygous  and  homozygous  positive  for  risk  allele.    
From  these  analyses,  we  have  selected  16  SNPs  based  on  the  statistics  obtained  from  
the  regression  analyses  or  on  general  interest  in  the  potential  function  of  the  nearby  gene  to  
have  an  effect  during  EBV  infection.  In  the  GWAS  studies,  the  gene  closest  to  the  identified  
SNPs   is   the   gene   allocated   to   potential   SNP   function.   We   have   therefore   kept   the  
nomenclature  with  the  risk  variant  number  (eg.  rs60600003)  and  closest  gene  (eg.  ELMO1)  
(Fig.  15A  and  Appendix  6).  The  SNP  that  appeared  significant  in  both  analyses  and  appeared  
most  interesting  was  the  SNP  downstream  of  the  EOMES  gene  (Fig.  15B  and  15C).  Having  
one  risk  allele  was  associated  with  elevated  expression  of  HLA-­DR  in  the  T  cell  compartment  
in  our  humanized  mice.  The  number  of  donors  homozygous  for  the  risk  allele  was  too  low  to  




Figure  15.  EOMES  gene  as  the  most  interesting  risk  allele  candidate.  (A)  List  of  16  SNPs  chosen  
based  on  logistic  and  beta  regression  analyses  or  on  interest.  SNPs  were  selected  from  a  list  of  110  
SNPs  published   in   two   large  GWAS  studies  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013).  20  donors  
were  SNP-­typed  and  110  SNPs  correlated  with  increase  in  activation  (HLA-­DR
+
)  in  T  cell  compartment  
in  animals  showing  T  cell  activation  above  20%.  The  SNP  number  and  nearest  gene  name  are  shown.  
Logistic  (B)  and  beta  regression  (C)  analyses  for  the  SNP  rs2371108  downstream  of  the  EOMES  gene.  
Response  indicates  association  with  the  increase  in  activation  (HLA-­DR
+
)  of  the  T  cell  compartment  at  
steady  state  in  NSG  mice.  Number  of  risk  alleles  indicates  homozygous  negative  (0.0),  heterozygous  
(1.0)  or  homozygous  positive  (2.0)  for  SNP.  One  point  indicates  one  donor.  
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4.2.2 Developing a SNP-typing method 
Next,  we  developed  an  in-­house  SNP  typing  method  to  be  able  to  SNP-­type  our  donors  
without  having  to  outsource.  We  found  sequences  flanking  the  SNP  of  interest  and  designed  
primers  around  400  base  pairs  on  each  end  of  the  SNP  (Appendix  7).  We  then  isolated  DNA  
from  the  CD34-­  fraction  of  our  frozen  donors,  ran  a  PCR  with  the  respective  primers  and  sent  
the  isolated  DNA  for  sequencing  (Fig.  16A).  We  were  able  to  obtain  clear  PCR  bands  of  each  
SNP  area.  The  region  around  the  SNP  downstream  of  the  EOMES  gene  is  very  complex  and  
it  was  difficult  to  design  primers  to  amplify  the  region  efficiently.  In  the  end,  a  region  of  around  
100  base  pairs  amplifies  well  (Fig.  16B  and  Appendix  8).  Upon  matching  the  sequence  to  the  
original   sequence   obtained   from   online   sources,   we   could   determine   if   the   donor   was  
homozygous  negative,  heterozygous  or  homozygous  positive   for   the  SNP,  according  to   the  




Figure  16.  Optimized  in-­house  SNP-­typing  protocol.  (A)  A  schematic  demonstrating  the  SNP-­typing  
process.  The  sequence  around  each  SNP  was  obtained  from  online  sources  and  primers  were  designed  
to  flank  around  400  base  pairs  on  each  side  of  SNP.  DNA  was  isolated  from  the  CD34
-­
  fraction  of  our  
donors  and  the  region  around  the  SNP  was  amplified  with  specific  primers  in  PCR.  The  correct  band  
was  then  excised  from  the  gel,  DNA  was  isolated  and  sent  for  sequencing.  (B)  Specific  bands  for  16  
SNPs  of   interest.  100bp   ladders  were  used  and  the  name  of   the  closest  gene  to  each  SNP  labelled  
above  band.   (C)  Example   sequencing   result   for  SNP   rs60600003.  The  nucleotide  of   risk  allele  was  
noted,  as  well  as  alleles  noted   in   the   Immunobase  database  and  gene  direction.  The  position  of   the  
SNP  is  enlarged  and  highlighted  in  a  section  of  the  original  sequence.  Two  peaks  at  SNP  position  in  
a  heterozygous  donor  and  one  peak  in  homozygous  negative  donor.
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4.2.3 Presence of the EOMES risk variant does not lead to differences in EOMES 
expression in bulk T cells  
Next,  we  wanted  to  investigate  in  vivo  functions  of  these  risk  variants.  Even  though  the  
odds  ratios  for  individual  risk  variants  are  low  (Bush  et  al.,  2010),  there  is  evidence  so  far  for  
a  few  SNPs  regulating  the  proximal  gene  expression  (Gregory  et  al.,  2012).  After  SNP-­typing  
our  donors,  we  selected  which  donors  would  be  suitable  for  reconstitution.  We  performed  two  
experiments,  which   included  6  different  donors.  The  SNP-­typing  of   these  donors   for  our  16  
SNPs  of  interest  can  be  found  in  Appendix  9.  As  all  the  donors  largely  differed,  we  chose  to  
first   investigate  one  SNP  of   interest;;   the  risk  variant  rs2371108  downstream  of   the  EOMES  
gene.  We  reconstituted  animals  with  donors  homozygous  positive  (+/+),  homozygous  negative  
(-­/-­)  or  heterozygous  (+/-­)  for  this  SNP  and  aimed  to  investigate  EOMES  expression  and  T  cell  
responses.    
After  reconstitution,  we  performed  EBV  infection  and  monitored  immune  responses.  As  
expected,  we  observed  a  decrease  in  the  frequencies  of  total  CD4
+  T  cells  (Fig.  17A)  as  a  result  
of  a   large  expansion  of  CD8+  T  cells   (Fig.  17B)  during   the  course  of  EBV   infection,  but  no  
marked   differences   between   the   three   groups   of   donors.   Additionally,   when   looking   at   the  
frequencies  of  EOMES+  CD4+  (Fig.  17C)  and  CD8+  (Fig.  17D)  T  cells  in  the  blood  during  the  
infection,  there  appeared  to  be  a  trend  in  week  4  of  infection  with  the  highest  frequencies  of  
EOMES  in  the  homozygous  negative  donor,  however  this  was  not  anymore  apparent  at  time  
of  sacrifice.  At  around  week  four  of  infection,  the  frequencies  of  EOMES+  CD8+  T  cells  reached  
up  to  90%  and  in  the  CD4+  T  cell  compartment  20-­30%  (Fig.  17C  and  17D).  Higher  frequencies  
of  EOMES+  CD8+  T  cells  in  the  blood  were  seen  in  the  homozygous  positive  donors  at  the  start  
of  experiment  both  in  PBS  and  EBV-­infected  animals  (Fig.  17D).  No  differences  are  however  
observed  in  the  total  numbers  of  both  CD4+  (Fig.  17E)  and  CD8+  T  cells  (Fig.  17F)  in  the  three  
donor  groups.      
In   the   spleen,   similar   patterns   were   observed.   The   frequencies   of   CD4+   T   cells  
expressing   EOMES   were   lower   than   in   CD8+   T   cells,   where   almost   100%   express   the  
transcription   factor   (Fig.   17G   and   17H).   Looking   at   the   total   numbers   of   these   cells,   no  





Figure  17.  No  difference  in  frequencies  and  total  numbers  in  donors  differing  for  EOMES  risk  
variant.  Animals  were  reconstituted  with  donors  homozygous  positive  (+/+),  homozygous  negative  (-­/-­)  









































































































































































































































































































































































after  reconstitution,  animals  were   injected  with  10
5
  EBV  infectious  units  or  PBS  intraperitoneally  and  
monitored   for  4.5  weeks.  The   frequencies  of  CD4
+
   (A)  and  CD8
+





   (C)   and  CD8
+





  (E)  and  CD8
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   T   cells   (H)   in   the   spleen   and   their   total   numbers   per   spleen   (I   and  J,   respectively)  were  
measured.  Data  shown  are  combined   from  two  experiments  and  contain  1   to  13  animals  per  group.  
Non-­significant   comparisons   are   indicated   and   based   on   the   Mann-­Whitney   U   test.   Each   symbol  
indicates  one  animal  (mean  ±  SEM). 
  
As   there  was   no   difference   in   the   frequencies   or   total   numbers   of   cells   expressing  
EOMES,  we  examined  the  protein  expression  of  this  transcription  factor.  For  this,  we  analysed  
the  median  fluorescence  intensity  (MFI)  of  EOMES  expressed  in  CD4+  and  CD8+  T  cells  and  
then  normalized  it  to  the  mean  MFI  value  of  PBS  animals  of  the  homozygous  negative  donor  
group.  We  have  not  observed  differences  in  EOMES  expression  in  bulk  CD4+  (Fig.  18A)  and  
CD8+  T  cells  (Fig.  18B)  in  blood  and  spleen  (Fig.  18C  and  18D,  respectively).  
 
 
Figure  18.  No  difference  in  EOMES  MFI  in  donors  differing  for  EOMES  risk  variant.  Animals  were  
reconstituted  with  donors  homozygous  positive  (+/+),  homozygous  negative  (-­/-­)  and  heterozygous  (+/-­


























































































































































































































































animals  were   injected  with   10
5
   EBV   infectious   units   or   PBS   intraperitoneally   and  monitored   for   4.5  
weeks.  The  median  fluorescent  intensity  (MFI)  of  EOMES  in  CD4
+
  (A)  and  CD8
+
  T  cells  (B)  in  the  blood  
and  MFI  of  EOMES  in  CD4
+
   (C)  and  CD8
+
  T  cells  (D)   in   the  spleen  was  measured.  Each  point  was  
normalized  to  the  average  MFI  of  PBS  animals  reconstituted  with  the  homozygous  negative  (-­/-­)  donor.  
Data  shown  are  combined  from  two  experiments  and  contain  1  to  13  animals  per  group.  Each  symbol  
indicates  one  animal  (mean  ±  SEM). 
 
Finally,  we  examined   the  viral   loads   in   the   three  different  donor  groups  during  EBV  
infection.  If  the  risk  variant  was  causal  to  the  EOMES  transcription  factor,  this  could  lead  to  
a  defect  in  T  cell  cytotoxicity  and  thus  lowered  EBV  immune  control.  As  expected,  we  observed  
an  increase  in  peripheral  blood  viral  loads  from  week  3  of  EBV  infection.  Interestingly,  even  
though  at  week  3,  animals  reconstituted  with  homozygous  negative  donors  show  the  highest  
viral   loads,  animals   reconstituted  with  homozygous  positive  donors  show   the  highest  blood  
viral   loads  at  sacrifice  (Fig.  19A).  However,  no  differences  are  observed   in   the  splenic  viral  
loads  between  the  donor  groups  (Fig.  19B).  
 
 
Figure  19.  Higher  blood  viral  loads  at  sacrifice  in  donors  +/+  for  EOMES  risk  variant.  Three  months  
after   reconstitution,  animals  were   injected  with  10
5
  EBV  infectious  units  or  PBS  intraperitoneally  and  
monitored  for  4.5  weeks.  Blood  (A)  and  spleen  (B)  EBV  viral  loads  at  time  of  sacrifice  (4.5  weeks  post  
infection  with  10
5
  EBV  infectious  units)  of  animals  reconstituted  with  donors  homozygous  positive  (+/+),  






























































Data  shown  are  combined  from  two  experiments  and  contain  3  to  13  animals  per  group.  **  p  <  0.01,  ***  
p  <  0.001,  significant  comparisons  are  indicated  and  based  on  the  Mann-­Whitney  U  test.  Each  symbol  





Large  GWAS  have  identified  over  two  hundred  risk  variants  outside  of  the  MHC  locus  
associated  with  MS  risk  (Sawcer  et  al.,  2011;;  Beecham  et  al.,  2013;;  Cotsapas  and  Genetics,  
2018;;   International   Multiple   Sclerosis   Genetics,   2019).   Of   these   variants,   while   a   few   are  
predicted   to   be   coding   variants   and   quantitative   trait   loci   for   gene   expression,   all   of   them  
coincide  with   areas  associated  with   regulatory   function  and   several   lie  within   transcription-­
factor  binding  sites  within  the  genome,  suggesting  an  importance  of  gene  expression  control  
in   MS.   In   addition,   linkage   disequilibrium   with   other   risk   variants   in   the   genome   further  
increases   chances   of   causal   effect   (Parnell   et   al.,   2014;;   Sawcer   et   al.,   2014).   The   genes  
closest  to  the  SNPs  interestingly  play  a  role  in  the  adaptive  immune  response,  mainly  in  T  cell  
activation,  proliferation  and  T  helper  cell  differentiation  (Sawcer  et  al.,  2014),  as  well  as  innate  
immunity  (Cotsapas  and  Genetics,  2018;;  International  Multiple  Sclerosis  Genetics,  2019).  The  
direct  effects  and  roles  of  these  risk  variants  are  largely  unknown.  Understanding  which  risk  
variants   are   causal   in   general,   but   also   causal   to   the   nearest   gene   is   important   to   better  
understand  MS  genetics,  pathogenesis  and  gene-­environment  interactions,  as  well  as  to  gain  
insights  into  existing  therapies  and  develop  new  ones.  
In  this  study,  we  developed  a  SNP-­typing  method  for  16  risk  variants  which  appeared  
to  be  associated  with  higher  basal  activation  in  our  humanized  mouse  model  or  were  of  interest  
to  us.  The  genes  closest  to  these  risk  variants  are,  among  others,  transcription  factors  or  their  
regulators,   or   associated   with   the   NFkB   pathway,   TNF   receptor   family,   signaling   or  
endocytosis.  As  each  donor  has  a  different  genetic  make-­up  and  comparing  several  SNPs  in  
donors  differing  in  many  risk  variants  would  be  very  challenging,  we  decided  to  focus  first  on  
one  risk  variant.  We  chose  the  SNP  rs2371108  downstream  of  the  EOMES  gene  (Beecham  
et   al.,   2013)   and   reconstituted   NSG   mice   with   donors   homozygous   positive,   negative   or  
heterozygous  for  the  EOMES  risk  variant.    
EOMES,  a  T-­box  transcription  factor  similar  to  T-­bet,  is  mainly  expressed  by  activated  
CD8
+   T   cells   and  both   resting  and  activated  NK  cells   (Intlekofer   et   al.,   2005)  and   is  a   key  
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regulatory   gene   involved   in   cell-­mediated   immunity   (Pearce   et   al.,   2003).   In  CD4+   T   cells,  
EOMES  is  expressed  by  only  a  portion  of  cells  at  steady  state,  but  expression  increases  during  
activation  (Lupar  et  al.,  2015).  Both  EOMES  and  T-­bet  regulate  IFNγ  expression  and  cytotoxic  
molecules   in   CD8+   T   cells,   such   as   perforin   and   granzyme   B   (Pearce   et   al.,   2003).   The  
combined   actions   of   these   two   transcription   factors   induce   a   non-­redundant   pathway   that  
controls  the  differentiation  of  effector  CD8+  T  cells.  In  addition,  animals  partially  deficient  for  
EOMES  and  fully  deficient  for  TBX21,  the  gene  encoding  T-­bet,  showed  loss  of  almost  all  IL-­
15-­dependent  cell  lineages;;  NKT  cells,  NK  cells  and  memory  CD8+  T  cells.  This  was  likely  due  
changes   in   the   ability   of   these   cell   types   to   respond   to   IL-­15   (Intlekofer   et   al.,   2005).  
Furthermore,  both  T-­bet  and  EOMES  work  together  to  sustain  expression  of  CD122,  the  B-­
subunit  of  the  IL-­2  and  IL-­15  receptors,  to  stimulate  survival  and  expansion  of  memory  CD8+  
T  cells  (Intlekofer  et  al.,  2005).  In  chronic  infections,  however,  EOMES  expression  is  increased  
in  CD8+  T  cells  and  supports  their  exhaustion.  In  addition,  EOMEShi  virus-­specific  CD8+  T  cells  
demonstrate  a   lower  co-­production  of   IFNγ  and  TNFα  and  an   increase   in  granzyme  B  and  
cytotoxicity,  even  with  lower  levels  of  degranulation  (Paley  et  al.,  2012).  
Even  though  there  is  no  published  work  to  date  investigating  this  specific  EOMES  risk  
variant,   there   has   been   some   work   done   on   the   EOMES   gene.   In   MS,   the   expression   of  
transcription  factors  that  control  T  cell  and  NK  cell  differentiation,  mainly  EOMES  and  TBX1,  
was  found  to  be  lower  and  highly  dysregulated  in  MS  patients  compared  to  healthy  controls.  
The  expression  of  these  two  transcription  factors,  which  share  similar  patterns  of  distribution  
amongst  immune  cells,  correlated  with  each  other,  as  well  as  with  other  transcription  factors  
known  to  regulate  T  and  NK  cells,  such  as  RUNX3  and  TOX.  Upon  examining  a  different  MS-­
associated   SNP   for   EOMES,   rs11129295,   it   was   found   to   be   associated   with   EOMES  
expression.   However,   the   low   expression   of   EOMES   in   MS   is   likely   a   combined   effect   of  
several  genetic  variants  (Parnell  et  al.,  2014).  In  a  later  study,  EOMES  and  TBX21  transcription  
factor  expression  correlated  with  HLA-­DR15  genotype,  but  not  with  serum  EBNA1  antibody  
titers  when  trying  to  predict  poor  EBV  immune  control  (McKay  et  al.,  2016).  Even  though  in  
one   large   analysis,   the  EOMES  SNP   rs11129295  was   an   expression   quantitative   trait   loci  
(eQTL)  for  EOMES  expression  (Westra  et  al.,  2013),  these  results  were  not  seen  in  controls  
or  MS  patients  in  a  smaller  cohort  (McKay  et  al.,  2016).  Thus,  the  effect  of  the  SNP  genotype  
on  gene  expression  is  not  large  enough  to  be  seen  in  small  cohorts  and  expression  association  
is  much  better  observed  at  the  disease  level  rather  than  using  SNP  genotype  alone  (McKay  et  
al.,  2016).  
In   a   model   of   EAE,   EOMES-­deficiency   yielded   more   FoxP3
+   CD4+   T   cells   and  
increased  protection  against  disease,  indicating  a  role  of  the  transcription  factor  in  maintaining  
a   balance   between   inflammatory   and   tolerance   inducing   responses   (Lupar   et   al.,   2015).  
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Additionally,  CD4+  T  cells  expressing  EOMES  were  shown  to  cause  a  late  onset  form  of  EAE  
and  were  increased  in  SPMS  patients,  compared  with  healthy  controls  or  patients  with  RRMS.  
These   CD4+   T   cells   shared   characteristics   of   cytotoxic   CD8+   T   cells,   such   as   granzyme  
B   expression   and   degranulation  measured   by   surface   CD107a   expression.   Signs   of   CNS  
inflammation   were   reduced   after   siRNA   blocking   of   granzyme   B,   suggesting   that   these  
EOMES+   CD4+   T   cells   could   act   as   pathogenic   lymphocytes   in   chronic   stages   of   CNS  
inflammation  (Raveney  et  al.,  2015).  
Outside   autoimmunity,   EOMES-­driven   KLRG1+   CD4+   T   cells   infiltrate   melanoma  
tumors  (Curran  et  al.,  2013).  In  another  mouse  model  of  melanoma,  double  stimulation  of  CD4+  
T  cells  by  CD134  and  CD137  lead  to  EOMES  expression  which  was  responsible  for  cytotoxic  
function  via  granzyme  B.  The  costimulatory  pathway  downstream  of  the  double  stimulation  not  
only   expanded   Ag-­specific   cytotoxic   CD4+   TH1   cells,   but   interestingly   also   imprinted   Ag-­
inexperienced  bystander  T  cells  with  similar  functions.  The  double  stimulation  was  additionally  
able  to  program  CD4+  T  cells  independently  from  CD8+  T  cells  to  control  the  murine  melanoma  
(Qui  et  al.,  2011).  Upon  the  recognition  of  self-­antigen  and   in   the  absence  of   inflammation,  
CD8+  T  cells  did  not  induce  T-­bet  and  EOMES  and  did  not  acquire  effector  functions,  boosting  
tolerance  to  these  antigens.  However,  in  an  inflammatory  environment  during  LCMV  infection,  
higher   expression   of   EOMES,   effector   cytokine   expression   and   effector   differentiation  was  
induced  in  autoreactive  CD8+  T  cells  (Jackson  et  al.,  2014).    
Looking   at   bulk   T   cells   in   peripheral   blood   and   splenocytes,   we   did   not   observe  
differences   in   frequencies   or   total   number   of   EOMES+   cells,   nor   differences   in   EOMES  
expression  in  animals  reconstituted  with  the  three  groups  of  donors  and  infected  with  EBV.  In  
fact,  this  SNP  lies  500  bp  downstream  of  the  EOMES  gene  and  it  is  possible  that  it  is  not  causal  
to   the  expression  of   this   transcription   factor.  This  does  not  exclude,  however,   that   this  may  
affect  the  expression  or  regulation  of  a  different  gene,  or  of  it  being  in  linkage  disequilibrium  
with  another  causal  risk  variant.  In  addition,  we  only  studied  bulk  T  cells  and  any  small  effect  
might  have  been  masked.  We  will  perform  T  cell  cloning  from  EBV-­infected  animals  and  buffy  
coats  and  investigate  EOMES  expression  in  individual  lymphoblastoid  cell  line  (LCL)-­restricted  
CD4
+  or  CD8+  T  cell  clones  by  FACS  analysis  and  Western  blot.  Additionally,  we  aim  to  look  
closer  at  T  cell  subsets  and  differences  in  EOMES  expression.  
We  have  also  seen  differences  in  viral  loads  in  our  EBV-­infected  animals.  Whether  the  
EOMES  SNP   could   lead   to   less   controlled   viral   loads,   hence   possibly   a   stronger   immune  
activation   during   acute   EBV   infection   still   needs   further   work.   To   gain   an   insight   into   this,  
however,  we  plan  to  perform  LCL  killing  assays  with  T  cell  clones  from  homozygous  positive,  
negative  and  heterozygous  donors.  Nevertheless,  the  differences  in  viral  loads  could  be  due  
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to  donor  variation  and  genetic  differences  which  we  did  not  compare  in  the  study  leading  to  
differences  in  the  immune  control  of  EBV.  
A   few   risk   variants   associated   with  MS   risk   have   been   studied   and   found   to   have  
a  causal   link  to  disease  development.  Homozygosity  for   the   intronic  risk  allele  of  CLEC16A  
rs12927335   demonstrated   higher   expression   of   SOCS1,   a   negative   regulator   of   cytokine  
signalling  and  regulation  of  homeostasis,  and  CLEC16A,  a  C-­type  lectin  involved  in  immune  
regulation,  in  CD4+  T  cells,  but  not  in  CD8+  T  cells  (Leikfoss  et  al.,  2015).  The  genotype  for  
another  CLEC16A  risk  variant  rs12708716  was  associated  with  the  expression  of  CLEC16A  
transcripts  in  the  thymus,  suggesting  thymus-­specific  regulation  (Mero  et  al.,  2011).  CLEC16A  
shows  higher  expression  in  the  white  matter  and  enhanced  levels  in  PBMCs  of  MS  patients  
than  controls.  Additionally,  it  plays  a  role  in  MHC  class  II  expression  and  antigen  presentation  
on  APCs  (van  Luijn  et  al.,  2015).  CLEC16A  also  has  an  effect  on  murine  thymic  epithelial  cell  
autophagy,   altering  T   cell   selection   (Schuster   et   al.,   2015),   however,   its   function   in  T   cells  
requires   further   study   (Leikfoss   et   al.,   2015).  Of   note,   this   risk   variant  was   included   in   the  
selection  of  risk  variants  in  our  initial  analysis.    
The  SNP  rs1800693   in  TNFRSF1A  does  not  change   the  extracellular  expression  of  
tumor  necrosis  factor  receptor  1  (TNFR1),  but  interestingly  causes  the  skipping  of  exon  6  and  
its  absence,  which  leads  to  the  receptor  lacking  the  transmembrane  and  cytoplasmic  domains.  
Therefore,  the  SNP  leads  to  higher  concentrations  of  the  soluble  form  of  TNFR1,  which  can  
block  TNF  and  hence  acts  as  a  TNF  neutralizer  (Gregory  et  al.,  2012).  This  is  an  important  
finding,  as  drugs  that  act  to  block  TNF  have  shown  to  lead  to  exacerbation  of  MS  (van  Oosten  
et  al.,  1996;;  Arnason  et  al.,  1999).  Another  MS-­associated  causal  risk  variant  is  rs12874404  
in  the  TNFRF13B  gene,  which  encodes  the  cytokine  B-­cell  activating  factor  (BAFF).  It   is  an  
insertion-­deletion  causal  variant,  which  yields  a  shorter  transcript  that  leads  to  the  increased  
production  of  soluble  BAFF,  as  well  as  being  an  eQTL  that  increases  TNFRSF13B  expression.  
The  risk  variant  also  increased  circulating  B  cells  and  levels  of  total  IgG,  IgA  and  IgM  (Steri  et  
al.,  2017).  
However,   identifying   causal   variants   is   challenging.   The   low-­frequency   variant  
rs117913124   in   the   CYP2R1   gene,   which   encodes   vitamin   D   25-­hydroxylase,   strongly  
associates  with  vitamin  D  levels.  Heterozygous  carriers  for  this  variant  have  an  increased  risk  
of  vitamin  D  insufficiency  and  MS.  However,  because  of  the  lack  of  functional  experiments,  the  
exact  function  of  this  variant  and  causality  cannot  be  confirmed  (Manousaki  et  al.,  2017).  In  
line  with  this,  risk  variants  in  the  IL7R  were  confirmed  to  be  associated  with  MS.  The  mRNA  
expression  of  both  IL-­7R  and  IL-­7  in  the  CSF  was  higher  for  MS  patients  than  controls,  implying  
a  pathophysiological  importance  of  this  pathway  in  the  CSF  of  MS  patients.  However,  genotype  
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for  the  risk  variant  rs6897932  did  not  correlate  to  IL-­7R  mRNA  expression  (Lundmark  et  al.,  
2007).  
With  our  model,  we  wish   to  replicate  current   findings  and  also   investigate  additional  
SNPs  for  causal  effects.  As  only  gene  expression  has  so  far  been  studied  for  the  CLEC16A  
risk   variant,   we   plan   to   examine   changes   in   protein   expression   on   different   cell   types.   An  
additional  SNP  of  interest  to  study  is  the  intronic  risk  variants  rs1782645  in  the  ZMIZ1  gene  
and  rs2726518  in  the  TET2  gene.  ZMIZ1  belongs  to  the  family  of  protein  inhibitor  of  activated  
STAT   (PIAS)-­like  co-­regulators,  believed   to   interact  with  and   regulate  several  DNA-­binding  
transcription  factors  (Shuai  and  Liu,  2005).  ZMIZ1  expression  is  reduced  in  MS,  increased  in  
response   to   vitamin   D   and   weakly   negatively   correlated   with   EBNA1   antibody   titers.   This  
indicates   involvement   in   disease   susceptibility   and   immune   dysregulation   (Fewings   et   al.,  
2017).  TET2  proteins  are  involved  in  the  epigenetic  control  of  DNA  transcription,  by  mediating  
DNA  methylation.  TET2  expression  is  down-­regulated  in  the  PBMCs  of  MS  patients  through  
the  aberrant  methylation  of  its  promoter  (Calabrese  et  al.,  2014).  Interestingly,  EBV  infection  
represses  TET2  mRNA  and  protein  levels  by  EBV  transcripts  BARF0  and  LMP2A.  Upon  the  
knockdown  of  TET2,  EBV   infection   led   to  de  novo  methylation  of   several   gene  promoters,  
leading  to  their  repression  (Namba-­Fukuyo  et  al.,  2016).  Interestingly,  TET2  mRNA  and  protein  
expression   correlated   with   the   EBV   type   III   latency   program,   with   the   depletion   of   TET2  
resulting   in   the  decrease  of   latent  gene  expression  and  switch   to   the   lytic  gene  expression  
program.  It  interacts  with  EBNA2  and  together,  they  cooperate  in  demethylation  of  loci  involved  
in  EBV-­driven  B  cell  transformation  (Lu  et  al.,  2017).  
 
 
4.4 Materials and methods 
 
4.4.1 Risk variant selection 
HFL  donors  were  SNP-­typed  for  the  110  risk  variants  described  in  the  GWAS  studies  Sawcer  
et  al.,  2011  and  Beecham  et  al.,  2013.  It  was  next  determined  how  many  animals  per  cohort  
showed   activation   (staining   positive   for   HLA-­DR)   above   25%,   termed   HLA-­DR   high.   The  
analysis  was  done  on  a  continuous  basis  using  the  frequencies  calculated  of  total  animals  in  
a  cohort   that  are  HLA-­DR  high.  To  determine  which   risk  variants  correlated  with   increased  
activation,  the  data  was  analyzed  by  Prof.  Dr.  Mark  Robinson.  A  logistic  regression  analysis  
and   a   following   beta   regression   analysis   were   performed   with   cut-­off   p>0.05,   displaying  
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increasing  activation  with  increasing  risk  allele  presence.  Using  these  analyses,  we  selected  
16  risk  variants  to  study  (Appendix  6).    
 
4.4.2 SNP-typing 
For   the   SNP-­typing   of   HLA-­DR15+   HFL   donors,   the   CD34-­   fraction   was   thawed   and   DNA  
isolated   (DNeasy  Blood  &  Tissue  Kit,  Qiagen)  as  per  manufacturer’s   instructions  with  DNA  
eluted  in  DEPC-­treated  H20  in  the  last  step  of  DNA  isolation.  DNA  yield  was  measured  by  the  
NanoDrop  (Thermo  Fisher  Scientific).      
The   sequence   400   bp   around   the   chosen   variants   (800   bp   total)   was   found   on  
ImmunoBase.org  and  verified  with  dbSNP  (NCBI).  Primers  were  designed  manually  (help  from  
online  tools;;  Appendix  4)  to  be  20-­28  base  pairs  in  length,  melting  temperature  58-­60°C,  GC  
content  40-­60%,  BLASTed  (NCBI)  to  verify  its  unique  position  in  genome  and  ordered  desalted  
and  without  further  modifications  (Microsynth).  Full  list  of  primers  see  in  Appendix  7.      
In  a  total  volume  of  50  µl,  600  ng  of  DNA  was  added  (800  ng  for  EOMES,  ZMIZ1,  AGBL2,  
ZC2HC1A),  1.25  µl  of  each  10  µM  primer  (Microsynth,  Appendix  7),  0.5  µl  DNA  Phusion  DNA  
polymerase  (Thermo  Fisher  Scientific),  10  µl  GC  buffer  from  kit,  1  µl  10mM  dNTPs,  3.5  µl  (7%)  
DMSO  (EOMES  no  DMSO)  and  DEPC-­treated  H20.  For  PCR  program,  stage  1:  30  seconds  
at  98°C,  stage  2:   (x35)  7  seconds  at  98°C,  20  seconds  at  60°C  (ZMIZ1,  AGBL2  62°C),  25  
seconds  at  72°C,  stage  3:  7  minutes  at  72°C  and  hold  at  10°C.  6x  DNA  loading  dye  (Thermo  
Fisher  Scientific)  was  added  to  the  PCR  product  and  it  was  loaded  on  a  1%  agarose  (Promega)  
gel  containing  10  000x  Gel  Red  (Biotium),   in  addition  to  7  µl  of  1  kB  or  100  bp  DNA  ladder  
(Solis  Biodyne).  The  gel  was  run  at  100V  for  2  hours.    
For   sequencing,   the   band   of   the   correct   size   (Appendix   8)   was   excised   from   the   gel   and  
cleaned-­up  to  isolate  DNA  according  to  manufacturer’s  instructions  (Wizard  SV  Gel  and  PCR  
Clean-­up   System,   Promega   Helix),   with   final   elution   in   DEPC-­treated   H20.   The   DNA   was  
measured   (NanoDrop)  and  sent   for   sequencing  with  pre-­mixed  3  µl   10  µM   forward  primer.  
Sequencing  .fasta  files  were  double  checked  for  clean  peaks  (FinchTV)  and  sequencing  .ab1  
files  were  matched  to  sequences  400  bp  around  the  variant  to  determine  the  nucleotide  at  the  
SNP  position.  SNP-­typing  protocol  was  first  verified  with  HFL  donors  that  were  already  SNP-­
typed   for   initial   analysis   and   risk   variant   selection.   Upon   protocol   verification,   further   non-­
characterized  HFLs  were  SNP-­typed  for  further  experiments.    
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4.4.3 Animal work  
NOD-­scid  γc
-­/-­  (NSG)  animals  (Jackson  Laboratory,  Bar  Harbor,  Maine,  USA)  were  maintained  
at  the  Institute  of  Experimental  Immunology,  University  of  Zürich,  under  specific  pathogen-­free  
conditions.  Newborn  pups  (1-­5  days  old)  were  irradiated  with  1  Gy  and  injected  intrahepatically  
5-­7  hours  later  with  1.5-­3  x  105  human  fetal   liver  (Advanced  Bioscience  Resources)-­derived  
and  HLA-­typed  CD34+  stem  cells.  Magnetic  bead  separation  (Miltenyi  Biotech)  was  used  to  
separate   CD34+   progenitor   cells,   based   on   manufacturer’s   instructions   (Miltenyi   Biotech).  
Isolated   cells   were   frozen   in   liquid   nitrogen.   After   twelve   weeks,   tail   vein   bleeding   was  
performed  and  peripheral  blood  analysed   for  human  cells  by   flow  cytometry.  Three  months  
old,   reconstituted  animals  were   intraperitoneally   injected  with  105  EBV  Raji   infectious  units  
(RIU)  or  PBS  and  monitored  for  4.5  weeks.  A  single  donor  was  used  to  reconstitute  animals  in  
each  experiment.    
 
4.4.4 EBV 
Human  embryonic  kidney  HEK293  cells  (ATCC),  containing  a  GFP-­encoding  wild  type  EBV  
BACmid  (p2089;;  kind  gift  from  H.  Delecluse)  (Delecluse  et  al.,  1998),  were  used  to  produce  
the  B95-­8  EBV  strain.  Raji  cells  (ATCC)  were  used  for  virus  concentrate  titration  and  GFP-­
positive  cells  were  analysed  after  two  days  by  flow  cytometry  (FACSCanto  II  or  LSR  Fortessa,  
BD  Biosciences)  to  calculate  EBV  RIU.  
 
4.4.5 Flow cytometry 
Collected  blood  was   lysed  using  ACK  lysing  buffer  (Gibco)  and  washed  with  PBS  to  obtain  
PBMCs.  Spleens  were  dissociated  using  a  70  µM  strainer  and  layered  on  Ficoll-­Paque  (GE  
Healthcare)   for   the   separation   of   mononuclear   cells   by   density   gradient   centrifugation.  
Beckman  Coulter  Act  diff  Analyzer  was  used  to  determine  total  numbers  of  leukocytes  from  
the  white  blood  cell  count.  PBMCs  or  splenocytes  were  stained  with  extracellular  antibodies  
for  20  minutes  at  4°C,  washed  and  kept  either  in  PBS  or  fixed  in  1%  paraformaldehyde  (PFA).  
For  intranuclear  staining,  extracellular-­stained  samples  were  fixed  and  permeabilized  with  the  
Foxp3/Transcription   Factor   Staining   Buffer   Set   (eBioscience,   Thermo   Fisher   Scientific)  
following   the   manufacturer’s   instructions.   Live/dead   near   IR   (Invitrogen)   or   Zombie   NIR  
(Biolegend)  was  used  for  live  cell  separation.    
Antibody  clones  used  in  this  study:  CD4  (OKT4,  RPA-­T4,  Biolegend),  CD8  (SK1,  Biolegend),  
EOMES  (WD1928,  eBioscience),  
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Samples  were  acquired  on  the  FACSCanto  II  or  LSR  Fortessa  (BD  Biosciences)  and  analysed  
using  the  Flowjo  Software  (Becton,  Dickinson  &  Company).    
 
4.4.6 Viral load calculation 
DNA  from  a  spleen  biopsy  was  processed  using  the  DNeasy  Blood  and  Tissue  Kit  (QIAGEN)  
and   DNA   from   whole   blood   was   extracted   using   the   NucliSENS   EasyMAG   System  
(bioMérieux),   according   to   the   manufacturers’   instructions.   EBV   DNA   was   quantified   with  
TaqMan   real-­time   PCR   (Applied   Biosystems),   with   modified   primers   for   the   BamH1  
W   fragment   (5′-­CTTCTCAGTCCAGCGCGTTT-­3′   and   5′-­CAGTGGTCCCCCTCCCTAGA-­3′)  
and  a  fluorogenic  probe  (5′-­FAM  CGTAAGCCAGACAGCAGCCAATTGTCAG-­TAMRA-­3′).  All  
samples  were  analysed  in  duplicates.    
 
4.4.7 Statistical analysis 
GraphPad  Prism  Software  was  used  for  statistical  analysis  and  the  Mann-­Whitney  U  test  was  
used   to   analyze   unpaired   data   with   a   non-­Gaussian   distribution.   A   p   value   <   0.05   was  
considered  statistically  significant.    
 
4.4.8 Ethics statement 
The   cantonal   veterinary   office   in   Zürich,   Switzerland,   approved   all   animal   experimentation  
(protocols  148/2011,  209/2014  and  159/17).  Experiments  were  conducted  according   to   the  
Swiss  Animal  Welfare  Act,  Tierschutzgesetz  (TSchG).  All  human  samples  were  approved  by  












MS  is  a  complex,  multifactorial  disease  with  >200  genetic  risk   factors   implicated,  as  
well  as  several  environmental  risk  factors.  The  strongest  genetic  risk  factor  is  the  HLA-­DR15  
allele  of  the  MHC  class  II  locus  and  in  addition,  over  200  single  nucleotide  polymorphism  risk  
variants  contribute,  albeit  weakly  individually,  to  MS  risk.  These  risk  variants  are  associated  
with  genes  with  roles  in  adaptive  immunity,  mainly  within  T  helper  cell-­related  pathways.  The  
environmental   risk   factor   implicated   in   MS   with   strong   evidence   is   EBV   infection   and  
interestingly,  HLA-­DR15  and  EBV  infection  synergize  to  increase  the  likelihood  to  develop  MS  
at  least  seven-­fold.  The  mechanisms  behind  the  interactions  between  the  genetic  risk  factors  
and  EBV  infection  remain  unclear.      
Together,   our   data   suggest   a   higher   basal   T   cell   activation   and   impaired   T   cell-­
mediated   immune   control   of   EBV   in   the   context   of   HLA-­DR15,   as   well   as   an   increased  
alloreactivity   in   HLA-­DR15-­restricted   CD4
+   T   cell   clones.   Upon   creating   an   HLA-­DR15  
transgenic  NSG  mouse  which  would  possibly  have  better  humoral  and  CD4+  T  cell  immunity,  
we  would  be  able  to  study  this  further.  This  model  would  also  serve  as  a  vessel  for  HLA-­DR15-­
restricted  CD4+  T  cell  clones  derived  from  MS  patients  and  to  study  their  homing,  reactivity  
and  possible  CNS  inflammation.  Finally,  single  risk  variants  confer  a  weak  effect  to  MS  risk,  
however,   they   likely   act   together   in   supporting   pathways   and   also   in   interacting   with  
environmental  factors.  When  looking  at  the  effect  of  the  SNP  downstream  of  the  EOMES  gene,  
we  did  not  see  an  effect  on  protein  expression  at  the  basal  level  or  during  EBV  infection  in  bulk  
T  cells.  We  will  study  this  further  and  also  plan  to  include  other  SNPs  in  our  analysis.  While  
HLA-­DR15  could  be  involved  in  immune  system  restriction,  single  risk  variants  could  play  a  
role  in  inflammation  dysregulation  and  lowering  the  threshold  of  T  cell  activation.  This  could  
impact   HLA-­DR15-­restricted   effector   T   cell   pathways   and   lead   to   defective   EBV   immune  
control,   as   well   as   heightened   inflammatory   settings   for   the   selection   and   survival   of  
autoreactive  lymphocytes,  triggering  or  perpetuating  damage  in  the  CNS  (Fig.  20).  
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Figure  20.  Suggested  mechanism  for   the   involvement  of  EBV  infection   in   the  development  of  
MS.   In  HLA-­DR15  positive  donors,  we  see  higher  viral   loads,  as  well  as  higher  T  cell  activation  and  
frequencies  of  CD8
+
  T  cells.  EBV  infection  could  save  autoreactive  (depicted  as  purple  nuclei)  B  cells  
from  apoptotic  deletion  and  high  T  cell  activation  autoreactive  or  cross-­reactive  T  cells   (depicted  as  
purple   nuclei)   restricted   by   HLA-­DR15.   During   EBV   persistence,   autoproliferating   EBV-­infected  
autoreactive   B   cells   could   stimulate   cross-­reactive   T   cells   in   an   HLA-­DR   dependent   manner   and  
maintain  their  survival.  Activated,  autoreactive  lymphocytes  could  home  to  the  CNS,  where  B  cells  might  
act  as  APCs  to  cross-­reactive  T  cells  and  trigger  CNS  inflammation.  


















































































6.3 Vectors (pMK-T and pDOI-5) 
 
                                                               
 
 
6.4 Online tools SNP primer design 
 
Melting  Temperature  (Tm)  Calculation  -­  www.biophp.org/minitools/melting_temperature/demo.php  
Reverse  complement  –  www.bioinformatics.org/sms/rev_comp.html  
DNA/RNA  GC  Content  Calculator  –  www.endmemo.come/bio/gc.php  
 
 
6.5 List of primers DR2 mouse 
 























DR2  1_F    
GAATTGAAGGAAGGCCGTC  
DR2  2_F    
CTACAGAGAACGTGGTGTG  
DR2  3_F    
CACAGGCCTGATCCAGAAT  





hDRA1U  F    
CTGGCGGCTTGAAGAATTTGG  
hDRA1U  R    
CATGATTTCCAGGTTGGCTTTGTC  
  
*  once  the  gene  is  in  the  pDOI5  plasmid,  the  DR2  #1_F  won't  bind  anymore  as  it  is  before  
the  EcoRI  site  on  pMK-­T  plasmid    
 
6.6 Logistic and beta regression  
 
Risk  variant   Gene   p  logistic  regression     p  Beta  regression  
rs3007421   PLEKHG5   0.00000     0.34231  
rs2283792   MAPK1   0.00016     0.90093  
rs6880778   PTGER4/DAB2   0.00000     0.03625  
rs1021156   ZC2HC1A/PKIA   0.00000     0.06543    
rs7120737   AGBL2   0.00476   0.4162  
rs1886700   CDH3   0.00291   0.19918  
rs2726518   TET2   0.61089   0.09516  
rs1014486   IL12A   0.00003   0.08676  
rs12927355   CLEC16A   0.00352   0.47443  
100
rs60600003   ELMO1   0.00002   0.17386    
rs2371108   EOMES   0.00000   0.0382  
rs35929052   IRF8   0.00000     0.11503  
rs1782645   ZMIZ1   0.00001   0.6269  
rs1800693   TNFRSF1A   0.00000   0.86966  
rs12296430   LTBR   0.01126   n/a  



































































6.7 List of SNP primers 
 
Risk  variant  gene   10  µM  forward  primer   10  µM  reverse  primer  
PLEKHG5   5’  ACAGCAGATCCGTGAAGAGGAAGC  3’   5’  TGTGCTGGGCATCTCACTGAGGAT  3’  
EOMES   Primer  5F    
5’  AGAAGCTGAGCTGTGTGCAG  3’  
Primer  9R    
5’  CCGATTGCCCACATCAGACTTAACCAA  
3’  
ELMO1   5’  CCCATCCATCACTGTATGTGCTACAG  3’   5’  CACTGCTTCCTGACCATGACTTCCT  3’  
ZMIZ1   Primer  3F    
5’  CTAGAATTTTGTGACTTGGTGAGGGGG  3’  
Primer  3R    
5’  CCCACCCCGATCTCTCATGTACAT  3’  
AGBL2   Primer  3F     Primer  3R    
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5’  TAGCCTGACGTTGTGGCATGTGC  3’   5’  TGAGATGGTGCATGGAGTGCACTTC  3’  
TNFRSF1A   5’  AGCTCGACATCTCCCCAGCCAT  3’   5’  GGTTAATGGCTTGCCTAGATTCACACT  
3’  
LTBR   5’  GCAATGGCAGTTGACAATGGGGTAAC  3’   5’  AGTTTATTGGCTCCTGGGATTGGGG  3’  
CLEC16A   5’  ATGGAGGGACTTGGACCTGACTC  3’   5’  GGACCCATCAACAAGGGTGGCTTA  3’  
CDH3   5’  CCCACTCTCAAACAGGTTACTGGC  3’   5’  TGAGAGCACCCTGCACTGGGTAA  3’  
WWOW   5’  GATTTCTTACTATCTTGGGCCTTCTTGG  3’   5’  CTTAGGGAATTGATGATCGGCTACTGT  
3’  
IRF8   5’  GTGGATGACCGTCCTTTTCAAGGAG  3’   5’  
AATTCAAGAGCCAAGAGAGTATTTTGCCC  
3’  
IL12A   5’  CAATTCAAGATAGTCTGACCATGCTACC  3’   5’  AAAGGACTTGGCAGACGTGGGAAG  3’  
TET2   5’  GAGGACTTTCGCATCTCTGTTGATAAG  3’   5’  CCAGTCTGAAAAGGCTCCATATACTGT  
3’  
PTGER4/DAB2   5’  GGTGTCAACAGCCATTGGATATCTACC  3’   5’  GAAGATGTCCTCTGTGGATTGTCACAC  
3’  
ZC2HC1A/PKIA   Primer  2F    
5’  GTAGGTTATTCCTCTTCTGGTCATGGAA  3’  















PLEKHG5   800  
EOMES   240  
ELMO1   752  
ZMIZ1   563  
107
AGBL2   363  
TNFRSF1A   791  
LTBR   799  
CLEC16A   769  
CDH3   782  
WWOW   742  
IRF8   731  
IL12A   575  
TET2   655  
PTGER4/DAB2   715  
ZC2HC1A/PKIA   595  
MAPK1   694  
 
 






















PLEKHG5   +/-­   -­/-­   +/-­   +/-­   -­/-­   -­/-­  
EOMES   +/+   -­/-­   +/-­   +/-­   +/+   +/-­  
ELMO1   -­/-­   -­/-­   -­/-­   -­/-­   -­/-­   -­/-­  
ZMIZ1   +/-­   +/-­   -­/-­   +/-­   -­/-­   +/-­  
AGBL2   -­/-­   -­/-­   na   na   na   na  
TNFRSF1A   -­/-­   -­/-­   +/-­   +/+   -­/-­   +/-­  
LTBR   +/+   +/+   +/+   +/+   +/+   +/+  
CLEC16A   +/+   +/+   +/+   na   +/+   na  
CDH3   -­/-­   -­/-­   -­/-­   -­/-­   +/+   +/-­  
WWOW   +/-­   +/-­   +/-­   -­/-­   -­/-­   -­/-­  
108
IRF8   +/+   +/+   +/-­   +/+   +/+   +/+  
IL12A   na   +/-­   +/-­   -­/-­   +/-­   -­/-­  
TET2   +/+   +/-­   +/+   -­/-­   +/+   +/-­  
PTGER4/DAB2   +/-­   +/-­   -­/-­   -­/-­   +/+   -­/-­  
ZC2HC1A/PKIA   na   -­/-­   -­/-­   -­/-­   +/-­   +/-­  
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